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Mitochondrial disorders are a group of clinically heterogenous conditions affecting 
multiple systems with a prevalence that is estimated to affect 1 in 4,300 individuals. 
Mitochondrial function is under the control of both the mitochondrial and nuclear 
genomes which encode >1200 mitochondrial proteins. Manifold biochemical pathways 
and possible gene targets contribute to the highly variable genotype-phenotype 
correlations observed in mitochondrial patients, posing distinct challenges in reaching a 
genetic diagnosis. Whole Exome Sequencing (WES) is a gene agnostic approach that has 
been hugely powerful in diagnosing mitochondrial disease patients and broadening the 
genotypic spectrum of disease. Mitochondrial genetic disease is largely understudied in 
Kuwait where levels of consanguinity reach 50% in the community. Studying the genetics 
and aetiology of mitochondrial disorders in Kuwait presents huge potential in identifying 
novel Mendelian causes of disease. 
I custom-designed mitochondrial disease criteria to evaluate and recruit patients 
suspected of mitochondrial disease in Kuwait. WES led to the diagnosis of 14 out of 22 
recruited families: 8 families harboured variants in known mitochondrial disease genes 
(SLC19A3, PDHX, SURF1, MPC1, TTC19, NDUFA13, NDUFB9 and RRM2B), 2 
harboured variants in a novel mitochondrial disease gene (LETM1), and 4 were diagnosed 
with phenocopies of mitochondrial disease (RNASEH2C, TREX1, VPS13B and ATP8A2). 
Functional validation of novel variant pathogenicity was performed in patient fibroblasts 
from 4 families. Functional validation was also carried out on additional mitochondrial 
patients from Newcastle and external collaborators (COX15, TTC19, NDUFAF3 and 
NDUFC2). Complexome profiling helped characterise the effect of NDUFC2 variants (a 
novel candidate gene) on Complex I assembly while a controlled lentiviral rescue 
experiment partially recovered protein expression and validated variant pathogenicity. 
My work highlights the potential of employing WES to identify novel causes of disease 
in understudied consanguineous populations and emphasises the importance of 
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Chapter 1. Introduction 
 
 Mitochondria 
Mitochondria are dynamic double-membraned cellular organelles, ubiquitous to all 
nucleated cells, that carry out many cellular metabolic processes including the Kreb’s 
cycle, fatty acid oxidation and oxidative phosphorylation (OXPHOS) (Nunnari and 
Suomalainen, 2012). In addition, mitochondria play a major role in calcium homeostasis, 
autophagy, apoptosis, and heme and iron-sulphur cluster biosynthesis (Contreras et al., 
2010; Glick et al., 2010; Stehling et al., 2014; Vakifahmetoglu-Norberg et al., 2017).  
Mitochondria were first described by Kölliker (1856), but Richard Altmann (1894) 
studied their structure and function describing them as "elementary organisms" 
resembling bacteria, sustaining metabolic and genetic functions, and he named them 
"bioblasts" (meaning "life germs") in the process (Dahl and Thorburn, 2001; O'Rourke, 
2010). However, the term "mitochondria" (meaning "thread granules") was coined by 
Carl Benda in 1898 (Reid and Leech, 1980) (Reid and Leech, 1980). Mitochondria are 
hypothesised to have originated from alpha-proteobacteria that were incorporated into 
eukaryote precursor cells via endosymbiosis; prokaryotes (the eukaryotic precursor cells) 
engulfed mitochondrial proteobacteria giving rise to the modern eukaryotic cells (Gray et 
al., 1999; Lane and Martin, 2010).  
1.1.1 Structure 
A mitochondrion is a double membraned organelle with an outer membrane (OMM) 
separating the mitochondrial intermembrane space (IMS) from the cell’s cytoplasm and 
an inner membrane (IMM) separating the space it encloses called the “matrix” from the 
IMS (Figure 1.1). The electron transport chain (ETC) complexes, along with adenosine 
triphosphate (ATP) synthase, are transmembrane proteins that reside within the IMM. To 
increase its surface area, the IMM forms numerous folds called cristae. The OMM 
possesses a number of transmembrane proteins that passively or actively transport ions 
and cofactors; an example is the voltage-dependent anion channel protein (VDAC) that 




Figure 1.1 Mitochondrial structures and membranes. 
The structure of the mitochondrial membranes and compartments. The matrix (yellow 
space) is the compartment enclosed by the mitochondrial inner membrane (IMM), while 
the mitochondrial intermembrane space (IMS, orange space) is the compartment located 
between the mitochondrial outer membrane (OMM) and the IMM. The OXPHOS 
complexes are depicted in the mitochondrial cristae. 
 
 
1.1.2 Mitochondrial dynamics 
Mitochondria are dynamic organelles that constantly fuse and divide allowing 
mitochondrial distribution to adapt to surrounding conditions during cell growth, division 
and differentiation (van der Bliek et al., 2013; Ni et al., 2015). This process of fission and 
fusion is directed by the dynamin family of large guanosine triphosphatases (GTPases) 
found in the cytosol. The processes of fission and fusion will be outlined below. 
1.1.2.1 Fusion 
Fusion of the OMM is mediated by members of the dynamin superfamily of GTPase 
proteins such as OMM-bound mitofusins Mfn1 and Mfn2 while IMM fusion is mediated 
by IMM bound OPA1 (Antonny et al., 2016; Giacomello et al., 2020). Upon binding 
GTP, mitofusins extend their structure from the outer membrane and interact with 
mitofusins on opposing mitochondria. GTP hydrolysis causes conformational changes in 
mitofusins reducing the distance between membranes while the release of GDP results in 
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the fusion of the opposing OMMs (Chen et al., 2003). Both mitofusins Mfn1 and Mfn2 
participate in OMM fusion through homomeric or heteromeric interactions.  
OMM fusion usually is accompanied by the fusion of the IMM (van der Bliek et al., 
2013). The alternative splicing of the IMM fusion mediating OPA1 gene results in the 
production of 8 isoforms of OPA1 protein; 3 cleavage sites along the polypeptide allow 
for further processing by peptidases such as OMA1 and Yme1L leading to the formation 
of the IMM-bound long-OPA1 (L-OPA1) and the IMS form short-OPA1 (S-OPA1) 
which has a similar structure to Drp1 (another member of the dynamin superfamily of 
GTPases that is encoded by DNM1L) (Figure 1.2) (Smirnova et al., 2001; Lee and Yoon, 
2016). Knockouts of the OMA1 and Yme1L allow for the accumulation of L-OPA1 
which did not affect fusion suggesting it plays a central role in IMM fusion; the expression 
of S-OPA1 in these knock out cells induced mitochondrial fission without influencing 
fusion suggesting both forms of OPA1 balance the process of IMM fission and fusion 
(Anand et al., 2014). 
1.1.2.2 Fission 
During the process of fission, Drp1 binds to the receptors mitochondrial fission factor 
(Mff), fission 1 (Fis1), mitochondrial dynamics proteins of 49 kDa and 51 kDa (MiD49 
and MiD51) anchored to the OMM between the mitochondria and the endoplasmic 
reticulum (ER) where the ER tubule wraps around the mitochondrial tubule (Ni et al., 
2015). At this ER-mitochondrial interface, Spire1C, a mitochondrial-bound actin-
nucleating Spire protein, induces the polymerisation of actin by the ER-associated actin 
modulator inverted formin 2 (INF2) where Drp1 binds to its receptors leading to the initial 
constriction of the mitochondrial tubule (Manor et al., 2015). Drp1 then forms a ring 
around the mitochondria and its GTPase activity further constricts the ring leading to 
mitochondrial fission. Mff triggers GTPase activity of Drp1 leading to mitochondrial 
fission while MiD51 inhibits the GTPase activity suggesting a regulatory role between 

















Figure 1.2 Mitochondrial Fusion and fission 
A Fusion of the OMM it facilitated by the dynamin proteins MFN1 and MFN2 binding and GTPase activity pulls the membranes together to 
fuse. Fusion of the IMM is mediated by L-OPA1 that bind to opposing IMMs and fuse the membranes together. 
B Mitochondrial fission initially involves the wrapping of the ER around a segment of mitochondria where MAMs (including Spire1C) bind the 
mitochondria to the ER and recruit DRP1 to form a ring. Subsequent to the formation of the ring, DRP1 constrict resulting in the formation of 2 
separate mitochondria.  
A B 
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1.1.3 ER-mitochondrial interactions 
The interaction between the ER and OMM takes place at points of contact named 
mitochondria-associated ER membranes (MAMs) (Patergnani et al., 2011). These 
junctions are linked to pathways facilitating and regulating mitochondrial fission, calcium 
homeostasis, autophagy and inflammation. During fission, MAMs contain ER-bound 
INF2 which plays a crucial role in facilitating the formation of the DRP1 ring (Marchi et 
al., 2014). These MAMs are points where mitochondrial fission takes place as a result of 
DRP1 ring formation and constriction (Friedman et al., 2011).  
In addition to its involvement in mitochondrial fission, there are other ER interactions 
with the mitochondria that are important for such diverse functions as calcium 
homeostasis, autophagy and inflammation. With regards to calcium homeostasis, the ER 
functions as a calcium storage and releases these ions, via the ER bound transmembrane 
protein inositol 1,4,5-trophosphate receptor (IP3R) at MAMs, for the mitochondria to take 
up (Marchi et al., 2018). There is evidence showing that IP3R bind to the OMM 
transmembrane protein VDAC facilitating the efficient transfer of calcium from the ER 
to the mitochondria. Calcium overload in the mitochondria results in apoptotic signalling 
(Marchi et al., 2018).  
Autophagy is the process of degrading cellular components and organelle due to damage 
or cellular starvation by forming autophagosome vesicles that fuse with lysosomes to 
form autophagolysosomes resulting in the digestion of the cellular components within 
(Glick et al., 2010). Autophagy induced by starvation triggers non-selective degradation 
of organelles such as the ER and mitochondria. Autophagy related genes (ATG) that 
localise in the cytosol and ER migrate to MAMs indicating importance of these junctions 
in autophogasome formation (Axe et al., 2011). ER-bound vesicle-associated membrane 
proteins (VAMP) associated proteins B and C (VAPB and VAPC) and OMM 
transmembrane protein Regulator of mitochondrial dynamics 3 (RMND3) were 
discovered to tether the organelles and their dissociation stimulated the formation of 
autophagosomes (Gomez-Suaga et al., 2017).  
In the inflammatory pathway, NOD-like receptor protein 3 (NLRP3) is an inflammasome 
that is activated by reactive oxygen species (ROS) (Zhou et al., 2011). As signal 
molecules, ROS do not travel long distances before they trigger a signal or are neutralised 
by superoxide dismutases (SODs). Therefore, NLRP3 which initially localises in the ER 
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is released into MAMs where ROS levels are more representative of mitochondrial 
oxidative stress levels.  
1.1.4 The mitochondrial genome 
Mitochondria have multiple copies of their own genome which is the only inheritable 
extra-nuclear DNA. The human mitochondrial DNA (mtDNA) molecule is a circular 
genome comprising 16,569 bp (Figure 1.3) (Anderson et al., 1981). The mitochondrial 
genome encodes 37 genes that are fundamental to mitochondrial function including 2 
rRNAs, 22 tRNAs and 13 polypeptides, which are all essential subunits of the OXPHOS 
complexes I, III, IV and ATP Synthase (complex V) (Anderson et al., 1981). These 
protein subunits are synthesised by the mitochondrial protein synthesis components. The 
strands of the mtDNA are assigned as heavy strand (H-strand) and light strand (L-strand) 
due to differences in buoyant densities in denaturing caesium chloride gradients based on 
their guanine and thymine content (Kasamatsu and Vinograd, 1974; Anderson et al., 
1981). The H-strand codes for 14 tRNAs, 12 polypeptides, and 2 rRNAs along with the 
two sites for transcription initiation HSP1 and HSP2 and the origin of L-strand replication 
OL. The L-strand codes for 8 tRNAs, 1 polypeptide, the transcription initiation site LSP 
and the origin of H-strand replication OH. Genes in the mitochondrial genome lack introns 
and some genes overlap such as the genes coding for complex I subunits ND4 and ND4L 
(MT-ND4 and MT-ND4L) as well as complex V subunits ATPase 6 and ATPase 8 (MT-
ATP6 and MT-ATP8).  
The displacement loop (D-loop) is a non-coding region (NCR) of mtDNA that 
incorporates a third DNA strand, homologous to the H-strand, named 7S DNA (Walberg 
and Clayton, 1981). This region is flanked by genes coding for tRNAs phenylalanine and 
proline and contained within it are the transcription promoters for the H-strand and L-
strand (HSP1, HSP2 and LSP) and the origin of H-strand replication site OH. Another 
NCR is located at the origin of L-strand replication site OL that is flanked by 5 tRNAs.  
Nucleated cells may contain high copy numbers of mtDNA packed into nucleoids ranging 
from hundreds to thousands per cell (Grady et al., 2018). Mitochondrial transcription 
factor A (TFAM) is a member of the high-mobility group proteins and is a DNA 
packaging component that binds to mtDNA within nucleoids and is present in large 
numbers to cover the length of the genome and it acts as transcription initiation factor 
(Alam et al., 2003; Kolesnikov, 2016). Other proteins identified in nucleoids are proteins 
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that play role in mtDNA transcription and replication such the mitochondrial transcription 
activator peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1a), the deactylase SIRT1, DNA helicase (Twinkle), mitochondrial single strand 
binding proteins (mtSSBs), mitochondrial RNA polymerase (POLRMT), and 
mitochondrial DNA polymerases POLG1 and POLG2 (Kolesnikov, 2016). 
In evolutionary terms, the reduction of mtDNA to its current size was due either to the 
loss of unnecessary proteobacterial function genes (such as those expressing proteins for 
cell wall synthesis), the availability of gene homologs in the nuclear genome (nDNA) 
providing substitute proteins to those in mtDNA such as genes expressing ribosomal 
proteins that duplicate and target mitochondrial translation (Mollier et al., 2002), or the 
unilateral transfer of genes from mtDNA to nDNA (Adams and Palmer, 2003). Fragments 
of the human mtDNA (mitochondrial pseudogenes) were located in different regions and 
chromosomes of the human nDNA providing evidence supporting the hypothesis of 
unilateral gene transfer from mtDNA to nDNA as a major evolutionary step leading to 






Figure 1.3 The mitochondrial genome 
A diagram highlighting the genes in the mitochondrial genome, the mitochondrial 
tRNAs (neon yellow) and rRNAs (purple) required for mitochondrial gene translation. 
Genes coding for complex I core subunits are in blue, cytochrome b (a complex III 
subunit) is in dark yellow, complex IV subunits are in orange, and complex V subunits 
are in green. The D-loop (grey) is the region that anchors the mitochondrial genome to 
the IMM. Genes on the heavy strand are depicted on the outer circle while the light 
strand is depicted in the smaller inner circle. Also highlighted are the transcription 
promoters (HSP1, HSP2, and LSP) and the origins of replication (OH and OL) on both 
strands.  
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1.1.5 Mitochondrial genetics 
Mitochondrial DNA associates with proteins forming nucleoprotein structures called 
nucleoids which are anchored to the inner mitochondrial membrane (Bogenhagen, 2012). 
These nucleoids are in close proximity to the mitochondrial respiratory chain which 
produces reactive oxygen species creating a hostile environment that may make mtDNA 
prone to develop mutations (Chinnery et al., 2000). Proteins associated with mtDNA in 
nucleoids do not protect mtDNA as efficiently compared to the histone protection of 
nDNA, which may also contribute to the frequency of accumulated mtDNA mutations 
(Kolesnikov, 2016). The presence of mtDNA mutations at varying levels is termed 
"heteroplasmy" where a mixture of wild-type and mutant mitochondrial genomes co-exist 
within a single individual or cell; whereas when all mtDNA copies are identical, this is 
termed "homoplasmy" (Figure 1.4).  
The mitochondrial genome is inherited maternally due to the high abundance of maternal 
mitochondria in the oocyte compared to the low number of mitochondria in the sperm 
during fertilisation (Hutchison et al., 1974). Moreover, mechanisms of paternal mtDNA 
degradation were discovered further supporting uniparental inheritance (Sato and Sato, 
2013; Yu et al., 2017).  
Maternally inherited mtDNA has repeatedly shown varying levels of mtDNA 
heteroplasmy in offspring; this variation is hypothesised to be the result of a "bottleneck" 
effect where a selection of mitochondria harbouring certain levels of heteroplasmy are 
transmitted to offspring (Chinnery et al., 2000; Friedman and Nunnari, 2014). Within a 
single individual, different tissues may harbour different levels of heteroplasmy due to 
asymmetric distribution of mitochondria during mitosis leading to a variation in affected 
organs amongst patients with similar mtDNA mutations. The threshold effect is a key 
factor in the presentation of mitochondrial disorders resulting from mtDNA mutations as 
the level of mutant heteroplasmy needs to exceed a certain threshold level (usually 60% 
and above) (Holt et al., 1990; Rossignol et al., 2003). When mutant heteroplasmy levels 
exceed this threshold level, this results in a significant defect in mitochondrial or 
respiratory function leading to symptoms developing in these tissues. For example, 
patients harbouring 2 different mutations affecting the same nucleotide mt.8993T>C and 
mt.8993>G in MT-ATP6 exhibited different threshold levels; patients with the 
mt.8993T>C mutation presented clinically when exceeding the threshold of 80% 
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heteroplasmy level, while patients with the mt.8993T>G mutation presented clinically at 
heteroplasmy levels below 60% (White et al., 1999). 
 
 
Figure 1.4 Mitochondrial genome heteroplasmy 
A representation of DNA heteroplasmy in the presence of variants within the number of 
mitochondrial genomes. Wild-type mtDNA genomes (green) and mutant mtDNA 
genomes (red) can both be present in the same mitochondria. The higher the number of 
mutant mtDNA, the higher the level of heteroplasmy. The 60% threshold is highlighted 




1.1.6 Nuclear encoded mitochondrial components 
Mitochondrial function is reliant on genes encoded in both the mitochondrial and nuclear 
genomes. Nuclear DNA encodes the vast majority of OXPHOS subunits, including the 
whole of complex II, alongside other genes that regulate OXPHOS and mitochondrial 
functions (>1,400 genes) (Lopez et al., 2000; Calvo et al., 2006). The MitoCarta2.0 
inventory (https://www.broadinstitute.org/scientific-
community/science/programs/metabolic-disease-
program/publications/mitocarta/mitocarta-in-0) lists 1158 genes encoding proteins 
involved in pathways that take place within the mitochondria (Pagliarini et al., 2008; 
Calvo et al., 2016). These genes include the 13 mtDNA genes encoding OXPHOS 
components, but all of the remaining mitochondrial respiratory chain subunits and 
accessory subunits, the mitochondrial ribosomal (mitoribosome) subunits and RNA 
polymerases requires for mtDNA gene expression, DNA polymerases necessary for 
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mtDNA replication and many other proteins required for mitochondrial maintenance are 
encoded by the nuclear genome. 
1.1.7 Replication of mtDNA 
Three different models of mtDNA replication have been described in the literature 
(Figure 1.5) (McKinney and Oliveira, 2013). All three models of replication initiate at 
the H-strand OH where the replicative mtDNA helicase TWINKLE binds and unwinds 
the dsDNA forming a replication fork where polymerase γ (POLG) binds and commences 
mtDNA replication in the 5' to 3' direction (Holt and Reyes, 2012; McKinney and 
Oliveira, 2013). Binding of mtSSB to the lagging strand protects it from degradation by 
nucleases. 
POLG is a heterotrimeric protein comprised of a single POLG-α subunit that carries out 
all the catalytic activities and two POLG-β subunits that regulate POLG-α activity 
enhancing the speed of DNA replication 100-fold (Ciesielski et al., 2016). The POLG-α 
subunit contains domains that facilitate 5' to 3' DNA synthesis, 3' to 5' exonuclease 
activity to repair error during replication, and 5' deoxyribophosphate lyase activity also 
required for repair mechanisms.  
1.1.7.1 Strand displacement replication 
The first model is the strand displacement replication model where replication initiates 
unilaterally from the origin of the H-strand` replication OH (McKinney and Oliveira, 
2013). When replication reaches two-thirds of the way around the mtDNA, the origin of 
L-strand replication OL is exposed; mitochondrial RNA polymerase (POLRMT) binds to 
OL and synthesises a 25nt primer allowing the binding of POLG and the initiation of L-
strand replication in the opposite direction (Robberson et al., 1972; Fusté et al., 2010). 
This results in the formation of 2 copies of the mtDNA which are then segregated. 
1.1.7.2 Ribonucleotides Incorporated Through Out the Lagging Strand (RITOLS) 
replication 
The second model theorises that after replication initiates at the OH origin of replication 
site, RNA is incorporated on to the lagging strand forming RNA:DNA hybrids that protect 
against nuclease cleavage (Yang et al., 2002; Yasukawa et al., 2006). The mechanism of 
RNA binding is not yet known but suggestions of primase activity and the binding of 
processed gene transcripts have been raised (Reyes et al., 2013) . When the OL origin of 
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replication site is exposed, replication initiates in the opposite direct in a similar fashion 
to the strand displacement replication model. The mechanism of RNA removal or 
conversion to DNA remains unknown although RNase H activity is suggested to play a 
role in the process (Holt and Reyes, 2012; Ciesielski et al., 2016; Zinovkina, 2019).  
1.1.7.3 Strand coupled replication 
A third model was proposed after experiments with mtDNA depletion following exposure 
to ethidium bromide demonstrated that other sites of replication initiation were 
discovered on the lagging strand in the region coding for cytochrome b and complex I 
subunits ND5 and ND6 (Holt et al., 2000; Bowmaker et al., 2003). This resulted in the 
simultaneous replication of both the H-strand and L-strand. Though this mechanism of 
replication is assumed to be a secondary form of replication, evidence of extensive use of 
this model of replication in chicken suggests species specific replication models 




Figure 1.5 mtDNA replication models 
A visual presentation of the 3 models of mtDNA replication described in Section 1.1.7. 
(McKinney and Oliveira, 2013). 
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1.1.8 mtDNA gene expression 
1.1.8.1 Transcription initiation 
Gene expression of mtDNA starts at transcription initiation sites (Montoya et al., 1982). 
TFAM binds to the promoter regions for H-strand transcription (HSP1 and HSP2) and L-
strand transcription (LSP), both located in the D-loop, and recruits the transcription 
complex heterodimer comprised of POLRMT and the mitochondrial transcription factor 
B2 (TFB2M) (Asin-Cayuela and Gustafsson, 2007). TFAM is hypothesised to cause a 
conformational change in mtDNA in order to recruit the transcription complex.  
1.1.8.2 Transcription elongation 
The transition from transcription initiation to elongation occurs when the transcription 
initiation factors TFAM and TFB2M are released from the transcription complex and the 
transcription elongation factor (TEFM) binds to POLRMT forming the transcription 
elongation (antitermination) complex (Minczuk et al., 2011). TEFM has been shown to 
play an important role in stabilising the synthesis and release of nascent RNA and 
facilitates the transcription of almost the whole mitochondrial genome by preventing the 
formation of secondary structures in the RNA during synthesis (Posse et al., 2015; Hillen 
et al., 2018). The transcription complex synthesises mtRNAs until transcription is 
terminated by one of a few uncovered and hypothesised termination mechanisms detailed 
below. 
1.1.8.3 Transcription termination 
The known termination mechanism involves mitochondrial transcription termination 
factor 1 MTERF1 that binds to the 3' end of the tRNA Leu(UUR) gene (MT-TL1) where is 
triggers termination upon interaction with the transcription complex (Kruse et al., 1989; 
Asin-Cayuela and Gustafsson, 2007). This termination site is linked with the transcription 
of mt-rRNAs where transcription initiates at HSP in the D-loop. This termination 
mechanism could result in a higher transcription rate of mt-rRNAs relative to other 
mtRNAs which has been observed in mitochondria (Roberti et al., 2009). The other 
known mechanism is the formation of a hairpin structure in newly synthesised mtRNA 
that interacts with the transcription complex resulting in the release of the transcription 
complex; this was observed in bacteriophages (Byrnes and Garcia-Diaz, 2014). In human 
mitochondria however, a suggested G-quadraplex formation in newly synthesised 
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mtRNA might be a possible mechanism of transcription termination (Wanrooij et al., 
2010).  
1.1.8.4 Transcript processing and maturation 
The result of mtDNA transcription are long polycistronic mtRNA molecules that require 
processing into respective mitochondrial tRNA (mt-tRNA), mitochondrial rRNA (mt-
rRNA), and protein coding mitochondrial mRNA (mt-mRNA) sequences (Figure 1.6) 
(Sanchez et al., 2011; D'Souza and Minczuk, 2018). These newly transcribed 
polycistronic mtRNAs colocalise into foci called mitochondrial RNA granules (MRG) 
where they are processed before their release into the mitochondrial matrix (Iborra et al., 
2004; Jourdain et al., 2016). In the MRGs, the mitochondrial tRNA punctuation model 
dictates that mtRNA are processed by RNase P and ELAC2 endonucleases at specific 
junctions between mtDNA genes resulting in the cleavage of these sites and the formation 
of individual mtRNA transcripts (Ojala et al., 1981). Post-cleavage, the transcripts are 
further modified.  
Transcripts of mt-mRNA are polyadenylated by mitochondrial Poly(A) polymerase 
(mtPAP) (excluding the ND6 transcript) (Slomovic et al., 2005). Leucine rich 
pentatricopeptide repeat containing protein (LRPPRC) and stem-loop interacting RNA-
binding protein (SLIRP) interact to form a complex that maintains and stabilises these 
polyadenylated mt-mRNA transcripts (Sasarman et al., 2010; Ruzzenente et al., 2012). 
Transcripts of mt-tRNA are extensively modified and a CCA trinucleotide is added to its 
3' end by tRNA nucleotidyl transferase 1 (TRNT1) before the binding of its corresponding 
amino acid (Chen et al., 1992; Nagaike et al., 2001). Thereafter, various positional 
modifications to the mt-tRNAs are carried out by an array of enzymes such as ABH1 and 
NSUN3 (Haag et al., 2016), MTO1 and GTPBP3 (Asano et al., 2018), MTU1 (Wu et al., 
2016b), TRIT1 (Yarham et al., 2014), TRMT5 (Powell et al., 2015), and PUS1 (Patton 
et al., 2005). The removal of poly(A) tails from the 3’ end of mt-tRNAs is performed by 
the 3’-5’ exonuclease PDE12 (2’ phosphodiesterase) (Pearce et al., 2017).  
After all the modifications have taken place, the mt-tRNAs need to be charged with their 
cognate amino acids. This is carried about by aminoacyl-tRNA synthetases (aaRS) of 
which most are unique to mitochondria (aaRS2) (Sissler et al., 2017). However, some are 
shared with the cytoplasmic pathways such as Glycyl-tRNA synthetase (GARS) (Chihara 
et al., 2007) and Lysyl-tRNA synthetase (KARS) (Tolkunova et al., 2000). Interestingly, 
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the charging of mt-tRNAGln takes place indirectly via the mitochondrial glutamyl-tRNA 
synthetase (EARS2) by charging it with a glutamate amino acid forming Glu-mt-tRNAGln, 
and then the glutamate is transamidated into Gln-mt-tRNAGln by the glutamyl-tRNAGln 
amidotransferase protein complex (GatCAB) (Nagao et al., 2009; Echevarría et al., 
2014).  
The mitochondrial 12S rRNA and 16S rRNAs transcripts undergo nucleotide 
modifications at several residues before their incorporation into the 28S small 
mitochondrial ribosomal subunit and 39S large mitochondrial ribosomal subunit 
respectively; these subunits bind to form the 55S mitoribosome (O'Brien, 1971; Gerber 
et al., 2017). These modifications are carried out by methyltransferases; NSUN4 and 
mitochondrial transcription factor 1B (TFB1M) modify 12S rRNA and TRMT61B, 
MRM1, MRM2, and MRM3 modify 16S rRNA while RPUSD4 carries out 
pseudouridylation of 16S rRNA (Metodiev et al., 2009; Lee et al., 2013; Metodiev et al., 
2014; Rorbach et al., 2014; Bar-Yaacov et al., 2016; Zaganelli et al., 2017). The fas-
activated serine threonine kinase domain 2 protein (FASTKD2) plays an essential role in 
the stability of the 16S rRNA and it plays a role in the assembly of the large ribosomal 
subunit (Antonicka and Shoubridge, 2015; Popow et al., 2015). Finally, the degradation 
of mtRNA is mediated by a complex formed by 2 proteins, polynucleotide phosphorylase 





Figure 1.6 Transcription of the mitochondrial genome 
A flow diagram outlining the various stages of mtDNA transcription, processing, and 
role in mitochondrial translation. The pathways and highlighted proteins involved are 
described in detail in Section 1.1.8. The transcription initiation pathway is described in 
Section 1.1.8.1, the transcription elongation pathway is described in Section 1.1.8.2, 
and the transcript processing and maturation pathway is described in Section 1.1.8.4. 
(Adapted from (D'Souza and Minczuk, 2018)). 
 
 
1.1.8.5 Mitoribosome structure  
The human mitoribosome is a 55S RNA-protein complex that is comprised of a 39S large 
subunit (mtLSU), a 28S small subunit (mtSSU), and 3 mtRNA molecules: the 16S rRNA, 
12S RNA and mt-tRNAVal (Amunts et al., 2015). By utilising cryo electron microscopy 
(cryo-EM), studies have determined that the mtLSU is comprised of 48 mitochondrial 
ribosomal protein subunits (MRPs) of which 21 are specific to mitochondria, and the 
mtSSU is comprised of 30 MRPs of which 14 are specific to mitochondria (Brown et al., 
2014; Amunts et al., 2015). In contrast to bacterial ribosomes, mammalian mitoribosomes 
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have a lower RNA:protein ratio where RNAs were replaced by 36 proteins specific to the 
mitoribosome (Greber et al., 2015; D'Souza and Minczuk, 2018). The assembly of the 
mitoribosome involves non-ribosomal proteins that act as assembly factors; these proteins 
include RNA modification enzymes, RNA chaperones, guanosine triphosphatases, 
DEAD-box RNA helicases, and kinases (Dennerlein et al., 2010; De Silva et al., 2013; 
Janer et al., 2015; Kim and Barrientos, 2018; Maiti et al., 2018; Fontanesi et al., 2020).  
1.1.8.6 Translation 
The translation process can be broken down into 3 steps; initiation, elongation and 
termination (Figure 1.7) (Smits et al., 2010). Proteins required for this process to be 
carried out including translation factors for the sequential steps, MRPs, and mt-tRNA 
synthetases are all nuclear encoded. Prior to the initiation of translation, mitochondrial 
methionyl-tRNA formyltransferase (MTFMT) formylate a portion of the met-tRNAMet in 
the mitochondria to form N-formylmethionine-tRNAMet (fMet-tRNAMet) which is used to 
initiate translation (Tucker et al., 2011). Mitochondrial translation factor mtIF3 binds to 
mtSSU and prepares for the initiation of mt-mRNA translation (Koc and Spremulli, 
2002). The initial formylated methionyl-tRNA binds to the mt-mRNA transcript with the 
assistance of GTP bound mitochondrial translation initiation factor 2 (mtIF2). This 
facilitates the release of mtIF3 while GTP hydrolysis on mtIF2 triggers its release and the 
mtLSU binds to the initiation complex forming the mitoribosome. The elongation of the 
polypeptide follows with the binding of the elongation factor Tu (mtEFTu) complex 
containing aminoacylated tRNA and GTP (Cai et al., 2000). Upon the complex's entry 
into the acceptor (A) site and the verification of codon-anticodon pairing, GTP hydrolysis 
releases the mtEFTu·GDP component of the complex. The mtEFTu·GDP is converted 
back to mtEFTu·GTP by the nucleotide exchange protein elongation factor Ts (mtEFTs) 
allowing for the formation of a new bond with a new aminoacylated tRNA. The peptide 
chain residues are translocated from the acceptor (A) and Peptide (P) sites to the P and 
Exit (E) sites by GTP hydrolysis of the elongation factor G1 (mtEFG1)·GTP resulting in 
the release of the tRNA bound to the peptide residue in the E site allowing a new 
elongation step to commence (Bhargava et al., 2004). Translation terminates when the 
mitochondrial release factor 1a (mtRF1a)·GTP recognises the stop codon, binds to the A 
site and catalyses the release of the newly formed polypeptide using GTP hydrolysis and 
dissociates from the mitoribosome (Soleimanpour-Lichaei et al., 2007). The dissociation 
of the mitoribosome into its subunits is catalysed by mitochondrial recycling factor 
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(mtRRF) and elongation factor G2 (mtEFG2)·GTP (Rorbach et al., 2008; Tsuboi et al., 
2009).  
It is key to note that mt-mRNA transcripts utilise a modified codon system than that used 
by nuclear mRNA transcripts. Compared to cytosolic translation, in mitochondrial 
translation AUA codes for an initiation methionine instead of isoleucine, AGG and AGG 
code for stop codons instead of arginine, and UGA codes for tryptophan instead of a stop 




Figure 1.7 Translation of mitochondrial mRNA  
Pathway outlining the translation of mt-mRNA in the mitochondria. Molecule 
abbreviations are referenced in Section 1.1.8.6. (Smits et al., 2010).  
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1.1.9 Mitochondrial protein import 
Since most of the mitochondrial proteome is encoded by nDNA and synthesised in the 
cytosol, protein import mechanisms are essential to ensure the translocation of these 
proteins to their destination in the mitochondria. The mitochondrial double membrane 
houses import machinery that imports mitochondrial proteins from the cytosol to the 
mitochondria via a number of pathways. It is important to note that the majority of 
research on mitochondrial protein import has been performed in yeast (Kang et al., 2018). 
Incoming proteins initially interact with the translocases of the outer membrane (TOM) 
complex. It consists of receptor subunits Tom20 and Tom22 that form a subcomplex that 
recognises cleavable N-terminus presequences; the Tom70 receptor subunit that 
recognises hydrophobic internal targeting sequences; the general import pore Tom40 
which is a transmembrane beta-barrel channel; and the small proteins Tom5, Tom6 and 
Tom7 that modulate the binding of the receptor subunits to Tom40 (Alconada et al., 1995; 
Pfanner et al., 1996; Dietmeier et al., 1997). The Tom70 receptor initiates the importation 
of the precursor protein through an ATP-dependent pathway while the Tom20-Tom22 
receptor subcomplex does not.  
The mitochondrial import stimulation factor (MSF) and the heat shock protein Hsp70 are 
important cytoplasmic chaperones that recognise signal sequences on newly synthesised 
mitochondrial precursor proteins (preproteins), maintain the protein in an unfolded state 
and guide them to the Tom-Tim complexes for importation into the mitochondrial matrix 
(Mihara and Omura, 1996). The MSF directs protein import by interacting with the 
Tom70 receptor subunit and an ATP-dependent step transfers the preprotein to the 
Tom22-Tom20 receptor subcomplex before translocation through the OMM; MSF directs 
the import of mitochondrial preproteins in the presence or absence of a signal sequence 
such as the case with importing the OMM transmembrane protein VDAC (Pfanner and 
Meijer, 1997). The Hsp70 chaperone guides preproteins to the Tom22-Tom20 receptor 
subcomplex in a non-ATP-dependent pathway.  
Preproteins are generally processed through one of 4 main pathways depending on the 
intended destination of the protein (Figure 1.8) (Wiedemann and Pfanner, 2017).  
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1.1.9.1 Matrix proteins 
Preproteins destined to be localised in the mitochondrial matrix pass through the 
translocase of the inner membrane (TIM) complex TIM23 (Neupert and Herrmann, 
2007). The complex is comprised of nine subunits of which 4 are membrane sectors 
(Tim50, Tim23, Tim22, and Tim17) and 5 are import motors (Tim44, Tim16, Tim14, 
mtHsp70 and Mge1). Mitochondrial 70 kDa heat shock protein (mtHsp70) is a chaperone 
localised in the matrix that binds to Tim44 with the assistance of the co-chaperone Mge1; 
the mtHsp70-Tim44 subcomplex directs preprotein translocation by binding to the 
imported polypeptide and pulling the preprotein through while maintaining it in an 
unfolded state on either side of the mitochondrial double membranes (Schneider et al., 
1996; Pfanner and Meijer, 1997). The mtHsp70 is then released from Tim44 and a new 
mtHsp70 binds to continue the process of protein translocation. The mitochondrial 
processing peptidase (MPP) cleaves off the N-terminal presequence after the protein is 
released into the matrix (Gakh et al., 2002). The membrane potential across the IMM is 
a necessary driving force in mitochondrial protein translocation but is not driven 
exclusively by the proton motive force since the amino terminal of the preprotein is 
positively charged and the matrix contains the negatively charged side of the membrane 
potential (Martin et al., 1991). 
1.1.9.2 Outer membrane transmembrane proteins 
Preproteins destined to form OMM beta-barrel transmembrane proteins contain a 
sequence motif recognised by the small Tim9-Tim10 chaperone complex that escort the 
protein to the sorting and assembly machinery (SAM) where they are inserted into the 
OMM (Höhr et al., 2015). SAM is comprised of the 3 core subunits Sam50, Sam37 and 
Sam35. Sam50 forms a beta-barrel and its N-terminus contains the polypeptide transport-
associated domain while the Sam35 and Sam37 subunits both face the cytosolic side of 
the OMM where Sam35 is a beta-signal receptor and Sam37 stabilises the SAM complex 
while assisting in the release of newly formed beta-barrel proteins. 
Some outer membrane preproteins containing only a single transmembrane domain are 
inserted into the OMM by the mitochondrial import complex (MIM) (Straub et al., 2016). 
1.1.9.3 Inner membrane transmembrane proteins 
Preproteins destined to localise to the IMM can be processed through 3 possible pathways 
(Höhr et al., 2015). The first is by inserting the protein into the IMM by the TIM22 
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complex which inserts proteins with multiple transmembrane domains. The second 
pathway inserts proteins with single membrane spanning domains into the IMM through 
the stop of protein translocation midway through the TIM23 complex followed by the 
insertion into the IMM. The final pathway involves the complete importing of the 
preprotein into the matrix where it is then inserted into the IMM via the oxidase assembly 
protein Oxa1.  
1.1.9.4 Intermembrane space proteins 
Preproteins destined to localisation in the IMS are processed in various possible 
pathways. One possible pathway takes place after translocation through the TOM 
complex where the mitochondrial IMS import and assembly (MIA) machinery (which is 
anchored to the IMM) reacts with the protein to form disulphide bonds via its core 
component Mia40 (Straub et al., 2016). Some IMM embedded proteins are bipartite 
proteins that have a cleavage site on the domain extending into the IMS; cleaving that site 




Figure 1.8 Import pathways of nuclear encoded mitochondrial proteins 
The 4 main pathways of mitochondrial protein import are highlighted in this diagram: 
Mitochondrial matrix proteins (brown pathway) are recognised by the mitochondrial 
targeting sequence (presequence) and imported through the Tom-Tim complexes into 
the mitochondrial matrix where MPP finally cleaves the presequence. 
OMM proteins destined to be beta-barrel proteins (red pathway) are imported through 
the TOM complex and guided by the Tim9-Tim10 chaperone complex to the SAM 
complex which insert it into the OMM. Some OMM proteins are inserted into by the 
MIM complex (pink pathway).  
Proteins destined to be IMM proteins (green pathway) are imported through the TOM 
complex and guided by the Tim9-Tim10 chaperone complex to the TIM22 complex 
which insert it into the IMM.  
IMS proteins (blue pathway) are imported through the TOM complex and guided by the 
MIA machinery and released into the IMS. 
(Wiedemann and Pfanner, 2017)  
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 Mitochondrial functions 
1.2.1 Metabolic pathways 
Mitochondria house metabolic pathways that reduce Nicotinamide Adenine Dinucleotide 
(NAD) and Flavin Adenine Dinucleotide (FAD) that donate their electrons to the ETC. 
This results in the pumping of protons from the matrix across the IMM into the IMS 
maintaining a proton gradient that it utilised by complex V to generate the cell's energy 
currency, ATP (Figure 1.9). 
Glycolysis takes place in the cytosol resulting in the generation of pyruvate which is 
imported into the mitochondrial matrix via membrane channels mitochondria pyruvate 
carriers MPC1 and MPC2 (Bricker et al., 2012). The pyruvate dehydrogenase complex 
(PDHc) converts pyruvate to acetyl-CoA. Three subunits (E1, E2 and E3) bind to form 
the PDHc which is regulated by a pair of phosphatases and a group of kinases that activate 
and inactivate PDHc respectively (Patel et al., 2014). Regulation is governed by a 
feedback loop that inactivates PDHc in the presence of high levels of acetyl-CoA and 
activates it in the presence of high levels of pyruvate. 
In the mitochondrial matrix, the tricarboxylic acid cycle (TCA cycle) utilises acetyl-CoA 
to generate NADH and FADH2 which donate their electrons to the inner membrane bound 
ETC complexes (Martínez-Reyes and Chandel, 2020). The matrix also houses the 
proteins responsible for fatty acid oxidation which breaks down fats into multiple acetyl-
CoA metabolites (Houten et al., 2016). 
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Figure 1.9 Metabolic pathways in the mitochondria 
A scheme illustrating the conversion of glucose into pyruvate which is imported into the 
mitochondrial and converted into Acetyl CoA via pyruvate dehydrogenase (blue 
molecule. Fatty acids (Fatty Acyl CoA) are broken down to Acetyl CoA within the 
mitochondrial matrix. Acetyl CoA enters the tricarboxylic acid cycle (TCA cycle) that 
results in the reduction of NAD+ to NADH and FAD into FADH2; these reduction 
reactions also take place in the fatty acid oxidation cycle. Reduced NADH and FADH2 
transfer their electron to the OXPHOS complexes I and II and the maintained proton 




1.2.2 OXPHOS complexes 
1.2.2.1 Complex I – NADH:ubiquinone oxidoreductase 
Mammalian NADH:ubiquinone oxidoreductase (Complex I), the largest of the respiratory 
chain complexes, plays a crucial role in the respiratory chain by maintaining the proton 
gradient across the mitochondrial inner membrane; it couples the transfer of 2 electrons 
from NADH through its subunits to ubiquinone (CoQ10) with the translocation of four 
protons from the mitochondrial matrix to the mitochondrial intermembrane space (Agip 
et al., 2018).  
The complex I multimeric protein is comprised of 44 different subunits encoded by both 
nuclear and mitochondrial genomes (Carroll et al., 2006; Balsa et al., 2012). Fourteen of 
the subunits are core conserved subunits which the mitochondrial genome encodes seven 
hydrophobic of these core subunits; the remaining subunits are encoded by the nuclear 
genome including hydrophilic subunits housing all the redox driving groups, one flavin 
mononucleotide (FMN) and eight iron-sulphur clusters (Vinothkumar et al., 2014; Wirth 
et al., 2016). The 30 accessory subunits play important roles in iron-sulphur cluster 
cofactor binding and protein assembly and stability. 13 assembly factors required for 
complex I assembly are also encoded in the nuclear genome (Sánchez-Caballero et al., 
2016). 
Electrons are transferred from reduced NADH to the FMN cofactor bound to ND1 (one 
of mitochondrial encoded core subunits) where it is then passed through 7 iron sulphur 
clusters and finally to a ubiquinone binding site where CoQ10 (Q) is reduced to ubiquinol 
(QH2) (Figure 1.10) (Friedrich, 2014). The conformational change at the ubiquinone 
binding site induces an electrostatic pulse that stimulates the translocation of protons 
through 3 mitochondrial-encoded antiporter subunits (ND2, ND4, and ND5) in addition 
to a fourth pathway found between subunits ND2 and ND4L (Wirth et al., 2016). The 
overall reaction that takes place in complex I is as follows: 




Figure 1.10 NADH:ubiquinone oxidoreductase 
Structural representation of NADH:ubiquinone oxidoreductase highlighting the electron 
transport pathway through complex I. FMN catalyses the oxidation of NADH to NAD 
then the acquired electrons travel through a chain of iron-sulphur clusters (red and 
yellow) and finally reduce a ubiquinone molecule (Q) to ubiquinol (QH2). The transport 
of electrons results in a conformational change in the membrane domain of the complex 
resulting in the active transport of protons from the matrix into the IMS. IMM: 
mitochondrial inner membrane; IMS: mitochondrial intermembrane space. 
 
 
1.2.2.2 Complex II - Succinate:ubiquinone oxidoreductase 
Succinate:ubiquinone oxidoreductase (Complex II) is an oligomer comprised of 4 nuclear 
encoded subunits (SDHA, SDHB. SDHC and SDHD) and 4 identified assembly factors 
(SDHAF1, SDHAF2, SDHAF3 and SDHAF4) are required for its assembly (Figure 1.11) 
(Rutter et al., 2010; Bezawork-Geleta et al., 2017). Complex II is the only ETC complex 
that plays an additional metabolic role in mitochondria; it catalyses the oxidation of 
succinate to fumarate in the Kreb's cycle pathway reducing a covalently attached FAD to 
its reduced form which is then oxidised and its pair of electrons are passed through a chain 
of iron-sulphur clusters within it ending up in one of two ubiquinone binding sites 
(Cecchini, 2003). The overall reaction that takes place in complex II is as follows: 
Succinate + Q ® Fumarate + QH2 
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Figure 1.11 Succinate:ubiquinone oxidoreductase 
Structural representation of Succinate:ubiquinone oxidoreductase highlighting the 
passage of electrons through complex II. Electrons from succinate reduce FAD to 
FADH2 and then pass through a series of iron-sulphur clusters and finally reduce 
ubiquinone (Q) to ubiquinol (QH2). A heme molecule (green) is found as part of the 
SDHC and SDHD structure but no clear molecular pathway has been deduced thus far. 
 
 
1.2.2.3 Coenzyme Q10 
In humans, CoQ10 is a benzoquinone ring with a polyisoprenoid side chain containing 
10 isoprene units (CoQ10) that resides within the inner mitochondrial membrane 
(Alcazar-Fabra et al., 2016). Synthesis of CoQ10 takes place in the inner mitochondrial 
membrane through the mevalonate pathway and the benzoquinone ring is later modified 
by a series of reactions (Bentinger et al., 2010). CoQ10 is an electron carrier that receives 
electrons from a number of sources most notably complex I and complex II of the 
mitochondrial respiratory chain and transfers them to complex III. The full reduction of 
CoQ10 requires 2 electrons, but upon stepwise reduction with a single electron, an 
intermediate semiquinone is formed that contains a free radical (Crofts et al., 2017). 
1.2.2.4 Complex III – Ubiquinol:cytochrome c reductase 
Ubiquinol:cytochrome c oxidoreductase (Complex III) is a transmembrane protein 
embedded in the mitochondrial inner membrane. It is a multiheteromeric protein 
composed of 11 subunits which all but one subunit are encoded in the nuclear genome; 
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the assembled complex forms a dimer which is the final functioning protein complex 
(Fernández-Vizarra and Zeviani, 2015). Redox cofactors are bound to 3 of these subunits; 
the function of the remaining 8 subunits is still being investigated. Six nuclear encoded 
assembly factors are required for the construction of complex III.  
In the Q cycle, complex III receives electrons from reduced CoQ10 (QH2) which it 
initially gained from complex I or complex II. Complex III transfers 2 electrons through 
its redox cofactors to cytochrome c (Cyt-c), which is also found in the IMS (Figure 1.12) 
(Trumpower and Gennis, 1994; Berry et al., 2000). This process is coupled with the 
pumping of protons from the matrix to the IMS to maintain the proton gradient utilised 
by complex V to produce ATP. The overall reaction that takes place in complex III is as 
follows: 
2QH2 + Q + 2 Cyt coxidised + 2H+matrix ® 2Q + QH2 + 2 Cyt creduced + 4H+IMS 
 
 
Figure 1.12 Ubiquinol:cytochrome c reductase 
Structural representation of ubiquinol:cytochrome c reductase highlighting the passage 
of electrons through complex III. At the quinone-binding site Qo site, 2 ubiquinol are 
oxidised to ubiquinone and the electrons then pass through 2 pathways that are part of 
the Q-cycle. The first pathway shows the passage of electrons through an iron-sulphur 
cluster to cytochrome c1 (c1) which in turn reduces cytochrome c (Cyt c). The other 
pathway shows the passage of electrons through 2 heme molecules, heme BL (BL) and 
Heme BH (BH), to the other quinone-binding site Qi site where ubiquinol is regenerated 
by reducing ubiquinone. The overall rection results in the translocation of protons from 
the matrix to the IMS. 
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1.2.2.5 Cytochrome c 
Cytochrome c (Cyt-c) is mitochondrial protein containing the iron cofactor heme c that 
localises in the IMS (Ow et al., 2008). It plays an important role in electron transport 
since its major role is the transfer of electron from complex III to complex IV of the 
mitochondrial respiratory chain (Chertkova et al., 2017). However, it also plays an 
important role in apoptosis via its release into the cytoplasm due to a death signalling 
cascade that results in the activation of caspases and the formation of apoptosomes 
(Goldstein et al., 2000). 
1.2.2.6 Complex IV – Cytochrome c oxidase 
Cytochrome c oxidase (Complex IV) is the terminal transmembrane protein in the ETC 
where electrons are transferred to the terminal electron acceptor, oxygen, to form water 
(Michel et al., 1998). The protein complex is composed of 13 subunits; the 3 core catalytic 
subunits – MTCO1, MTCO2, and MTCO3 – are encoded by mtDNA and the remaining 
10 subunits are encoded in nDNA (Kadenbach and Hüttemann, 2015). Complex IV 
assembly requires over 20 nuclear encoded accessory factors and additional ancillary 
proteins play an important role in the incorporation of cofactors including 3 copper ions, 
2 heme moieties, and magnesium, sodium and zinc ions (Carr and Winge, 2003). 
Complex IV is an oligomeric protein that can also form a dimer with itself forming a 
larger complex (Carr and Winge, 2003).  
Complex IV couples the transfer of electrons from Cyt-c to molecular oxygen with the 
translocation of protons from the matrix into the IMS with a ratio of 1 proton translocated 
for every electron transferred to the terminal electron acceptor oxygen (Figure 1.13). The 
overall reaction that takes place in complex IV is as follows: 




Figure 1.13 Cytochrome c oxidase 
Structural representation of cytochrome c oxidase highlighting the passage of electrons 
through complex IV. Copper centre CuA catalyses the oxidation of cytochrome c, then 
the electrons pass through Heme a to a Heme a3/CuB centre that catalyses the reduction 
of oxygen (O2) into water (H2O). 
 
 
1.2.2.7 Complex V – ATP synthase 
ATP synthase (complex V) is a transmembrane protein that localised in the IMM that 
utilises the proton motive force, generated and maintained by the ETC, to bind inorganic 
phosphate (Pi) to adenosine diphosphate (ADP) and forming ATP. The protein consists 
of 2 sectors; the FO sector that is embedded within the IMM and the F1 sector that 
protrudes out of the IMM into the matrix (Figure 1.14). The FO sector is comprised of a 
c-ring subunit that is formed by 8 copies of the c subunit, a stalk formed by a single copy 
of subunits a, b, d, F6 and an oligomycin sensitive-conferring protein (OSCP) bound to 
the end of the stalk (Jonckheere et al., 2012). Subunits e, f, g and A6L are membrane 
proteins associated with the F0 sector. The F1 sector is formed of 3 copies of α and β 
subunits wrapped around a central stalk comprised of the subunits γ, δ and ε. Subunits a 
and A6L are encoded in the mitochondrial genes ATP6 and ATP8 respectively while the 
rest of the subunits are nuclear encoded. The assembly of the F1 sector requires the ATP 
synthase assembly factors 1 and 2 (ATPAF1 and ATPAF2), and the assembly of the 
complex as a whole requires the presence of transmembrane protein 70 (TMEM70) 
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(Cizkova et al., 2008). Complex V utilises the proton motive force to drive the rotation 
of the γ subunit resulting in conformational changes in the α and β subunits that have 
ADP and Pi bound to them. The conformational changes result in the formation and 
release of 3 ATPs per full rotation. 
 
 
Figure 1.14 Structure of ATP synthase 
Structural composition of ATP synthase and a summarized depiction of the reaction that 






Complexes I, III and IV can bind together within the IMM to form supercomplexes or 
respirasomes that consist of a single complex I heteromer, a complex III dimer and a 
complex IV heteromer (Figure 1.15) (Cogliati et al., 2016). Supernumerary and 
accessory subunits of these complexes participate in the formation of bonds between the 
complexes (Wu et al., 2016a). In addition, the replacement of certain subunits of these 
respiratory chain complexes participate in the binding between complexes such as the 
substitution of complex IV subunit COX7A2 with the supercomplex assembly factor 1 
(SCAF1) resulting in the formation of the III2+IV supercomplex (Wu et al., 2016a). 




Figure 1.15 OXPHOS Supercomplexes 
Configuration of OXPHOS complexes CI, CIII and CIV within the structure of a 
respirasome. (Adapted from (Wu et al., 2016a)) 
 
 
1.2.2.9 Reactive Oxygen Species production 
Reactive oxygen species (ROS) are a group of oxygen-based molecules carrying electron 
radicals as a product of the redox reactions that take place in the mitochondrial respiratory 
chain (Ray et al., 2012). These molecules cause oxidative damage to DNA and cellular 
structures such as proteins by reacting with sulphur containing residues such as cysteine 
and altering the structure of the protein. The cell expresses ROS neutralising proteins such 
as superoxide dismutase (SOD) and a mitochondrial specific superoxide dismutase 
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(MnSOD) to reduce the rate of such damaging reactions (Murphy, 2009). ROS also play 
a role in cellular signalling mediating apoptosis, autophagy, inflammatory responses and 
mitochondrial dynamics (Bolisetty and Jaimes, 2013). 
1.2.3 Other mitochondrial functions 
1.2.3.1 Apoptosis 
Apoptosis is the process of programmed cell death that is initiated by two main pathways, 
an intrinsic and an extrinsic pathway, in addition to a third known pathway (Ashe and 
Berry, 2003; Elmore, 2007). The extrinsic pathway involves the tumour necrosis factor 
receptor (TNFR) superfamily of proteins, which are plasma membrane proteins, initiating 
a reaction cascade leading to apoptosis. The intrinsic pathway involves the mitochondrial 
bound B-cell lymphoma-2 (BCL-2) family of proteins that regulate apoptosis via 
inhibition and induction pathways. Apoptosis is triggered by signals such as oxidative 
stress, Ca2+ concentration overload, ER stress and DNA damage resulting in the release 
of apoptosis promoting factors from the IMS to the cytosol (Martinou, 1999; 
Vakifahmetoglu-Norberg et al., 2017). Death-promoting factors include Cyt-c, AIF 
(Apoptosis-Inducing Factor) EndoG (Endonuclease G), SMAC/DIABLO (Second 
Mitochondria-derived Activator of Caspases/ Direct IAP [inhibitor of apoptosis]) Binding 
mitochondrial protein) and HTRA2 (HtrA Serine Peptidase 2). Their release into the 
cytosol triggers a cascade reaction leading to the activation of caspases (a family of 
proteases) while AIF and EndoG translocate via independent pathways to the nucleus and 
induce DNA fragmentation and chromatin condensation hence leading to apoptosis 
(Elmore, 2007; Kilbride and Prehn, 2013; Vakifahmetoglu-Norberg et al., 2017). 
1.2.3.2 Mitochondrial Autophagy (Mitophagy) 
Mitochondrial autophagy (mitophagy) degrades damaged mitochondria to maintain a 
functioning mitochondrial network and reduce the effects of oxidative stress caused by 
ROS and reduce the rate of apoptosis which is also triggered by mitochondrial 
dysfunction due to stress and damage (Grosso et al., 2017). PTEN -inducible putative 
kinase 1 (Pink1) is continuously imported into the matrix and digested by mitochondrial 
proteases; but upon membrane depolarisation Pink1 is not imported and degraded 
resulting in its accumulation at the OMM (Saito and Sadoshima, 2015). Pink1 recruits 
and phosphorylates MFN2 which in turn binds a (Parkin) resulting in a cascade reaction 
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triggering the mitophagy process leading to the degradation of the depolarised 
mitochondria.  
1.2.3.3 Calcium Homeostasis 
Calcium handling is crucial for the regulation of cellular metabolism, signalling cell 
proliferation and initiating apoptotic cascades (Contreras et al., 2010). The fluctuation in 
calcium concentration is influenced by the activity of calcium channelling transmembrane 
proteins found in the plasma membrane and membranes of cell organelles including 
mitochondria. Low calcium concentrations in the mitochondria lead to a reduction of ATP 
synthesis while a surge in calcium concentration in the matrix opens the mitochondrial 
permeability transition pore resulting in the release of apoptosis inducing factors and 
therefore cell death (Contreras et al., 2010; Shao et al., 2016). Calcium uptake, which is 
driven by the membrane potential, is mediated by mitochondrial calcium uniporter (mCU) 
and its homologs along with Ca2+/H+ antiporters and numerous other calcium channels 
(Duchen, 2000).  
1.2.3.4 Iron-Sulphur and Heme Cluster Biogenesis 
Iron-sulphur clusters (ISC) are protein cofactors that play important roles in the 
mitochondrial, cytosolic and nuclear protein activity such as electron transport, reaction 
catalysis, sulphur activation, iron homeostasis, and nuclear protein activity including 
DNA synthesis, repair and telomere maintenance (Stehling and Lill, 2013; Stehling et al., 
2014).  
ISC biosynthesis takes place in the mitochondrial matrix and involves approximately 30 
proteins found both in the mitochondria and the cytosol (Stehling and Lill, 2013). The 
ISC assembly machinery involves 17 proteins (Stehling et al., 2014). Ferrous iron is 
initially imported into the mitochondria via a proton motive force driven mechanism 
involving the mitochondrial solute carriers mitoferrin 1 and 2 (MFRN1 and MFRN2) 
(Stehling et al., 2014). Cysteine desulphurase (Nfs1-Isd11) catalyses the transformation 
of cysteine to alanine and retains the sulphate. Frataxin (Yfh) acts as a in iron donor, since 
free iron is not found in the cell, donating it iron to the cysteine desulphurase complex 
(Lill, 2009). An electron is donated to the process by a reaction involving ferridoxin 
reductase (Arh1) and ferridoxin (Yah1) leading to the formation of a [2Fe-2S] cluster on 
the scaffold protein Isu1. The newly formed iron-sulphur cluster is released from the 
scaffold and is chaperoned by a number of proteins including the gluteradoxin GLRX5 
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to either its apoprotein destination or exported into the cytosol via the Atm1 (an ABC 
transported) to be incorporated into cytosolic proteins through the Cytosolic Iron-sulphur 
protein Assembly (CIA) machinery (Stehling and Lill, 2013). In the mitochondria, Fe-S 
clusters are inserted into their target proteins by the assembly proteins Isa1, Isa2 and Iba57 
converting the target protein from an apoprotein to a holoprotein (Lill, 2009). These 3 
proteins (ISCA1, ISCA2 and IBA57) play a critical role in the maturation of [4Fe-4S] 
clusters (Sheftel et al., 2012). 
Heme is another iron containing protein cofactor that catalyses redox reaction and acts as 
an electron carrier in iron incorporating proteins such as haemoglobin, myoglobin and 
cytochromes (Ajioka et al., 2006). Heme consists of an iron molecule surrounded by 4 
pyrroles (tetrapyrrole); Ferrachelatase catalyses the insertion of a ferrous iron molecule 
into the tetrapyrrole containing molecule protoporphyrin IX resulting in the formation of 
the heme cofactor. The pathway of heme biosynthesis involves proteins localised in both 
the mitochondrial compartments and cytosol where the synthesis process initiates in the 
mitochondria, progresses in the cytosol and finally returns to the mitochondria where the 
formation of heme is completed (Hamza and Dailey, 2012). 
 Mitochondrial disorders 
As discussed throughout this introduction, mitochondria play a role in many important 
cellular functions and there are hundreds of nuclear genes involved in these functions, 
including the expression of the mtDNA encoded subunits, the import of mitochondrial 
bound proteins, apoptosis, and iron-sulphur and heme cluster biosynthesis. As a 
consequence, the term mitochondrial disorder is an umbrella term for many different 
pathologies of mitochondrial dysfunction with high morbidity and mortality that present 
with a wide array of symptoms affecting multiple systems (Stenton and Prokisch, 2020; 
Thompson et al., 2020a). 
1.3.1 Clinical features of mitochondrial disease 
Clinical syndromes that were later categorised as mitochondrial disorders have been 
described since the 1800s. Theodore Leber described patients with visual loss as a 
consequence of optic nerve involvement (Leber, 1871; Yu-Wai-Man et al., 2002); Denis 
Leigh described patients with "subacute necrotizing encephalopathy" who presented with 
neurodegenerative and ophthalmological symptoms with the possible involvement of the 
heart, liver, kidneys or gastrointestinal tract (Leigh, 1951); and Kearns and Sayre detailed 
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patients with chronic progressive external ophthalmoplegia (CPEO), retinitis pigmentosa 
(RP), and cardiomyopathy frequently accompanied by small stature, progressive 
weakness of facial, pharyngeal and peripheral muscles, deafness, abnormal 
Electroencephalogram (EEG) and increased proteins in the cerebrospinal fluid (CSF) 
(Kearns and Sayre, 1958; Kearns, 1965). These phenotypes were named Leber Hereditary 
Optic Neuropathy (LHON), Leigh syndrome (LS) and Kearns-Sayre syndrome (KSS) 
respectively. Myoclonic epilepsy with ragged red fibres (MERRF) and mitochondrial 
encephalopathy, lactic acidosis and stroke-like episodes (MELAS) are two other clinical 
syndromes that were described as mitochondrial disorders (Fukuhara et al., 1980; 
Pavlakis et al., 1984). Many other syndromes with various symptoms were later added to 
the collective list of mitochondrial disorders. 
The prevalence of mitochondrial disorders is estimated to be at least 6.2/100,000 for 
paediatric cases and adult mitochondrial cases are more than 1/4,300 (Chinnery et al., 
2000; Skladal et al., 2003; Schaefer et al., 2004; Gorman et al., 2015). 
Mitochondrial disorders are heterogeneous in their clinical presentations meaning a single 
deleterious mutation can lead to varying symptoms even among siblings harbouring the 
same variant. Disease might present with a single organ affected or it might be multi-
systemic in its presentation. Mitochondrial disorders can result in symptoms affecting the 
ophthalmologic system resulting in CPEO, RP, nystagmus, ptosis, or visual acuity; or it 
can affect the auditory system leading to hearing impairment or loss (Gorman et al., 
2016). Most notably, neurological and brain symptoms can develop in patients resulting 
in a variety of symptoms including delay in psychomotor development, stroke-like 
episodes, seizures, myoclonus, ataxia, and encephalopathy with MRI and CT scan 
findings that include lesions and hyperintense signals in the brain along with abnormal 
EEG. Muscle fatigue and weakness are also prominent phenotypes of mitochondrial 
disorders that could present as hypotonia, ataxia or dysphagia among other presentations 
(Munnich et al., 1996). Cardiac symptoms have been observed in mitochondrial disorder 
patients with left ventricular hypertrophy as a key finding in an echocardiogram (Meyers 
et al., 2013).  
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1.3.2 Biochemical investigations and findings in mitochondrial disease 
1.3.2.1 Biomarkers of mitochondrial disease 
Certain metabolites involved in mitochondrial pathways are biomarkers that can be 
measured to help determine if mitochondrial disease is suspected in a patient (Boenzi and 
Diodato, 2018). Due to the absence of a reliable single biomarker to suggest 
mitochondrial disease, various biomarker findings are considered by physicians during 
this process . For example, elevated lactate levels in the blood and CSF are indicators of 
metabolic stress suggesting mitochondrial dysfunction (Robinson, 2006). Brain magnetic 
resonance spectrometry (MRS) might find elevated levels of lactate and lactate/creatine 
ratios in the brain also(Lunsing et al., 2017). Accompanying some hypotonic symptoms 
might be elevated levels of creatine kinase (CK). Other biomarkers measured in 
association with mitochondrial disease include serum pyruvate levels, serum and urinary 
amino acids, urinary organic acids, and acylcarnitines (Shaham et al., 2010; Boenzi and 
Diodato, 2018).  
Fibroblast growth factor 21 (FGF-21) is a hormone that regulates metabolism and 
increased serum levels have been observed in obese individuals (Dushay et al., 2010), in 
individuals who ingest fructose (Dushay et al., 2015), in patients with non-fatty acid liver 
disease (NAFLD) (Li et al., 2010), and in mitochondrial patients with muscle 
involvement (Davis et al., 2013; Fisher and Maratos-Flier, 2016). Growth differentiation 
factor 15 (GDF-15) is a member of the transforming-growth factor b (TGF-b) 
superfamily and elevated serum levels have been reported in patients with cardiac disease 
(Hagström et al., 2017), renal disease (Nair et al., 2017), and prostate cancer (Li et al., 
2015). In addition, GDF-15 has shown high specificity and sensitivity in patients with 
mitochondrial disease (Yatsuga et al., 2015). Together, FGF-21 and GDF-15 have been 
shown to help differentiate patients with mitochondrial myopathy from other myopathies 
(Lehtonen et al., 2016). FGF-21 and GDF-15 have both been shown to be potential 
biomarkers of mitochondrial disease but caution is necessary regarding other influencing 
factors (Scholle et al., 2018).  
1.3.2.2 BN-PAGE and SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and blue 
native polyacrylamide gel electrophoresis (BN-PAGE) are two methods of detecting 
protein levels in tissue (Schägger, 2006; Wittig et al., 2006).  
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Proteins extracted from biopsy and established cell lines are run on a polyacrylamide gel 
and then labelled by specific antibodies; comparison between control and patient protein 
levels can help determine any reduction or overexpression of proteins in the tissue. BN-
PAGE keeps and detects protein complexes in their tertiary form while SDS-PAGE 
detects individual complex subunits. These results only give an indication of any overall 
differences in protein expression at the tissue level.  
1.3.2.3 Biochemical OXPHOS and respiratory oxygen consumption assays 
Mitochondrial function can be analysed in muscle biopsy samples using biochemical 
assays that assess the function of individual OXPHOS complexes (Frazier et al., 2020). 
This assay can be performed on homogenised muscle samples or isolated mitochondria 
from cultured patient fibroblast cell lines and therefore only presents an overall picture of 
OXPHOS defects at the tissue level rather than at the cellular level. An alternative method 
to assess for mitochondrial OXPHOS complex deficiencies is measuring the rate of 
oxygen consumption using high-resolution respirometry in patient cell lines or 
permeabilised tissue samples (Pesta and Gnaiger, 2011; Germain et al., 2019). In 
addition, OXPHOS deficiencies can also be determined in patient tissue homogenates and 
isolated mitochondria by microscale oxygraphy using the Seahorse Extracellular Flux 
Analyser (Invernizzi et al., 2012).  
1.3.3 Histological/histochemical and immunohistochemical investigation 
techniques and findings in mitochondrial disease 
Levels of heteroplasmy vary amongst cells due to asymmetric distribution of 
mitochondria during mitosis. This could result in different levels of OXPHOS protein 
function amongst a group of cells. This mosaic pattern of OXPHOS defect could indicate 
a difference in heteroplasmy levels, as opposed to a more uniform pattern due to nDNA 
mutations associated with complex IV assembly (Pronicki et al., 2008; Roos et al., 2019). 
The following assays describe methods of analysing patient tissue and cell lines to detect 
any overall protein expression differences or functional defects in OXPHOS complexes 
I-IV at the tissue level in addition to identifying specific cells with RRF, functional 
defects in complexes II and IV, or protein expression variation in complexes I and IV 




Figure 1.16 Histological, histochemical, and immunohistochemical methods of analysing muscle tissue from a patient with a single large 
scale mtDNA deletion. 
A Histological analysis with H&E staining was used to assess muscle morphology and modified Gomori trichrome staining was used to look for 
RRFs as seen around highlighted muscle fibre (*). Histochemical reactions in separate COX and SDH and sequential COX/SDH staining identify 
muscle fibres that are deficient in complex IV activity as seen in the highlighted muscle fibre (*). 
B The quadruple immunofluorescence assay uses antibodies to quantify the levels of complex I (NDUFB8), complex IV (COX1), cell size 
(laminin) and mitochondrial mass (porin). The highlighted muscle fibre (*) has a clear complex I and IV deficiency and has an accumulation of 




1.3.3.1 H&E histological stain and modified trichrome Gomori histological stains 
Haematoxylin and eosin (H&E) stain the nucleic acids and proteins respectively enabling 
the differentiation between the nucleus and the cytosol (Fischer et al., 2008). Modified 
Gomori trichrome stains muscle fibres blue and mitochondria red. Intense red staining 
outlining blue stained fibres, termed ragged-red fibres (RRF), indicates the accumulation 
of mitochondria as a result OXPHOS complex deficiency (Olson et al., 1972; Egger et 
al., 1981; Moraes et al., 1992). RRFs may be present in a mosaic pattern among muscle 
cells due to varying levels of heteroplasmy in the cells leading to mosaic OXPHOS 
deficiency. Subsequent assays can help indicate which of the OXPHOS complexes is 
affected.  
1.3.3.2 Cytochrome c oxidase and succinate:ubiquinone oxidoreductase 
histochemical assay 
Cytochrome c oxidase and succinate:ubiquinone oxidoreductase (COX/SDH) 
histochemical staining is applied to biopsy sections and provides a visual presentation of 
respiratory activity in complex IV (COX) and the fully nuclear encoded complex II 
(SDH) (Old and Johnson, 1989; Sciacco and Bonilla, 1996). The sequential application 
of these stains assists in pointing out any complex deficient cells, indicating the presence 
of a mitochondrial defect within these cells, and suggesting which genome the causative 
variant could be located in. Complex II deficiency indicates the presence of a variant in 
the nuclear genome since all its subunits and assembly factors are exclusively nuclear 
encoded.  
In comparison to the biochemical assay, this method can detect mosaic OXPHOS 
deficiencies at the cellular level while the biochemical assay only provides an overview 
of OXPHOS protein deficiency within the tissue.  
1.3.3.3 Quadruple Immunofluorescence  
A recently developed technique applies immunofluorescent labelling to detect complex I 
and IV expression levels in biopsy samples at the cellular level. This method utilises 
antibodies that target complex I and complex IV subunits, and porin (VDAC) to detect 
the abundance of complexes I and IV and determine the mitochondrial mass (Grünewald 
et al., 2014). An antibody targeting the basement membrane protein laminin is used to 
outline muscle cells in muscle biopsy samples while a tyrosine hydroxylase targeting 
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label is used to highlight neuron cells in brain biopsy samples (Grünewald et al., 2014; 
Rocha et al., 2015). This helps determine cell borders to ensure accurate detection of any 
mosaic complex deficiencies.  
1.3.4 Causes of mitochondrial disease 
1.3.4.1 mtDNA associated mitochondrial disorders 
Mutations in mtDNA have been studied intensively and certain groups of symptoms have 
been linked to mutations within certain genes (Lloyd and McGeehan, 2013). MELAS is 
commonly associated with a mutation in the gene encoding mitochondrial tRNA leucine 
(MT-TL1) at the nucleotide position 3243, m.3243A>G in mt-tRNALeu(UUR) (Goto et al., 
1990). However, clinical heterogeneity has been observed in patients harbouring 
m.3243A>G as it has been associated with an array of clinical presentations such as 
hearing impairment, diabetes and gastro-intestinal disturbance, and research suggests that 
nuclear factors could be influencing clinical presentation in patients (Nesbitt et al., 2013; 
Pickett et al., 2018). The heteroplasmy level of the m.3243A>G is a factor that affects the 
disease burden in patients; heteroplasmy levels of m.3243A>G measured vary depending 
on the different patient samples with heteroplasmy levels gradually decreasing with age 
in blood samples compared to muscle and urine samples (Grady et al., 2018). Moreover, 
80% of MELAS cases have been associated with m.3243A>G while the remaining 20% 
have been associated with other mtDNA mutations (Schon et al., 2012; Gorman et al., 
2016).  
MERRF is largely associated with a mutation in the gene encoding mitochondrial tRNA 
lysine (MT-TK) at the nucleotide position 8344, m.8344A>G in mt-tRNALys (Yoneda et 
al., 1990). However, more than 10 other mtDNA point mutations and mtDNA 
rearrangements and deletions have also been associated with MERRF (Lorenzoni et al., 
2014). Other mitochondrial syndromes such as LHON, Pearson syndrome and KSS have 
been associated with various mtDNA mutations such as point mutations, large scale 
deletions, and rearrangements. These mtDNA mutations are either maternally inherited 
as described in Section 1.1.5 or can be sporadic de novo mutations. 
1.3.4.2 nDNA associated mitochondrial disorders 
So far, 1,145 genes related to mitochondrial function are nDNA encoded which raises a 
challenge in locating causal mutations if mutations in the 37 mtDNA genes are excluded. 
Mutations in over 300 nuclear genes have been associated with mitochondrial disorders 
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so far (Stenton and Prokisch, 2020; Thompson et al., 2020a). NGS has facilitated the 
identification and verification of variants in many genes related to mitochondrial function 
(Frazier et al., 2019; Stenton and Prokisch, 2020; Thompson et al., 2020a). I will discuss 
the application in further detail in Chapter 4. 
Patient cell lines are crucial in confirming the pathogenicity of a novel variant by 
performing rescue experiments by assessing the effect on protein function and expression 
(Haack et al., 2012; Alston et al., 2016a; Danhauser et al., 2016). Many studies also 
perform complementation experiments and yeast models of the genotyped mutations to 
help determine whether a variant is pathogenic (Bricker et al., 2012; Haack et al., 2012; 
Haack et al., 2013; Lieber et al., 2013; Bianciardi et al., 2016; Thompson et al., 2016; 
Sommerville et al., 2017). Novel variants are frequently associated with certain 
phenotypes but studies with larger cohorts that are genotyped with the same variant or 
variants in the same gene present a more accurate frequency of phenotypes among cases 
(Sommerville et al., 2017; Repp et al., 2018; Saoura et al., 2019). More detailed 
description of these approaches is outlined later in Chapter 5. Alternatively, a cumulative 
retrospective comparison of reported cases with new cases also helps expand the clinical 
phenotypes associated with the reported gene variants (Kropach et al., 2017; Habibzadeh 
et al., 2019). 
1.3.4.3 Complex multigenic mitochondrial disease 
Clinical heterogeneity of mitochondrial disease phenotypes in patients with the 
m.3243A>G mutation is a puzzling challenge to investigate. Evidence of nuclear 
modifiers have been suggested to play a role in the observed variety of phenotypes in 
these patients and can be associated with certain phenotypes (Pickett et al., 2018; Boggan 
et al., 2019). 
1.3.4.4 Genotype-phenotype correlation. 
Mitochondrial disorders often show a weak genotype-phenotype correlation, but some 
mutations and symptoms show a high genotype-phenotype correlation. An example of 
these are AGK, GTPBP3, MTO1 and ELAC2 gene mutations are highly associated with 
cardiomyopathy (Mayr et al., 2012; Lightowlers et al., 2015; Saoura et al., 2019). On the 
other hand, a low genotype-phenotype correlation is observed in LS patients due to the 
various mutations identified in more than 85 genes present in both mtDNA and nDNA 
encoding the numerous OXPHOS complex subunits and different mitochondrial 
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functions (Lake et al., 2019). Further complicating and weakening the genotype-
phenotype correlation in LS patients are alternative phenotypes reported in patients that 
are genotyped with mutations in genes associated with LS (Rahman et al., 2017). This 
poses as a challenge that need to be overcome while genetically investigating 
mitochondrial disease patients. 
1.3.5 Genetic studies of mitochondrial disease 
Mitochondrial disorders were first associated with mtDNA mutations due to evident 
maternal inheritance of the disorder. However, the absence of mtDNA mutations in 
addition to evidence of autosomal or X-linked inheritance of the disorder in patients led 
to the investigation of nDNA mutations (Stenton and Prokisch, 2020).  
Targeted gene sequencing was the method used to diagnose mitochondrial disorders and 
OXPHOS activity results from patient muscle biopsies helped narrow down which 
mitochondrial protein complex or enzyme to sequence based on findings; this resulted in 
the discovery of many mitochondrial disease genes (Frazier et al., 2019). This targeted 
method requires biopsy samples, which are painful for patients especially from paediatric 
cases. Upon the introduction of next-generation sequencing (NGS) techniques, the field 
shifted from using targeted sequencing methods to gene agnostic approaches such as 
whole exome sequencing (WES) where the protein coding regions of all genes are 
sequenced, or whole genome sequencing (WGS) which includes sequencing of non-
coding regions. Moreover, NGS studies can be performed to look for possible causative 
variants before acquiring any biopsy samples. Due to price reduction for utilising this 
high-throughput technique, WES became more affordable and cost effective and many 
patients have been analysed leading to a better understanding of the genotype-phenotype 
relationship of mitochondrial disorders (Calvo and Mootha, 2010; Wadapurkar and Vyas, 
2018). Recent cohort studies investigating mitochondrial disorders employed WES and 
not only resulted in the discovery of novel mutations in genes already associated with 
mitochondrial disorder but discovered novel genes associated with mitochondrial 
disorders (Haack et al., 2010; Haack et al., 2012; Lieber et al., 2013; Yang et al., 2013; 
Taylor et al., 2014; Wortmann et al., 2015). The results of these investigations will be 
discussed in more detail in Chapter 4. 
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1.3.5.1 Classification of called variants 
Called variants identified in genetic studies are classified using criteria published by the 
American College of Medical Genetics and Genomics (ACMG) (Richards et al., 2015). 
The criteria take into consideration the frequency of the identified variant in the genetic 
databases; in silico predictions of pathogenicity by available tools; availability of 
functional studies related to the variant; segregation of variant within the family; location 
of the variant in relation to previously identified variants; and the patient’s phenotype 
relative to previously reported cases. This classification system is useful as a universal 
tool and it categorises variants into 5 distinct groups: “pathogenic”, “likely pathogenic”, 
“uncertain significance”, “likely benign”, and “benign”. With the help of these criteria, 
called variants can be categorised using available data and updated depending on the 
availability of more recent supporting evidence.  
However, ethical issues are raised when the method of genome sequencing identifies 
variants that are not related to the diagnosis of the investigated patient. Interpretation of 
“incidental findings” that are associated with other diseases or risk factors pose an ethical 
question of whether to report it to the patient or not (Holm et al., 2017). More importantly, 
the interpretation of such findings (especially “pathogenic” and “likely pathogenic” 
variants) may increase the harm of false-positive results that are reported back to patients 
as they may not be accurate findings based on the method of sequencing used. Therefore, 
extreme care and discretion need to be practiced in such scenarios. 
 Kuwait and the Middle East 
1.4.1 Population and ancestry 
The Central Bureau of Statistics in Kuwait estimated the population of Kuwait in 2018 
was 4.2 million (Central Bureau of Statistics, 2018). Approximately 1.35 million of the 
population are Kuwaiti nationals comprising about 30% of the total population. The 
Kuwaiti population can be divided into 3 genetics subgroups of different ancestries 
(Alsmadi et al., 2013). The first subgroup is of Persian ancestry with genetic analysis 
showing European and West Asian origins; the second subgroup is of Saudi tribe ancestry 
with a genetic analysis showing a high level of Arabian ancestry; and the third subgroup 
is of Bedouin (tent-dwellers) ancestry with a distinct genetic mixture of Arabian and 
African origin. Ancestral markers including those of French Basque and the Brahui and 
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Kalash tribes from Pakistan were found in the genotyped Kuwaiti cohort (Alsmadi et al., 
2013). 
1.4.2  Consanguinity 
Consanguinity, defined as union between second cousins or closer, and the practice of 
endogamy are major factors affecting clinical genetics (Tadmouri et al., 2009). 
Consanguineous marriages are common practice in many parts of the world with 
preference estimated in at least 20% of the global population with more than 8.5% of 
children worldwide having consanguineous parents (Modell and Darr, 2002). 
Consanguinity rates reaching and exceeding 50% are reported in many Arab countries 
with rates of first cousin marriages exceeding 20% (Tadmouri et al., 2009). Prevalence 
of inherited disorders among consanguineous populations is often higher than in non-
consanguineous populations (Skladal et al., 2003; Shawky et al., 2013). This has been 
observed in Kuwait where levels of consanguinity exceeding 50% have been reported 
(Al‐Awadi et al., 1985; Radovanovic et al., 1999; Tadmouri et al., 2009; Al-Kandari and 
Crews, 2011). 
1.4.3 Diagnosis of Mitochondrial disease in Kuwait 
Mitochondrial disorders have been reported in Kuwait with phenotypes including Leigh 
syndrome in 3 affected siblings with consanguineous parents (Abdul-Rasoul et al., 2002); 
lactic acidosis and developmental delay associated with PDH deficiency in 4 patients 
from 2 consanguineous families (Ramadan et al., 2004); ethylmalonic encephalopathy in 
2 cases, both from 2 consanguineous first cousin marriages, both presented with 
developmental delay, hypotonia, lactic acidosis and encephalopathy with one patient 
exhibiting complex IV deficiency in a muscle biopsy (Heberle et al., 2006); another 
ethylmalonic encephalopathy case, whose parents are consanguineous double first 
cousins, was also reported that presented with developmental delay, myoclonic epilepsy, 
hypotonia, elevated lactate and encephalopathy (Ismail et al., 2009); and LHON in a large 
family with consanguineous grandparents (Behbehani et al., 2014). No genetic analyses 
were reported for the 3 siblings with reported Leigh syndrome, however patients from the 
2 consanguineous families with reported PDHc deficiency were reported homozygous for 
novel nonsense mutations in the PDHX gene, one of the pair of ethylmalonic 
encephalopathy patients was homozygous for a novel single nucleotide deletion in the 
ETHE1 gene causing a frameshift leading to early termination of translation, and the final 
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ethylmalonic encephalopathy was homozygous for exon 4 deletion in the ETHE1 gene. 
Furthermore, two coinherited mtDNA mutations were identified in the large family with 
LHON but the presence of consanguinity did not necessarily rule out maternal inheritance 
as a possible mode of inheritance. With the high rate of consanguinity in Kuwait and its 
surrounding regions, diseases can seem like autosomal dominant with varied penetrance 
if thorough family history is not taken. Therefore, mtDNA inheritance cannot be ruled 
out. 
In Kuwait, mitochondrial disease patients are primarily investigated based on available 
clinical data and mtDNA is sequenced for mutations using DNA extracted from blood. 
Due to the lack of expertise in Kuwait, no muscle biopsies are obtained from patients 
compared to how mitochondrial disease patients are assessed in specialised centres 
around the world. This requirement in diagnosing mitochondrial disease is only obtained 
if patients travel abroad to the United Kingdom or the United States for specialist advice 
and diagnosis. There are no clear indicators that muscle biopsies will be acquired in 
Kuwait soon. 
1.4.4 Research in the Middle Eastern Arab population 
Genetic disorders in the Middle Eastern Arabs were investigated using linkage analysis, 
candidate gene analysis, and contemporary DNA (cDNA) sequencing prior the 
introduction of NGS. This resulted in the identification of novel candidate gene associated 
with mitochondrial function (TK2, PDHB, SLC19A3, and SLC25A22) (Saada et al., 2001; 
Brown et al., 2004; Molinari et al., 2005; Zeng et al., 2005). In addition, novel pathogenic 
variants in Middle Eastern Arabs were identified in established mitochondrial disease 
genes (PDHX, ETHE1, MPV17, and SLC25A20) (Al Aqeel et al., 2003; Ramadan et al., 
2004; Heberle et al., 2006; Spinazzola et al., 2008).  
1.4.5  Impact of NGS on the discovery of novel candidate genes in the Middle East 
Upon the introduction of NGS, a number of patient cohorts from the Middle East were 
investigated for suspected genetic disorders (Ben-Rebeh et al., 2012; Dixon-Salazar et 
al., 2012; Shamseldin et al., 2012; Alazami et al., 2015; Yavarna et al., 2015; Alfares et 
al., 2017; Anazi et al., 2017; Monies et al., 2017; Maddirevula et al., 2019). These studies 
involved over 2,000 families (mostly consanguineous) and led to the successful diagnosis 
of more than half the investigated families and the discovery of more than 170 novel 
candidate genes associated with genetic disease (Table 1.1) (Alahmad et al., 2019). More 
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recently, studies utilising NGS have identified novel candidate genes associated with 
mitochondrial function while investigating Middle Eastern families (MFF, FBXL4, 
ELAC2, PET100, ISCA2, PMPCA, SLC39A8, SLC25A42, YME1L1, MIPEP, MICU2, 
COX5A, COQ5, and NUDT2) (Shamseldin et al., 2012; Haack et al., 2013; Lim et al., 
2014; Al-Hassnan et al., 2015; Boycott et al., 2015; Jobling et al., 2015; Eldomery et al., 
2016; Hartmann et al., 2016; Shamseldin et al., 2016; Baertling et al., 2017a; Shamseldin 
et al., 2017; Malicdan et al., 2018; Yavuz et al., 2018).  
 
 
Table 1.1 Diagnosis and novel candidate gene discoveries in studies that utilised NGS 
to investigate patient cohorts in the Middle East 
Reference Families Diagnosed Novel candidate genes 
Shamseldin et al., 2012  10 families  10 families 2 novel candidate genes 
Ben-Rebeh et al., 2012 34 families 34 families 0 
Dixon-Salazar et al., 
2012 118 families 32 families (37 %) 
22 novel candidate gene  
(19% of cohort) 
Alazmi et al., 2015 143 families 104 families (73%) 69 novel candidate genes 
Yavarna et al., 2015 149 probands 89 families (60%) 
7 novel candidate genes  
(5% of cohort) 
Anazi et al., 2016 337 families 196 families (58%) 3 novel candidate genes 
Alfares et al., 2017 454 probands 22 probands (5%) 0 
Monies et al., 2017 1000 families 340 families (34%) 75 novel candidate genes reported  
Total 2245 families 1027 families 178 novel candidate genes 
(Alahmad et al., 2019) 
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1.4.6 Founder mutations in the Middle Eastern population 
Founder mutations in novel mitochondrial disease genes such as PET100, ISCA2, 
PMPCA, and NUDT2 were identified in unrelated families when investigated as part of 
their respective cohorts (Table 1.2) (Lim et al., 2014; Al-Hassnan et al., 2015; Jobling et 
al., 2015; Yavuz et al., 2018). For example, a cohort of five unrelated consanguineous 
families were investigated leukodystrophy and neurological regression using NGS and 
all patients were homozygous for a founder mutation identified in the novel mitochondrial 
disease gene ISCA2 (p.Glu77Ser) which codes for a protein that plays a critical role in 
the maturation of [4Fe-4S] clusters (Sheftel et al., 2012; Al-Hassnan et al., 2015). 
Functional study on fibroblast cell line of an ISCA2 patient who was homozygous for the 
founder mutation revealed defects in multiple OXPHOS complexes in addition to defects 
in the a-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes when 
compared to controls and therefore validated the mutation’s pathogenicity (Lebigot et al., 
2017). Patients from nine more consanguineous Saudi families who were investigated for 
infantile onset leukodystrophy were genotyped with the same ISCA2 founder mutation 
using WES and targeted mutation sequencing (Alfadhel et al., 2018).  
Other novel variants identified in mitochondrial disease genes were established as 
founder mutations in the Middle East after further investigations (SLC39A8, SLC19A3, 
ELAC2, FARS2, SLC25A42, and MICU) (Alfadhel, 2017; Riley et al., 2017; Shinwari et 
al., 2017; Almannai et al., 2018a; Almannai et al., 2018b; Musa et al., 2018). The founder 
mutation in ELAC2 (which codes for mitochondrial RNase Z, a protein responsible for 
the endonucleolytic cleavage at the 3’ termini of mt-tRNA transcripts in mitochondria) 
was first identified in a cohort of patients investigated for infantile cardiomyopathy where 
functional studies on patient fibroblasts revealed defects in OXPHOS subunits and 
showed an accumulation of unprocessed mt-tRNA transcripts compared to controls 
(Brzezniak et al., 2011; Haack et al., 2013). The founder mutation was later identified in 
19 unrelated consanguineous Middle Eastern families that were investigated for infantile 
cardiomyopathy (Shinwari et al., 2017; Saoura et al., 2019). So far, more than 10 founder 
mutations in mitochondrial disease genes have been reported.   
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Table 1.2 List of founder mutations and common mitochondrial disease diagnoses 
reported in the Middle Eastern population, observed phenotypes, and therapeutic 
treatments. 





27 variants reported. 
Elevated 3MGA; lactic 
acidosis; apnoeic episodes 
MRI: Basal ganglia lesions, 
cerebral and cerebellar atrophy; 
MRS lactate peak 
N/A 





elevated lactate, multiple 
OXPHOS defects 
N/A 
ETHE1 Persulphide Dioxygenase 
34 variants reported. 
2 variants exclusively 
reported in Arabs: 
c.505+1G>T; p. exon 4 
skipping 
And genetic deletion of 
exon 4 
Ethylmalonic encephalopathy, 
ethylmalonic aciduria, elevated 
C4 and C5 acylcarnitines 
(SCAD patients have higher C4 











1. Early-onset epileptic 
encephalopathy 










MRI: leukodystrophy, spinal 
cord involvement 









Elevated liver transaminase, 











1. Early-infantile Leigh-like 
syndrome. 
2. Childhood biotin-thiamine 
responsive basal ganglia 
disease. 
3. Adult Wernicke's-like 
encephalopathy 
Biotin, thiamine 




Variable clinical phenotype 
MRI: iron deposits in globus 
pallidus and substantia nigra 
N/A 
SERAC1 Serine Active Site containing 1 42 variants reported. 
2 phenotypes: 
1. Hypotonia with 
progressive spasticity, 
dystonia, hearing loss, 
elevated 3MGA 
2. Complicated hereditary 
spastic paraplegia 
Key finding: 
MRI: "putaminal eye" 
N/A 
(Alahmad et al., 2019)  
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1.4.7 Preventable mitochondrial disease in the Middle East 
One of the earliest reported neurological presentations that mimicked mitochondrial 
diseases in the Middle East is Biotin-Thiamine responsive Basal Ganglia Disease 
(BTRBGD) (Ozand et al., 1998). Patients from 8 consanguineous Arab families had 
varying neurological presentations but a consistent MRI finding of basal ganglia lesions 
was reported in all patients. Supplementation of biotin was identified as an effective 
treatment for the neurological presentations in the patients. Linkage analysis studies and 
targeted candidate gene sequencing identified mutations in SLC19A3 which codes for a 
plasma membrane protein that functions as a thiamine transporter (Zeng et al., 2005). 
One of the identified SLC19A3 mutations was identified in patients from 13 unrelated 
consanguineous Saudi families and was established as a founder mutation (Alfadhel et 
al., 2013).  
With regards to genotype-phenotype correlation, 3 major phenotypic presentations have 
been associated with SLC19A3 mutations: early-onset Leigh-like syndrome, childhood 
biotin-thiamine responsive basal ganglia disease, and adult Wernicke’s-like 
encephalopathy (Alfadhel and Tabarki, 2018). MRI findings of basal ganglia lesions are 
reported in all the aforementioned presentations in addition to patients with Leigh 
syndrome which is associated with over 85 genes resulting in a weak genotype-phenotype 
correlation (Lake et al., 2019). It is key to point out that patients diagnosed with early-
onset Leigh syndrome due to an SLC19A3 mutation were less responsive to the biotin 
supplementation and had high rates of early mortality (Alfadhel, 2017). 
1.4.8 Treatment of mitochondrial diseases in the Middle East 
So far, there are no curative treatments established for mitochondrial disease, however 
there are therapeutic approaches that help alleviate some symptoms caused by 
mitochondrial dysfunction (Lake et al., 2016; Slone et al., 2018). These include the 
enhancing of OXPHOS complex function using supplements such as the aforementioned 
biotin, antioxidants such as co-enzyme Q10, vitamins C and E, and also include 
substances that enhances mitochondrial biogenesis. For example, SLC19A3 patients 
respond well to biotin supplementation, and clinical symptoms of ETHE1 patients 
improve after treatment with metronidazole (a bactericide) and N-acetylcysteine (Ozand 
et al., 1998; Viscomi et al., 2010). Genetic counselling for families with confirmed 
 80 
genetic disease can help reduce the chances of having affected offspring by opting for 
Preimplantation Genetic Diagnosis.  
 Aims 
Throughout this introduction I have discussed the structure and various functions and 
roles of mitochondria as a cellular organelle, how these mitochondrial functions are 
controlled by proteins encoded in the mitochondria’s own genome in addition to the 
nuclear genome and outlined how mitochondrial dysfunction has been associated with 
clinically heterogeneity in patients harbouring mutations in these genes. The diagnosis of 
mitochondrial disease has been challenging due to weak genotype-phenotype correlation 
reported in patients. I highlight the importance of NGS in recent years in the rapid 
diagnosis of Mendelian mitochondrial disease in patients and the rapid discovery of novel 
mitochondrial disease genes.  
Specifically, my aims for this project were to recruit and select patients suspected of 
mitochondrial disease in the highly consanguineous population of Kuwait by evaluating 
the patients’ suggestive mitochondrial disease phenotype, family history suggestive of 
Mendelian inheritance of disease, and the availability of a thorough clinical history of 
disease progression. With the assistance of clinical specialist in Kuwait and Newcastle, I 
developed modified mitochondrial disease criteria to score the probability of 
mitochondrial disease involvement in patients. Selective sequencing of mtDNA 
mutations in patients were mostly excluded prior to recruitment. 
After recruitment, I used WES as a first-tier genetic analysis method in search of nDNA 
variants associated with mitochondrial function and disease. Upon the identification of 
candidate pathogenic variants, I genotyped patients’ family members to confirm the 
segregation of the variant within the family. Dependant on the availability of tissue 
samples from patients, I validated the pathogenicity of novel variants in patients using 
functional analysis methods such as western blotting and BN-PAGE and reported my 
findings. My research finally utilised a range of functional investigation methods to 
investigate a novel mitochondrial disease gene, validated the pathogenicity of the 
identified variants, and investigated the molecular aetiology of disease in patient 
fibroblast cell lines. 
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2.1.1.1 General laboratory 
Analogue Tube Roller Thermo Scientific 
Benchtop Centrifuge 5417R (Refrigerated) Eppendorf 
Benchtop Centrifuge 5418 Eppendorf 
Benchtop Centrifuge 5804 Eppendorf 
Dry Heat Block Techne 
Magnetic stir bars Fisherbrand 
Microcentrifuge, Technicomini Griffin Education 
pH Meter 3510 Jenway 
Stirrer, Ceramic Plate U151 Stuart 
Vortex Genie 2 Scientific Industries 
Water Purification System, NANOpureII Barnstead 
2.1.1.2 Genetic analysis 
Genetic Analyser, ABI 3130xl Applied Biosystems 
Electrophoresis Unit, HU10 Mini-Plus Horizontal Unit Scie-Plas 
NanoDrop Spectrophotometer, ND-1000 Thermo Scientific 
UVP PCR Cabinet FisherScientific 
Thermal Cycler, Veriti 96 Well Applied Biosystems 
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2.1.1.3 Cell culture  
Aspiration System Vacusafe Integra 
Benchtop Centrifuge, Universal 32 Hettich 
Class II Microbiological Safety Cabinet, BH-EN-2004 Faster 
CO2 Cell culture Incubator, MCO-18AIC Panasonic 
LED Microscope, Leica DM IL Leica 
2.1.1.4 Western blotting 
Imaging System, ChemiDoc MP Bio-Rad 
Mini Trans-Blot Cell system Bio-Rad 
Mini-Protean Tetra Cell system Bio-Rad 
Orbital Shaker, SSL1 Stuart 
Plate Reader, SpectraMax M5e Multimode Molecular Devices 
2.1.1.5 BN-PAGE 
Motor Drive Homogeniser Glas-Col 
Teflon-Dounce homogeniser Glas-Col 
Ultracentrifuge, Optima MAX-XP Beckman Coulter 
XCell Surelock Mini-Cell Electrophoresis System ThermoFisher Scientific 
2.1.2 Consumables  
96-Well PCR Plate, Semi-Skirted, Clear StarLab 
PCR tubes (200µl) StarLab 
Cellstar Aspirating Pipette Greiner Bio-One 
Cellstar Disposable Tubes (5ml, 10ml, 25ml) Greiner Bio-One 
Cellstar Falcon Tubes (50ml) Greiner Bio-One 
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Chromatography Paper, 3mm Whatman 
DNeasy Blood and Tissue Kit Qiagen 
Flat-bottom 96 well plate TTP 
Immobilon-P PVDF membrane (0.45µm) Merck 
Microfuge tubes (0.6ml, 1.5ml, 2ml) Starlab 
Nunc-Cryotube Vials Thermo-Scientific 
Parafilm M 
Syringe Filter Unit, 0.22µm, polyethersulphone, 33mm 
gamma sterilised 
Millex-GP 
Syringes without Filters, 10 ml Fisher Scientific 
Syringes without Filters, 50 ml Fisher Scientific 
Ultracentrifuge glass tubes Beckman Coulter 
Universal tubes, 20ml Starlab 
2.1.3 Chemicals and reagents 
2.1.3.1 General reagents 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Dimethyl Sulphoxide (DMSO)  Sigma-Aldrich 
Ethanol, 100% Fisher Chemical 
Glycerol Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Liquid Nitrogen BOC 
Methanol, 100% Fisher Chemical 
Phenylmethylsulphonyl fluoride (PMSF) Roche 
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2.1.3.2 Polymerase chain reaction (PCR) reagents 
Colourless GoTaq Reacting Buffer, 5X Promega 
Deoxyribonucleotide Triphosphate (dNTP) Mix, 2mM Bioline 
GoTaq G2 DNA Polymerase, 5U μl-1 Promega 
Ambion™ Nuclease-free water Invitrogen 
Orange G powder Sigma-Aldrich 
Tris-Acetate-EDTA (TAE) Buffer Formedium 
2.1.3.3 Sanger sequencing reagents 
Big Dye Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 
Exonuclease I, 20U µl-1 Thermo Scientific 
FastAP, thermosensitive Alkaline Phosphatase, 1U μl-1 Thermo Scientific 
Hi-Di formamide Applied Biosystems 
2.1.3.4 Tissue culture reagents 
Amphotericin (Fungizone) Gibco 15290018 
Dulbecco’s Modified Eagle Medium Gibco 41965039 
Dulbecco’s Phosphate buffered saline X1 (DPBS) Gibco 14190250 
Foetal Bovine Serum (FBS) Gibco 16000044 
Minimum Essential Media Gibco 11095080 
MEM Non-essential Amino Acid Solution (100X) Sigma-Aldrich 11140035 
MEM Vitamins Gibco 11120037 
Penicillin and Streptomycin Solution Gibco 15070063 
Sodium pyruvate Gibco 11360070 
TrypLE Express Gibco 12605010 
Uridine Sigma-Aldrich U3750 
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2.1.3.5 Agarose gel electrophoresis reagents 
Agarose (Molecular Grade) Bioline 
1 kb DNA Ladder, 0.1 µg µl-1 Promega 
SYBR Safe DNA Gel Stain, 10,000X Invitrogen 
2.1.3.6 SDS-PAGE and Western blot reagents 
Acrylamide/Bis-acrylamide, 30%, 29:1 Bio-Rad 
Detection Reagents, Amersham ECL Prime Western Blotting GE Healthcare 
Blue Wide Range Protein Ladder Cleaver Scientific 
Dried Skimmed Milk Powder Marvel 
Glycine Sigma-Aldrich 
N, N, N’, N’- Tetramethyl ethylenediamine (TEMED) Sigma-Aldrich 
Polysorbate 20 (Tween-20) Acros Organics 
Protein Assay Dye Reagent Concentrate Bio-Rad 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich 
Trisma Base Sigma-Aldrich 
2.1.3.7 BN-PAGE reagents 
Coomassie Blue Thermo Scientific 
D-Mannitol Sigma-Aldrich 
Dodecyl maltoside (DDM) Sigma-Aldrich 
Ethylene glycol-bis(b-aminoethyl)-N, N, N’, N’- tetra acetic acid 
(EGTA) 
Sigma-Aldrich 
N-dodecyl-b-maltoside Thermo Scientific 
NativeMark™ Unstained Protein Standard Invitrogen 
NuPAGE™ Anode Buffer, Running Buffer (20X) Invitrogen 
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NuPAGE™ Cathode Buffer (20X) Invitrogen 
NuPAGE™ Transfer Buffer (20X) Invitrogen 
NativePAGE™ 4-16%, Bis-1.0 mm, Mini Protein Gel, 10-well Invitrogen 
Pierce BCA Protein Assay Kit ThermoFisher 
Scientific 
Ponceau S Sigma-Aldrich 
NativePAGE™ sample buffer, 4X Invitrogen 
2.1.3.8 Vector cloning reagents 
BamHI restriction enzyme NEB 
CutSmart buffer NEB 
EcoRI restriction enzyme NEB 
In-Fusion HD Enzyme Premix TaKaRa Bio 
pLVX-TetOne-Puro vector TaKaRa Bio 
2.1.3.9 Lentiviral transduction reagents 
Foetal Bovine Serum, Dialysed Gibco 
Doxycycline TaKaRa Bio 






2.1.4.1 PCR amplification 
PCR master mix 1X GoTaq reaction buffer 
200μM dNTPs 
1.2μM mixture of forward 
and reverse primers  
0.8U GoTaq G2 polymerase 
Nuclease-free water 
2.1.4.2 Agarose gel electrophoresis 
DNA Loading Dye 50% Glycerol 
50% dH2O 
Orange G (to colour) 
Store at toom temperature 
ExoFAP 10U Exonuclease I 
1U FastAP 
Tris-Acetate-EDTA (TAE) Buffer, 1X Store at room temperature 
2.1.4.3 Tissue culture 
Growth Media Dulbecco’s Modified Eagle Media (DMEM) high glucose 
10% Foetal Bovine Serum (FBS) 
1X Non-essential amino acids 
1% penicillin/streptomycin 
50µg ml-1 Uridine 
Store at 4°C 
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Transport Media Minimal Essential Media (MEM) 
10% FBS 
1mM Sodium pyruvate 
MEM Vitamins 
1X Non-essential amino acids 
1% penicillin/streptomycin 
2.5µg ml-1 Amphotericin B 
2.1.4.4 Western blotting 
Ammonium Persulphate (APS), (w/v) 10% Store at -20°C 
Bromophenol Blue 1% (w/v) Store at -20°C 
Cell Lysis Buffer 50mM Tris-HCl, pH 7.4 
130mM NaCl2 
2mM MgCl2 
1% Nonidet P-40 
1X EDTA protease inhibitor cocktail 
tablet 
1mM PMSF 
Store at -20°C 
Running Buffer, 10X 192 mM Glycine 
25 mM Tris 
0.1% SDS 
Store at room temperature 





0.01% Bromophenol blue 
Store at -20°C 
Sodium Dodecyl Sulphate (SDS) (w/v) 
10% 
Store at room temperature 
Transfer Buffer, 10X 192 mM Glycine 
25 mM Tris 
0.02% SDS 
15% Methanol 
Store at room temperature 




Store at room temperature 
Tris-HCl, 0.5M, pH 6.8 Store at room temperature 
Tris-HCl, 3.75M, pH 8.5 Store at room temperature 
2.1.4.5 BN-PAGE 
Acetic Acid (w/v) 8% Store at room temperature 
Bovine Serum Albumin, 10% Store at -20°C 
Coomassie Blue, 5% Store at -20°C 
Dodecyl maltoside (DDM), 2% Store at -20°C 
Homogenisation Buffer 600mM D-Mannitol 
10mM Tris-HCl, pH 7.4 
1mM EGTA 
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0.1 BSA  
1mM PMSF 
Phenylmethylsulphonyl Fluoride (PMSF) 100mM Store at -20°C 
Solubilisation Buffer 1X protein sample buffer 
2% DDM 
10% Glycerol 
Store at -20°C 
Transfer Buffer 1X 1X NativePAGE Transfer Buffer 
10% Methanol 
2.1.5 Software 
Alamut Interactive Biosoftware 
FinchTV (Version 1.4.0) Geospiza Incorporated 
Image Lab (Version 6.1) Bio-Rad 
Mutation Surveyor SoftGenetics 




2.2.1 Recruitment of patients 
Patients were recruited from Kuwait via the Kuwait Medical Genetics Centre (KMGC). 
The recruitment of the patients was approved by the Ethical Committee at KMGC.  
Some patients included in this study were recruited from the NHS Highly Specialised 
Service for Rare Mitochondrial Disorders in Newcastle upon Tyne, UK, from the King 
Saud bin Abdulaziz University for Health Sciences in Jeddah, Saudi Arabia, and from the 
Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan, Italy. Clinical summaries, 
DNA samples, and fibroblasts were provided by the respective centres. 
DNA from patients and their families and patient skin biopsy samples were sent to the 
NHS Highly Specialised Service for Rare Mitochondrial Disorders in Newcastle upon 
Tyne. DNA and fibroblast cell lines were obtained from the Mitochondrial Diagnostic 
Service Lab following submission of a tissue and DNA request form.  
A detailed outline of the recruitment and selection process is described in Chapter 3. 
2.2.2 Ethical guidelines 
All procedures were approved and performed under the ethical guidelines of the NHS 
Highly Specialised Service for Rare Mitochondrial Disorders in Newcastle upon Tyne 
and with the Helsinki Declaration of 1975, as revised in 2013. Informed consent was 
obtained from patients and/or guardians for research purposes. 
2.2.3 Extraction of DNA samples from recruited patients and families 
DNA extraction from recruited patient and families was performed at KMGC by lab 
technicians. DNA was extracted from blood using the standard phenol-chloroform DNA 
extraction method and stored in -80°C freezer for future investigations. 
2.2.4 Control fibroblast cell lines 
Appropriate age-matched control fibroblasts were obtained from the NHS Highly 
Specialised Service for Rare Mitochondrial Disorders for research purposes. This 
comprised of 4 paediatric fibroblast cell lines and 2 adult fibroblast cell lines. 
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2.2.5 Whole exome sequencing 
Whole exome sequencing was performed at the Newcastle Genomics Core Facility at 
Newcastle University led by Dr Jonathan Coxhead as follows: For patients from families 
1-13 and families 15-17, coding regions were enriched with Nextera Rapid Exome 
Capture (Illumina) and sequenced with 100 bp paired-end reads on an Illumina 
NextSeq500 platform. An in-house bioinformatics pipeline was applied to the raw 
FASTQ files by Dr Helen Griffin, and Dr Angela Pyle using a high-performance 
computing cluster at Newcastle University. The pipeline utilises a Linux command line 
and Bash Shell scripts that is able to simultaneously run multiple exome analyses 
followed by the removal of duplicate reads using FastUniq (version 1.1) (Xu et al., 2012). 
The Burrows-Wheeler Alignment tool (BWA, version 0.7.12) was utilised to align the 
raw sequence read to the human genome reference sequence (GChr38) resulting in the 
generation of an alignment file in Sequence Alignment/Map (SAM) (SAMtools version 
0.1.19) format (Li and Durbin, 2009). SAM files contain the aligned genetic sequences 
and are converted to a Binary Alignment/Map (BAM) format and variants were detected 
using Freebayes (version 1.0.2) (Garrison and Marth, 2012).  
Variants were functionally annotated by the ANNOVAR tool to highlight which genes 
the variants are located in, whether they are in a coding or non-coding regions (NCR) of 
the gene, which exon they fall in, and the affected amino acid (Wang et al., 2010). The 
variants were annotated using the reference genome databases RefSeq, UCSC Genome 
Browser, and Ensembl Genes (Rosenbloom et al., 2015; Aken et al., 2016; O'Leary et al., 
2016). The variants were further annotated with allele frequencies reported in a number 
of exome databases including the genome aggregation database (gnomAD) (Lek et al., 
2016), National Heart, Lung and Blood Institute Exome Sequencing Project (NHLBI 
ESP) (Exome Variant Server), and 1000 genomes project (Genomes Project et al., 2015). 
For patients from family 14 and families 18-22, exome capture was acquired using the 
Twist capture kit, sequenced using the Illumina NovaSeq 6000 system in 100 bp reads. 
An in-house bioinformatics pipeline was applied to the raw FASTQ files by Dr Fiona 
Robertson using a high-performance computing cluster at Newcastle University.  
The pipeline utilises a Linux command line that is able to simultaneously run multiple 
exome analyses followed by the removal of duplicate reads using Picard (version 1.130) 
(https://broadinstitute.github.io/picard/). The BWA tool (version 0.7.12) was utilised to 
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align the raw sequence read to the human genome reference sequence (GChr38) resulting 
in the generation of an alignment file in SAM format (Li and Durbin, 2009). 
Genetic variants were detected using Varscan (version 2.4.3) ((Koboldt et al., 2012) 
http://dkoboldt.github.io/varscan/) and functionally annotated by Ensembl Variant Effect 
Predictor (VEP, version 96) ((McLaren et al., 2016) 
https://www.ensembl.org/info/docs/tools/vep/index.html) to highlight which genes the 
variants are located in, whether they are in a coding or NCR of the gene, which exon they 
fall in, and the affected amino acid. The variants were annotated using the reference 
genome databases RefSeq, UCSC Genome Browser, and Ensembl Genes (Rosenbloom 
et al., 2015; Aken et al., 2016; O'Leary et al., 2016). The annotated variants of the various 
patients were compared using BEDtools (version 2.19.0) ((Quinlan and Hall, 2010) 
https://github.com/arq5x/bedtools2). 
2.2.6 In silico analysis of candidate gene variants 
In silico analysis of the effect of detected variants were performed using the protein 
prediction tools PROVEAN (Choi et al., 2012; Choi and Chan, 2015), Polyphen-2 
(Adzhubei et al., 2010), SIFT (Ng and Henikoff, 2001; Kumar et al., 2009) and CADD 
(Kircher et al., 2014). In addition, 14 in silico protein damage predicting tools including 
the previously mentioned prediction tools were used to analyse the effects of the variant 
using a new website that summarises these predictions in a single report (Jiang et al., 
2017). The gnomAD version 2 database, a database compiling reported variants in the 
genomes and exomes of 141,456 clinically normal individuals, will be searched for the 
suspected WES variants to ensure its absence or presence at a very low minor allele 
frequency (MAF) and to exclude the presence of any homozygous individuals in the 
database (Lek et al., 2016). 
2.2.7 Oligodeoxynucleotide primers for PCR 
Primers used for genetic studies were made available from the Mitochondrial Diagnostic 
Services Lab or were custom-designed and ordered from Integrated DNA Technologies. 
A full list of all primers used is provided in Appendix A. 
2.2.8 Custom primer design 
Exonic regions harbouring the identified variants of interest were targeted along with 200 
bps flanking upstream (5’) and downstream (3’) using genomic sequences from the 
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UCSC genome browser website (Kent et al., 2002). Custom-designed forward and 
reverse primers were generated using Primer3 (Koressaar and Remm, 2007). The 
generated primer sequences were checked for common single nucleotide polymorphisms 
(SNPs) using SNPCheck3 (https://genetools.org/SNPCheck/snpcheck.htm). Final 
primers were flanked by universal M13-derived sequences that preceded each primer: 
forward (5’- TGTAAAACGACGGCCAGT -3’) and reverse (5’- 
CAGGAAACAGCTATGACC -3’). Primers were ordered from Integrated DNA 
Technologies and primers were prepared in aliquots of 10 µM stocks containing both the 
forward and reverse primers. 
2.2.9 Polymerase chain reaction (PCR) 
DNA was extracted from peripheral blood of patients and their family members using the 
phenol-chloroform DNA extraction method. The concentrations of DNA samples were 
measured using the NanoDrop Spectrophotometer (Section 2.1.1.2). 
PCR amplification of the identified variants was performed by adding 1.0μl of the 
patients’ DNA to 24.0μl of PCR master mix (see Section 2.1.4.1) and subjected to the 
PCR reaction heating steps as outlined in Table 2.1.  
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2.2.10 Gradient PCR for primer optimisation 
All primers were initially tested on a control human genome using a PCR reaction with 
an annealing temperature of 62°C. Should the PCR not result in any specific amplified 
PCR product, a reaction programmed using a gradient of annealing temperatures (58°C , 
60°C, 62°C, 64°C and 66°C) was utilised to determine which of these temperatures is 
optimal for DNA amplification with the used primers. Should the gradient programme 
not result in any amplification of DNA, the gradient PCR was repeated with the addition 
of 10% DMSO to each sample. 
2.2.11 Agarose gel electrophoresis 
To cast a 1% agarose electrophoresis gel, 1.0g of agarose was dissolved in 100ml of 1X 
TAE buffer and heated up in a microwave until the agarose dissolved. Once dissolved, 
the solution is allowed to cool down until it was warm to the touch and then 4µl of SYBR 
Safe DNA gel stain was added to the solution and then poured with an appropriate comb 
added to form wells and was left to solidify. The gel was then submerged in 1X TAE 
buffer and samples were loaded into the wells.  
A ladder marker (1kb) was loaded into a well and DNA samples were loaded in 
neighbouring wells. DNA samples were loaded with equal amounts of DNA loading dye 
(4µl of PCR product with 4µl DNA Loading Dye). The agarose gel was subjected to 
Step Temperature (°C) Duration 
Initiation 94 4 minutes 
Denaturation 94 45 seconds 
Annealing 62 45 seconds 
Extension 72 45 seconds 
Final extension 72 5 minutes 
Hold 4 Indefinitely 
30 cycles 
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electrophoresis at 100V for 30 minutes at room temperature. The gel was imaged using 
the ChemiDoc MP to visualise DNA bands using the UV transilluminator setting 
according to manufacturer guidelines.  
2.2.12 Sanger sequencing 
PCR products were treated with ExoFAP to clean up the mixture prior to cycle 
sequencing. In a 96-well PCR plate, 5µl of PCR product were added in duplicate for each 
sample, and 1.5µl of ExoFAP were added to each PCR product. The plate was capped 
using an adhesive plastic sheet and the solution was mixed and briefly spun down in a 
centrifuge. The mixture was run in a PCR heating programme as follows: 37°C for 15 
minutes then 80°C for 15 minutes, and concluding with a hold step at 4°C. This reaction 
neutralises any unbound dNTPs and PCR primers that might interfere with the cycle 
sequencing reaction. 
To make up a 20µl cycle sequencing reaction mixture, the following components were 
added to the PCR product and ExoFAP mixtures: 7.5µl of nuclease free water, 3µl 5X 
BigDye v 3.1 sequencing buffer, 2µl BigDye v 3.1 ready reaction mix and 1µl of universal 
forward or reverse primer. The 96-well PCR plate was sealed with an adhesive sheet and 
the solution was mixed and briefly spun down in a centrifuge. The cycle sequencing 
reaction heating steps were as follows in Table 2.2:  
 
Table 2.2 PCR protocol for Cycle Sequencing 
 
 
Step Temperature (°C) Duration 
Initiation 96 1 minute 
Denaturation 96 10 seconds 
Annealing 50 5 seconds 
Extension 60 4 minutes 
Hold 4 Indefinitely 
35 cycles 
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2.2.13 Ethanol precipitation of DNA 
DNA from the cycle sequencing products were obtained by ethanol precipitation prior to 
sequencing. The seal on the 96-well PCR plate was removed and to each sample the 
following were added: 2µl of 125mM EDTA, 2µl of 3M sodium acetate solution, and 
70µl of 100% ethanol. The plate was sealed and the inverted to mix the solutions in each 
well and left at room temperature for 15 minutes. The plate was then centrifuged at 2,000g 
for 30 minutes at room temperature. As soon as the spin was over, the plate seal was 
removed, and the supernatant was removed by inverting the plate on tissue paper and 
tapped gently. The plate was kept inverted and fresh tissue paper was placed under it and 
the plate was spun up to 100g to remove any excess solution in the wells. The wells were 
then washed with 70µl of 70% ethanol and the plate was sealed and spun at 1,650g for 
15 minutes at room temperature. As soon as the spin was over, the plate seal was removed, 
and the supernatant was removed by inverting the plate on tissue paper and tapped gently. 
The plate was kept inverted and fresh tissue paper was placed under it and the plate was 
spun up to 100g to remove any excess solution in the wells. Thereafter, the plate was 
allowed to air dry and shielded from light for 10 minutes. The plate was sealed and kept 
in a freezer at -20°C until ready to sequence.  
When ready for sequencing, 10µl Hi-Di formamide was added to each sample and the 
plate was heated to 95°C for 2 minutes and then placed on ice for 1 minute. 
2.2.14 DNA sequencing 
DNA samples in the 96-well PCR plate were sequencing using an ABI 3130xl Genetic 
Analyser with the help of colleagues at the Mitochondrial Diagnostic Service Lab. 
Completed DNA sequencing results were retrieved from the ABI 3130xl Genetic 
Analyser as .ab1 files showing an electropherogram of raw DNA base sequences. 
Mutation Surveyor (SoftGenetics) or FinchTV (Geospiza) software were used to analyse 
the sequencing files and determine the genotypes of controls, patients, and their families. 
2.2.15 Acquiring patient fibroblast cell lines from skin biopsies 
Surviving patients living in Kuwait with novel variants of interest had a skin biopsy 
obtained by Dr Ahmad Alaqeel, a clinical colleague at the KMGC, and stored in Transfer 
Media (see Section 2.4.1.2) at ambient room temperature. The biopsy samples were sent 
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to the NHS Highly Specialised Service for Rare Mitochondrial Disorders in Newcastle 
upon Tyne, UK.  
2.2.16 Establishing primary cell lines from skin biopsies 
Dr Gavin Falkous (NHS Highly Specialised Service for Rare Mitochondrial Disorders, 
Newcastle upon Tyne) established the primary fibroblast cell line from the obtained 
patient skin biopsies by slicing the biopsy samples and placing them in T25 flasks. The 
samples were cultured in Growth Media (see Section 2.4.1.2) at 37°C in 5% CO2. The 
established fibroblast cell lines were split once they reached 80% confluency. 
2.2.17 Culturing of fibroblasts 
Skin fibroblasts were cultured in T75 flasks with Growth Media (see Section 2.4.1.2) at 
37°C in 5% CO2.  
2.2.18 Subculturing of fibroblasts 
Fibroblasts were expanded until they reached 60-80% confluency. Upon reaching this 
confluency, culture media was removed and TrypLE Express was added (2 ml in a T75 
flask) and the flask was incubated at 37°C for 5 minutes. The flasks were tapped gently 
for cells to detach and were checked under a microscope. Afterwards, 6 ml of culture 
media was added to the flask and the mixture was transferred to a 20 ml universal tube. 
The tube was centrifuged at 1,200 rpm (Hettich Universal-32 benchtop centrifuge) for 5 
minutes. The supernatant was disposed of and the pellet was resuspended in 1 ml of 
culture media. To expand the cell line, the resulting cell suspension was split into 2-3 
culture flasks by aliquoting 500 µl or 330 µl (respectively) into flasks containing culture 
media. 
2.2.19 Harvesting of cells 
The cell suspension resulting for the centrifugation step in the previous Section (2.2.17) 
is aliquoted into a 1.5ml tube and centrifuged at 3,000 rpm for 3 minutes at room 
temperature. The supernatant was removed, and the pellet was flash frozen in liquid 
nitrogen and stored in -80°C freezer.  
2.2.20 Freezing of cells 
The cell pellet resulting for the centrifugation step in the previous Section (2.2.17) was 
suspended in 0.5ml of FBS with 10% DMSO and placed in a CoolCell Cell Freezing 
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Container (Biocision) and placed in a -80°C freezer. After a minimum of 24 hours the 
tubes were transferred into a liquid nitrogen containing storage vessel. 
2.2.21 Western blotting  
2.2.21.1 Preparation of cell lysates for protein analysis  
Fibroblasts from patients and controls were harvested and treated with Cell Lysis Buffer 
(see Section 2.1.4.3) vortexed for 30 seconds and kept on ice for 3 minutes. The mixture 
was vortexed again for 30 seconds and then centrifuged at 8,000g for 5 minutes at 4°C. 
The supernatant was transferred to a new tube and flash frozen in liquid nitrogen and 
stored at -80°C. The protein concentration was estimated using the Bradford assay. 
2.2.21.2 Bradford assay 
The protein concentration of cell lysates was determined using a Bradford assay. BSA 
was used to produce a standard curve formed of known concentrations; these were 
duplicates of 0, 2, 5, 10, 15 and 20 mg ml-1 made up in a total volume of 800µl. Cell 
lysates were diluted using 1µl and 2µl of cell lysate in a final volume of 800µl with ddH2O 
for each sample. 200µl of Protein Assay Dye Reagent Concentrate (Bio-Rad) was added 
to each sample before being vortexed and incubated for 5 minutes at room temperature. 
Afterwards, 200µl of each sample, starting with the standard curve, was loaded in 
duplicate into a flat-bottom 96-well plate. The plate was then read at 595nm using a 
SpectraMax M5e Multimode Plate Reader (Molecular Devices).  
The concentrations of the cell lysates were then estimated by determining the average 
concentrations of the 1µl and 2µl duplicates for each sample using the standard curve 
generated by the SoftMax Pro software based on absorbance readings. These were then 
used averaged to estimate the concentrations of each cell lysate. 
2.2.21.3 Assessment of steady-state protein levels by western blotting 
A volume of cell lysate equating to 50µg of total protein was treated with Sample 
Dissociation Buffer (see Section 2.1.4.3) and incubated at 37°C for 15 minutes and then 
loaded into a 12% acrylamide gel that was cast using the Mini-Protean Tetra Cell system 
prepared by casting a 12% Resolving Gel and then casting a 3.75% Stacking Gel (see 
Table 2.3) above it to load the cell lysate samples. The gel was placed in Running Buffer 
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(see Section 2.1.4.3) and subjected to electrophoresis at 200V for approximately 50 
minutes.  
 
Table 2.3 Polyacrylamide gel casting reagents and solutions 
Reagents are listed in Section 2.1.3.6 and solution mixtures are outlined in Section 2.1.4.3 
 
The proteins were transferred on to a Polyvinylidene fluoride (PVDF) membrane in by 
layering the PVDF membrane and acrylamide gel and laying them between 2 sheets of 
Whatman paper using the Mini Trans-Blot Cell system (Bio-Rad), placed in Transfer 
Buffer (see Section 2.4.1.3) and run at 100V for 1 hour. The membrane was check for 
successful transfer of the marker ladder bands and was blocked in 5% skimmed milk in 
TBS-T buffer (see Section 2.1.4.3) for 1 hour before immunoblotting (see Section 
2.2.22). 
2.2.22 Blue Native-PAGE 
2.2.22.1 Enrichment of mitochondria 
Fibroblast cell lines cultured to 80% confluency in at least 2 T225 flasks were harvested. 
The harvested cells were suspended in Homogenisation Buffer (see Section 2.1.4.4) and 
kept on ice. The suspension was homogenised using a Teflon-Dounce homogeniser 
(Glas-col) with 15 passes at 80 rpm at 4°C and then centrifuged at 400g for 10 minutes 
 12% Resolving Gel 3.75% Stacking Gel 
Acrylamide/Bis-acrylamide 30% 29:1 2ml 0.625ml 
3.7M Tris HCl, pH 8.5 0.5ml - 
0.5M Tris HCl, pH 6.8 - 1.25ml 
dH2O 2.395ml 3.02ml 
10% SDS 50µl 50µl 
10%APS 5µl 5µl 
TEMED 50µl 50µl 
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at 4°C. The supernatant was collected, and the pallet was resuspended in homogenisation 
buffer and the homogenisation process was repeated a further 2 times and the resulting 
supernatants were also collected. The collected supernatant samples were centrifuged at 
400g for 10 minutes at 4°C to remove any transferred debris and the supernatants were 
collected again. The collected supernatants were centrifuged at 11,000g for 10 minutes at 
4°C and the supernatant was discarded. The pellet was resuspended in a homogenisation 
buffer lacking BSA and PMSF and flash frozen in liquid nitrogen and stored at -80°C.  
2.2.22.2 Solubilisation of enriched mitochondria  
Samples pellets were suspended in Solubilisation Buffer while on ice and mixed using a 
glass spatula and incubated for 30 minutes. The suspensions were transferred to glass 
ultra-centrifuge tubes and centrifuged using an ultra-centrifuge at 100,000 g for 15 
minutes at 4°C. The supernatant was collected, and the protein concentration was 
estimated using the Pierce Bicinchoninic Acid (BCA) Protein Assay Kit. 
2.2.22.3 BCA protein assay 
The protein concentration on solubilised samples was determined using a BCA assay 
(Pierce). Bovine serum albumin (BSA) was used to produce a standard curve formed of 
known concentrations; these were 250, 125, 50, 25, 5 and 0 µg ml-1. Concentrations were 
measured by diluting 1µl and 2µl of the solubilised samples in a total of 100µl ddH2O for 
each sample. Samples were vortexed and 25µl of each sample was added in duplicates to 
a flat-bottom 96-well plate.  
The BCA Assay mixture was prepared as follows: 50 parts Reagent A: 1 part Reagent B. 
200µl of the BCA Assay mixture was added to each sample in the plate and then shaken 
and incubated for 30 minutes at 37°C. Afterwards, the plate was then read at 562nm using 
a SpectraMax M5e Multimode Plate Reader (Molecular Devices).  
The protein concentrations of the solubilised samples were then estimated by determining 
the average concentrations of the 1µl and 2µl duplicates for each sample using the 
standard curve generated by the SoftMax Pro software based on absorbance readings. 
These were then used averaged to estimate the concentrations of each solubilised sample. 
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2.2.22.4 Assessment of OXPHOS complex assembly using BN-PAGE 
OXPHOS complexes were assessed in enriched mitochondrial pellets solubilised with 
DDM by BN-PAGE in patient and control fibroblast cells. 15 µg of protein were mixed 
with 5 µl of 5% Coomassie Blue and run on precast NativePAGE™ 4-16%, Bis-Tris, 
mini protein gel and subjected to electrophoresis in 1X NuPAGE™ cathode buffer at 150 
V for 30 minutes using the XCell Surelock Mini-Cell electrophoresis system. The cathode 
buffer was replaced with 1X NuPAGE™ anode buffer and run at 300 V for 3 hours.  
The proteins were transferred on to a PVDF membrane in by layering the PVDF 
membrane and acrylamide gel and laying them between 2 sheets of Whatman paper using 
the Mini Trans-Blot Cell system (Bio-Rad), placed in 1X NuPAGE™ Transfer Buffer 
(see Section 2.4.1.4) and run at 100V for 1 hour. The membrane was check for successful 
transfer of the marker ladder bands and was blocked in 5% skimmed milk in TBS-T buffer 
(see Section 2.1.4.3) for 1 hour before immunoblotting (see Section 2.2.22). 
2.2.23 Immunoblotting 
The PVDF membranes were incubated with a primary antibody of target protein 
(Appendix B) diluted as recommended in 5% milk in TBS-T and incubated at room 
temperature for 3 hours or at 4°C overnight. The primary antibody was then removed, 
and the membrane was washed with TBS-T 3 times for a period of 10 minutes each. The 
membrane was then incubated in the respective Horseradish peroxidase (HRP) 
conjugated secondary antibody (diluted as recommended in 5% milk in TBS-T) at room 
temperature for 1 hour. The secondary antibody was then removed, and the membrane 
was washed with TBS-T 3 times for a period of 10 minutes each. The membrane was then 
treated with Electrochemiluminescence (ECL) prime (GE Healthcare) using 1:1 mixture 
of the substrates for 5 minutes and bands were visualised on a ChemiDoc Imager MP 
(Bio Rad).  
2.2.24 Analysis of respiratory chain complex activity 
These studies were performed by Dr Langping He at the NHS Highly Specialised Service 
for Rare Mitochondrial Disorders in Newcastle upon Tyne, UK. 
Mitochondrial respiratory chain enzyme activities were assayed spectrophotometrically 
as previously described in patient fibroblasts (Frazier et al., 2020) and in muscle samples 
(Bugiani et al., 2004). In summary, respiratory chain activities of complexes I-IV are 
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measured in enriched mitochondrial fractions through assays that either measure a 
decrease or increase in absorbance spectrophotometrically of the enzyme substrate or a 
linked substrate; all respiratory chain enzyme activities are normalised to the activity of 
citrate synthase (CS), a mitochondrial matrix enzyme of the TCA cycle and marker of 
mitochondrial content.  
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Chapter 3. Identification of a paediatric patient cohort in 
Kuwait with suspected mitochondrial disease 
 
 Introduction 
Due to the clinical heterogeneity associated with mitochondrial disease, criteria have been 
developed to predict the likelihood of mitochondrial disease involvement in patients 
(Wolf and Smeitink, 2002; Morava et al., 2006). These clinical diagnostic criteria take 
into account the clinical presentation and findings in a patient at a certain time, while 
other reports published by Joost et al. (2012) and Chi (2015) provide a detailed flowchart 
outlining how patients are investigated. Some diagnostic flowcharts try to avoid the need 
for a muscle biopsy when suspecting mitochondrial disease since a “genetics first” 
approach has become a more rapid and cost-effective method in recent years. However, 
many of the aforementioned criteria continue to include a section for histological and/or 
biochemical findings in muscle biopsies of patients which may support the suspicion of 
mitochondrial disease. Pathogenic variants and deletions in the mitochondrial genome 
have been associated with maternally-inherited mitochondrial disease, whereas variants 
in the nuclear genome follow Mendelian patterns of mitochondrial disease inheritance 
(autosomal, sex-linked, and de novo) (Stenton and Prokisch, 2020; Thompson et al., 
2020a). The “genetics first” approach, especially when using next generation sequencing 
methods can help avoid the need for a muscle biopsy to confirm suspicions of 
mitochondrial disease involvement (Raymond et al., 2018). Should a patient not be 
diagnosed using this approach, the need for a muscle biopsy is justified for follow-up 
biochemical investigations and multi-omics approaches to reach a diagnosis. 
Confirmed mitochondrial disease cases have been scored using scales that assess disease 
progression in patients: Newcastle Mitochondrial Disease Adult Scale (NMDAS) 
(Schaefer et al., 2006), Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) 
(Phoenix et al., 2006) and International Paediatric Mitochondrial Disease Scale (IPMDS) 
(Koene et al., 2016). These scales are useful in longitudinal studies and meticulously 
gather information repeatedly. However, these scales were not fit for this project as they 
were utilised on confirmed mitochondrial disease cases, while a primary aim of this study 
is to diagnose mitochondrial disease cases in Kuwait by initially reviewing and selecting 
highly suspected cases. 
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Kuwait’s population of 4.2 million is comprised of 1.3 million Kuwaiti nationals and 3.1 
million foreigners residing in Kuwait (Central Bureau of Statistics, 2018). Amongst the 
populations of Kuwait and other Arab country population, the practice of consanguinity 
and endogamy are common with rates exceeding 50% in some regions (Modell and Darr, 
2002; Tadmouri et al., 2009). The prevalence of inherited disorders in such populations 
with high rates of consanguinity is often higher than in non-consanguineous populations 
and has a major effect on the clinical genetics of the population (Skladal et al., 2003; 
Shawky et al., 2013). 
Patients in Kuwait referred to the Kuwait Medical Genetics Centre (KMGC) from 
governorate and specialised hospitals were reviewed for recruitment to the study. KMGC 
primarily employs Sanger sequencing of mtDNA for suspected pathogenic mutations. 
However, diagnosis rates for mitochondrial disease were poor considering the population 
is highly consanguineous. We required a process to evaluate and prioritise cases based on 
ranked suspicion of mitochondrial disease involvement to include in the study. This 
would help exclude cases presenting with phenocopies of mitochondrial disease.  
For recruitment of cases to the study, we required criteria that scored the presentation and 
findings of patients at the time of assessment and review. I opted to develop criteria that 
took into account the available and gathered clinical data of patients and helped assess 
whether they are suspected of having mitochondrial disease. Depending on the scores and 
time of recruitment, cases were recruited to the study over the period of two and a half 
years and were prioritised for unbiased genetic testing using WES.  
Upon the identification of likely pathogenic variants in the recruited patients, a 
segregation study confirmed the variant segregated within the family pedigree. Skin 
biopsies were acquired from patients when possible and functional studies using Western 
blotting and Blue Native-PAGE to assess the effect of the identified variants on protein 
expression and OXPHOS complex assembly when suspected. 
 Aims 
The aim of this chapter is to outline the scheme used to recruit cases suspected of 
mitochondrial disease involvement to the study. This includes a flowchart of how patients 
were reviewed by experts and a description of a mitochondrial disease criteria used to 
score patients. This is followed by descriptions of clinical presentations and 
investigational findings in patients suspected of mitochondrial disease and recruited for 
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the study. Limitations of the recruitment process and findings that strongly support 
suspicion of mitochondrial disease involvement are discussed in addition to advantages 
of the recruitment process  
 Methods  
Kuwait is divided into six governorates: The Capital, Hawalli, Al Farwaniya, Mubarak 
Al-Kabeer, Al Ahmadi and Al Jahra governorates. Five major government hospitals serve 
these governates and the Al-Sabah Health Region houses multiple specialised hospitals 
where patients from the major hospitals are referred to for specialised care and follow-
up. KMGC is one of these specialised medical centres and is located adjacent to the 
Maternity Hospital in the Al-Sabah Health Region (Figure 3.1).  
The governorates have Health Centres providing General Physician Clinics that serve 
every residential area. When necessary, these clinics refer patients to specialists based at 
the major Governorate Hospitals or the Al-Sabah Health Region to provide specialised 
care and follow-up. Alternatively, patients admitted to the Intensive Care Units of the 
major hospitals are also seen by (and referred to) the appropriate specialists based at the 
hospital. 
Patients suspected of genetic disorders are referred to the KMGC for genetic investigation 
and diagnosis. Clinicians specialised in genetic disorders review referred patients with 
the benefit of referral notes which chart the course of disease with a summarised clinical 
history, previously requested test results, and imaging reports. A detailed family pedigree 
is drawn, and required tests, scans and genetic analyses are requested based on the 
suspected genetic disorder.  
Cytogenetic karyotyping and Fluorescent in situ hybridisation (FISH) protocols are run 
by two separate laboratories at KMGC to identify any chromosomal aneuploidies or 
deletions. The molecular genetics laboratory uses various genetic analysis techniques 
such as Restricted Fragment Length Polymorphism (RFLP), Amplification-Refractory 
Mutation System (ARMS)-PCR, Quantitative-PCR (qPCR), Multiplex Ligation-
dependent Probe Amplification (MLPA), and Sanger sequencing to genotype point 
mutations, indels or large deletions in genes associated with known genetic disorders. 
Sanger sequencing of mtDNA is performed for patients suspected of mitochondrial 
disease to search for mutations in disease associated genes; no nDNA mutations 
associated with mitochondrial disorders are genotyped or targeted at KMGC. In some 
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genetically undiagnosed cases, patient DNA samples are sent to commercial companies 
(e.g., CentoGene, CGC and GeneDx) that provide genetics analysis services such as WES 





Figure 3.1 Map of Kuwait Governorates and locations of main hospitals that refer 
cases to KMGC in the Al-Sabah Health Region 
A map of Kuwait with its 6 governorates labelled and shaded in different colours. 
Circles are locations of the main public hospitals that refer cases to KMGC. The red star 
is the location of KMGC within the Al-Sabah Health Region where patients are referred 
to. (Adapted from Vemaps.com (Vemaps, 2019)) 
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3.3.1 Selection of patients suspected of mitochondrial disease in Kuwait for study 
cohort 
The recruitment scheme used for recruitment of patients in Kuwait is outlined in Figure 
3.2 with the number of cases. This section describes the review steps in detail.  
3.3.1.1 Paediatric metabolic specialist review 
Paediatric cases in Kuwait suspected of mitochondrial disease were reviewed by Dr 
Buthaina Albash a paediatric metabolic specialist based at KMGC. Out of a total of 250 
cases reviewed and investigated 136 were excluded from recruitment by the metabolic 
specialist based on clinical expertise due to poor clinical details, missing investigational 
results, or suspicion of alternative disorders other than mitochondrial disease. The 
remaining 114 cases were recruited for this study and consents were obtained from 
participating patient families. Of the recruited cases, 21 cases were previously 
investigated by WES. The majority of reviewed families were related either as first 
cousins, second cousins, or distant cousins due to high rate of consanguinity within the 
population of Kuwait which results from societal practices.  
3.3.1.2 Mitochondrial Disease Criteria Scoring 
The remaining 93 cases were scored using Mitochondrial Disease Criteria (MDC) based 
on the Morava criteria that is aimed at assessing paediatric cases suspected of 
mitochondrial disease involvement (Figure 3.3) (Morava et al., 2006). Modifications to 
the published criteria include the renaming of the morphology column to “tissue findings” 
after the addition of respiratory chain enzyme activities to morphological tissue findings. 
Furthermore, an additional row separating “Highly Suggestive Findings” was added to 
“Suggestive Findings”. Patients were scored based on findings identified from personal 
history, family history, and clinical examination.  
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Figure 3.2 Flowchart outlining filtration and selection scheme of patients suspected 
of mitochondrial disease in Kuwait for the study cohort 
The flowchart outlines how candidate cases from Kuwait are reviewed, investigated and 
excluded at different stages of the recruitment process. Cases referred to the Kuwait 
Medical Genetics Centre are reviewed and investigated by a metabolic specialist and 
cases were excluded based on clinical opinion. Selected families were then excluded 
based on genetic analysis status and the remaining were reviewed and scored with the 
MDC. Cases not pending investigation results, nor excluded based on score, were 
reviewed by a mitochondrial disease specialist. Cases were either excluded, 
investigated, or approved for the study based on clinical expertise in the field. Approved 
cases were prioritised and recruited, but some cases were not reachable or consent for 
research was not obtained resulting in a reduction in number of cases recruited.  
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 MRI suggestive 
Elevated CSF lactate 
Elevated serum lactate 
 
RCC enzyme deficiency* 
Reduced COX staining** 
Ragged red fibres** 
Abnormal mitochondria/ EM 
Suggestive 
Findings 
(1 point each) 
Hypotonia 










GI Tract (dysmotility) 










Failure to thrive  
Family history 
Elevated pyruvate 
Elevated L/P ratio 
Elevated alanine 
Abnormal urine organic 
acids 
MRI symmetric lesions  
MRI cerebral atrophy 
MRS elevated lactate  
Reduced SDH staining 
 
Max Limit 2 2 3 4 4 
 
Figure 3.3 Mitochondrial disease criteria used to score presentations and investigation results of patients referred to the study. 
CSF; cerebrospinal fluid; CNS: central nervous system; COX: Cytochrome c oxidase; EEG: electroencephalogram; EM: electron microscopy; 
EMG: electromyogram; GI tract: gastrointestinal tract; ECHO: echocardiogram; RCC: respiratory chain complex; SNHL: sensorineural hearing 
loss. Scores 2-4: possible mitochondrial disease; Scores 5-7: probable mitochondrial disease; Scores ³8: definite mitochondrial disease. * 2 points 
for isolated complex deficiency, 4 points for multiple complex deficiency. ** 4 points each
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Scoring using these criteria emphasised highly suggestive findings paving the way to 
compile and score cases to recruit for the study. Based on the Morava et al. (2006) criteria, 
maximum limits are placed for all categories. This resulted in the sacrifice of criteria 
sensitivity to mitochondrial disease in order to maintain high specificity towards 
mitochondrial disease characterisation. The maximum limits were not changed for any of 
the categories. 
3.3.1.2.1 Neuromuscular / CNS 
The first category scores Neuromuscular presentations and highlights ophthalmoplegia 
and facies myopathica as presentations highly associated with mitochondrial disease. The 
second category scored central nervous system (CNS) presentations and investigational 
findings were developmental regression and ataxia in patients were emphasised as highly 
suspected of mitochondrial disease involvement. The first two categories each had a 
maximum of 2 points each to avoid inflation of scores in these categories where multiple 
presentations and findings are not necessarily suggestive of mitochondrial disease only 
but other disorders as well.  
3.3.1.2.2 Multiple system involvement 
The third category scored the involvement of multiple systems in patient presentations. 
Organs included high energy dependent organs such as the heart, GI tract, kidneys, and 
liver. Affected functions commonly associated with mitochondrial disease such as vision 
and hearing were also included along with neuropathy, failure to thrive and a family 
history of mitochondrial disease. This category’s maximum limit is set to 3 to account for 
multisystem involvement in scored patients without inflating the score. That is to say, 
once multisystem involvement is established there is no additional diagnostic benefit 
from simply scoring more organ involvement 
3.3.1.2.3 Metabolic and Imaging 
The fourth category scores “Metabolic and Imaging” findings after investigations. This 
includes blood, cerebrospinal fluid (CSF) and urine investigations along with MRI 
neuroradiological scans. Elevated lactate in blood and CSF were highlighted as findings 
highly associated with mitochondrial disease. MRI findings suggestive of mitochondrial 
disease involvement such as Leigh syndrome and basal ganglia disease were also highly 
associated with mitochondrial disease (Lake et al., 2016). The maximum limit for this 
category was set to 4 to account for investigative results. 
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3.3.1.2.4 Tissue findings 
The fifth and final category was modified compared to the Morava criteria that focused 
solely on cell morphology in tissue samples. The category scores “Tissue findings” and 
includes respiratory chain enzyme activities in tissue, which deficiencies are likely 
indicators of mitochondrial disease in patients in addition to reduced staining of complex 
IV, ragged red fibres, and electron microscope findings showing abnormal mitochondrial 
structures. The maximum limit for this category was also set to 4. 
3.3.1.2.5 Scoring patients 
Highly suggestive findings score 2 points each, while suggestive findings score 1 point 
each. Morphological findings of reduced complex IV activity and ragged red fibres score 
4 points each as they are clear indicators of mitochondrial disease (Zafeiriou et al., 1995). 
As suggested by the Morava criteria, the scores were grouped into 3 categories. Scores 
between 2 and 4 points suggest a possible mitochondrial disease involvement, a score 
between 5 and 7 points suggest probable mitochondrial disease involvement, and a score 
of 8 and greater suggest definite mitochondrial disease involvement.  
Mitochondrial disorders fall under the umbrella of inborn errors of metabolism (IEM) 
disorders often with overlapping clinical features such as axial hypotonia, developmental 
delay and failure to thrive. Consequently, patients were thoroughly investigated at KMGC 
to exclude any other IEM disorders prior to consideration for the study.  
Most mitochondrial diagnostic criteria heavily relied on functional and biochemical 
findings from patient biopsy samples, which were not always available for this patient 
cohort. As biopsy investigations are not routinely performed in Kuwait, we were 
concerned that his would influence the scoring system, depleting patient scores and 
suggestive of no mitochondrial disease involvement. To compensate for this in the 
recruitment process, more emphasis was placed on the availability of radiological MRI 
findings and corresponding clinical presentations suggestive of mitochondrial disease 
such as bilateral symmetric involvement of the basal ganglia, brainstem, corpus callosum, 
and the cerebellum (Lake et al., 2016). The availability of laboratory and test results 
supported candidacy of patients for recruitment. Consequently, the adapted version of the 
Morava criteria relied more on the first four categories that can be reported, investigated 
and scored in most patients. Only a few referred cases had muscle biopsies collected and 
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analysed which heavily increased their chances of recruitment based on the biopsy 
findings.  
3.3.1.2.6 Paediatric neurologist review 
The highest scoring patients were further reviewed by a paediatric neurologist and one of 
my Ph.D. supervisors, Prof Robert McFarland, a specialist in mitochondrial disease based 
at the Wellcome Centre for Mitochondrial Research Newcastle University. This allows 
the input of longstanding clinical expertise to select those patients most likely to have a 
mitochondrial disease and where possible, classify them further on clinical grounds e.g., 
Leigh Syndrome, Congenital Progressive External Ophthalmoplegia (CPEO), mtDNA 
depletion syndrome (MDDS) as well as confirming selected patients or excluding cases 
that were suggestive of disorders other than mitochondrial disease. Many patients were 
excluded from the study due to the lack of clinical data, laboratory findings or radiological 
imaging.  
On a number of occasions, the metabolic specialist at KMGC shortlisted several 
mitochondrial disease patients and invited Prof McFarland to Kuwait to view the cases in 
clinic. This resulted in the recruitment of a further seven families to our study. The cases 
were scored, and consent was obtained for recruitment. DNA from probands and their 
family members was extracted from peripheral blood and sent to the Wellcome Centre 
from Mitochondrial Research (WCMR) in Newcastle. Proband DNA samples were 




3.4.1 Clinical reports of recruited patients  
This section describes the clinical phenotypes and finding of patients recruited in our 
cohort.  
3.4.1.1 Family 1  
Patient 1-I (MDC score: 7) was a Kuwaiti Arab Bedouin female patient born to 
consanguineous first cousin parents. She was born by normal delivery at 37 gestation 
weeks with birth weight of 2.9 kg. She presented from birth with hypertrophic 
cardiomyopathy with echocardiography showing ventricular hypertrophy and small 
arterial septal defect (ASD). At the age of 4 months, she was considered to be 
developmentally delayed and was noted to have generalised hypotonia, abnormal hearing, 
nystagmus, and was found to have a pericardial effusion. Brain MRI scan showed a thin 
corpus callosum. She passed away at the age of 1 year and 2 months and the cause of 
death was not reported. She had 2 affected older brothers who also passed away early in 
life. No mtDNA mutations were reported for Patient 1-I. 
The older (affected) brother of I-1 (Patient 1-II; MDC score: 11) was born at full term 
after an uneventful pregnancy with birth weight of 2.9 kg. He was developmentally 
delayed from early life only being able to hold his head and show a social smile at 6 
months. After his immunisation at 6 months, he became febrile and floppy. His 
development progressed slowly achieving the ability to roll at the age of 1 year and later 
developed hearing problems and nystagmus. Severe hypotonia was later noted with 
normal reflexes and he was fitted with hearing aids and started wearing glasses. Blood 
investigations showed a slight increase in lactate, thyroid stimulating hormone (TSH) and 
uric acid levels and mildly elevated aspartate aminotransferase (AST) level. A muscle 
biopsy was obtained from the patient and respiratory chain enzyme activity analysis 
showed reduced overall activities in complexes I to IV. There are conflicting reports on 
whether he developed hypertrophic cardiomyopathy. He passed away around the age of 
2 years and 9 months and the cause of death was not reported. 
The younger (affected) brother of I-1 (Patient 1-III; MDC score: 5) was born at 36 weeks 
gestation with birth weight of 2.7 kg. His mother had gestational diabetes. He presented 
with concentric cardiomyopathy from birth, showed developmental delay, and became 
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hypotonic with episodes of lactic acidosis with elevated pyruvate and increased lactate to 
pyruvate ratio. In addition, blood investigations revealed elevated Creatine Kinase (MM 
and MB), ALT, and 3-b-hydroxybutyrate levels increased as well. He passed away around 
the age of 1 year and 3 months and the cause of death was not reported.  
Upon comparison of presentations and progress of disease in the affected siblings of this 
family, the proband and her younger brother presented more similarly than their older 
affected brother.  
3.4.1.2 Family 2  
Patient 2 (MDC score: 10) is a 5 year-old Jordanian Arab female patient living in Kuwait 
born to consanguineous paternal first cousin parents. She was born at full term with birth 
weight 3.0 kg. Family history revealed multiple neonatal deaths. The patient was 
exclusively breast fed. Around the age of 1 month, the patient developed excessive crying 
with abnormal movements for 3 days before becoming lethargic and admitted to the 
hospital. She developed 2 episodes of general tonic-clonic seizures during her admission 
and were controlled by IV phenobarbitone. CSF lactate (3.83 mmol/l), blood lactate (7.33 
mmol/l) and blood pyruvate (111 μmol/l) were all elevated with a significantly high 
lactate/pyruvate ratio (66) reported. CT head scan at 1 month showed areas of 
hypodensity in the central brain stem and thalami suggestive of a metabolic disorder. The 
EEG rhythms in the awake state were slow but there was no evidence of epileptiform 
discharges. This finding supported the suggestion of metabolic disease involvement. 
MRI brain scan at 1 month showed bilateral symmetric high T2 signals in the lentiform 
nuclei (sparing the caudate), pons and medulla oblongata suggestive of mitochondrial 
disease involvement (Figure 3.4). The patient was started on L-carnitine, coenzyme Q, 
Thiamine and a ketogenic diet. Blood lactate levels normalised during the following 












Figure 3.4 Brain MRI neuroradiological images for Patient 2 
Axial (A) and coronal (B) MRI brain scan images for Patient 2 at 1 month showing 
bilateral symmetric T2 signals in the thalami (yellow arrows)  
 
 
3.4.1.3 Family 3  
Patient 3 (MDC score: 7) is a 10 year-old Syrian Arab male patient living in Kuwait born 
to consanguineous first cousin parents. He was born at full term by normal delivery with 
birth weight 3.2 kg and Apgar scores of 9 and 10 at 1 minute and 5 minutes respectively. 
He presented from birth with seizures and tachypnoea accompanied by elevated CK and 
alanine levels in blood, elevated lactate in both CSF and blood (>13 mmol/L) and elevated 
blood pyruvate levels resulting in a high lactate/pyruvate ratio. Developmental delay was 
noted from the second month of life and hypotonic limbs with persistent lactic acidosis 
were later observed at the age of 5 months. He had a generalised tonic-clonic seizure at 
the age of 5 years.  
Brain MRI scan at 5 years revealed T1, T2 and FLAIR signals in the upper pons and 
midbrain of the left side and bilateral signals in globus pallidus with involvement of 
internal capsule. Restricted diffusion also reported bilaterally in globi pallidi. Thinning 
of the posterior part of the corpus callosum was also reported along with mild dilatation 
of lateral and third ventricles. The EEG report noted abnormal background activity and 







that were controlled using sodium bicarbonate. No mtDNA mutations were reported for 
Patient 3. Family history revealed Patient 3 has an older affected brother who presented 
with a similar phenotype. 
3.4.1.4 Family 4  
Patient 4-I (MDC score: 8) was the first-born Syrian Arab female child to consanguineous 
first cousin parents who live in Kuwait. She was born at full term by normal delivery after 
an uneventful pregnancy with birth weight of 3.6 kg. She was investigated in Syria for 
hypertrichosis at the age of 2 years and was diagnosed with congenital adrenal hyperplasia 
prompting treatment with oral hydrocortisone; this clinical diagnosis was later revoked 
when serum cortisol, 17 hydroxyprogesterone, androstenedione and testosterone levels 
were normal before and after adrenocorticotropic hormone (ACTH) stimulation test. At 
2 years and 8 months, she was noted to have developmental delay with body 
measurements below the 5th centile (weight: 9.5 kg, height: 83 cm; head circumference: 
46 cm. She was slightly hypotonic with reduced DTRs; besides synophrys and hirsutism 
no dysmorphic features were noted. Measured serum lactate was slightly elevated (2.8 
mmol/l). An MRI brain scan at 2 years 9 months showed bilateral high T2 signals 
involving the caudate nuclei, cerebral peduncles, dorsal midbrain, colliculi and distal 
medulla. Furthermore, high T2 signals in the cerebellar white matter just below the level 
of middle cerebellar peduncles at the region of dentate nuclei were also reported. At 3 
years and 5 months, she was noted to exhibit a long philtrum, hypertelorism, 
brachycephaly, mild clinodactyly, generalised hypertrichosis and normal female 
genitalia. At 4 years and 6 months, she developed a severe pneumonia requiring 
intubation and assisted ventilation, but unfortunately, she passed away. 
Her first younger brother, Patient 4-II (MDC score: 9), was born at full term after an 
uneventful pregnancy with birth weight of 3.5 kg. He was healthy until the age of 2 
months when he became floppy and started to lose weight. At 12 months, he was noted 
to have delayed development, hypotonia with hyporeflexia, generalised muscle weakness, 
muscle wasting and failure to thrive. His body measurements were all below the 5th 
centile. Serum lactate was elevated on several occasions (over 3.0 mmol/l). An MRI brain 
scan at 15 months showed diffuse cerebral atrophy and high signal intensity lesions 
involving the cerebral peduncles, periaqueductal grey and the cerebral white matter. His 
development started to regress and became bed bound. His vision and feeding were 
deteriorating, and he developed ophthalmoplegia, ptosis, bulbar weakness, and wasting 
 118 
and weakness of all muscles. He was socially interactive but had a clear intellectual 
disability. A follow-up MRI brain scan at 20 months revealed changes in deep white 
matter of frontal, parietal, temporal and occipital lobes as well as increased signal 
intensity in cerebral peduncles, dorsal brain stem, cerebellar white matter and dentate 
nuclei. He was admitted in an unconscious state shortly after this MRI scan but recovered 
after 3 days of assisted ventilation on the paediatric intensive care unit. He later developed 
hypoventilation associated with bradycardia. His respiration deteriorated until he passed 
away at the age of 21 months. 
Their younger affected brother, patient 4-III (MDC score: 7), was born at 37 gestation 
weeks by emergency caesarean section due to oligohydramnios complication during 
pregnancy. His birth weight was 3.0 kg with Apgar scores of 8 and 9 at 1 minute and 5 
minutes respectively He was doing well until the age of 14 months when his development 
started to regress, and he became spastic. Serum lactate levels were elevated (4.2 mmol/l) 
and an MRI brain scan at 18 months showed bilateral symmetrical high T2 and T2-FLAIR 
signal areas in deep cerebellar white matter, deep pyramidal tract of lower pons, medulla 
and in midbrain (Figure 3.5). At 19 months, he presented with ptosis, hypertonia in both 
upper and lower limbs with hypotonic neck and axial muscles and was microcephalic 
(head circumference below 3rd centile). Investigations confirmed elevated lactate levels 
(3.75 mmol/l) and uncovered elevated levels of pyruvate (173 µmol/l), creatine kinase 
(540 U/L), and creatinine (84 µmol/l). He arrested suddenly and passed away at home. 















Figure 3.5 Brain MRI neuroradiological image for Patient 4-III. 
Axial MRI image of Patient 4-III at 18 months showing bilateral symmetric high T2-
FLAIR signals in the medulla oblongata (yellow arrows).  
 
 
3.4.1.5 Family 5  
Patient 5-I (MDC score: 8) is a 13 year-old Arab Bedouin male patient born at full term 
to consanguineous first cousin parents who live in Kuwait. His delivery was by caesarean 
section due to pre-eclampsia with birth weight 3.2 kg followed by an uneventful postnatal 
period. He was repeatedly admitted with a wheezy chest and gastro-oesophageal reflux 
disease (GORD). At 3 months, he was admitted due to recurrent seizures presenting as 
cyanosis and apnoea and was diagnosed with epilepsy. He was started on Phenobarbitone 
to control his seizures and domperidone and cimetidine to treat his GORD. He stopped 
his medication at the age of 2 with no reports of seizures or GORD thereafter. At 6 
months, he was presented with lactic acidosis and was started on Thiamine and sodium 
bicarbonate. At 15 months, he was reported to have global developmental delay and only 
started walking at the age of 2 years; he did not form sentences until the age of 9 years. 
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At 4 years, his weight was at the 50th centile and his head circumference was <5th centile. 
Routine blood investigations were normal except for elevated lactate (4.5 mmol/l). At 13 
years, he was noted to have a short stature, thin body habitus, mild brachycephaly and 
mild dysmorphic features with no facial weakness. No mtDNA mutations were reported 
for Patient 5-I. 
The younger brother, Patient 5-II (MDC score: 9), is a 9 year-old male patient born full 
term by caesarean section due to breech presentation with birth weight 3.520 kg. He was 
admitted to NICU for 12 days due to transient tachypnoea of the newborn and lactic 
acidosis. His serum lactate and ammonia levels were elevated (9.2 mmol/l and 124.9 
µmol/l respectively). His ammonia levels normalised but his serum lactate remained 
slightly elevated at 3.15 mmol/l. At 1 month, he was diagnosed with GORD and was 
started on domperidone and ranitidine. For his lactic acidosis, he was also started on 
sodium carbonate and commenced a ketogenic diet. At 13 months he was noted to be 
hypotonic, had global developmental delay (delayed gross motor skills and speech), and 
had mild dysmorphic features. He started walking at 22 months but by 30 months he was 
frequently falling especially while running. At 9 years, he was noted to have a short 
stature, thin body habitus and mild brachycephaly. 
Their younger sister, patient 5-III (MDC score: 5), is a 2 year-old female patient that was 
admitted to the NICU due to respiratory distress, cyanosis and reluctance to feed; she was 
diagnosed with GORD. By the age of 7 months, she had repeat attacks of lactic acidosis. 
She was started on Thiamine and sodium bicarbonate in an attempt to treat the lactic 
acidosis and is now on a ketogenic diet managed by a dietician.  
3.4.1.6 Family 6  
Patient 6 (MDC score: 6) was an Egyptian Arab male patient born to consanguineous first 
cousin parents who live in Kuwait. His mother had pregnancy induced hypertension but 
gave birth to him at full term with a birth weight of 2.7 kg with no neonatal issues 
reported. At 4 months of age, he presented with nystagmus, myopia and hypotonia. At 18 
months he experienced a seizure attack. At 20 months he was diagnosed with bilateral 
sensorineural hearing loss and was fitted with hearing aids 2 months later. By the age of 
2 years, the patient was noted for midfacial hypoplasia and was developmentally delayed 
(delayed speech, only sounds). At 3 years, he was admitted due to hypoglycaemia and 
had metabolic acidosis. Laboratory tests revealed low blood glucose level (2.0 mmol/L, 
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normal range 3.9 - 7.1 mmol/L), elevated serum lactic acid (10 mmol/L) which 
normalised after the hypoglycaemic attack, elevated liver function enzymes ALT 187 
IU/L and AST 225 IU/L (normal range < 40 IU/L for both), and urine organic acid showed 
significantly elevated adipic acid. An ECHO at 3 years revealed mild left ventricular 
hypertrophy, pericardial effusion, and minimal mid cavity obstruction. He later developed 
cataracts and subsequently developed vision loss. A brain MRI scan at 3 years showed 
mild reduction in brain volume. The patient developed another seizure attack at the age 
of 8 years and passed away shortly after; no report on the cause of death was available. 
No mtDNA mutations were reported for Patient 6. 
3.4.1.7 Family 7 
Patient 7-I (MDC score: 8) was a Syrian Arab female born to consanguineous second 
cousin parents. She was born at full term by caesarean section delivery due to breech 
position with a birth weight of 2.7 kg and Apgar scores of 2 at 1 minute, 7 at 5 minutes, 
and 9 at 10 minutes. She was admitted to the NICU for 7 days due to mild respiratory 
distress, subgaleal haematoma and jaundice. At 2 years, her development was delayed but 
no regression was noted. She continued to gain skills (walking, speech, vision and 
hearing) until the age of 4 years when she suddenly lost her ability to speak. She gradually 
lost her motor skills, developed progressive hypertonia, became ataxic then wheelchair-
bound, and lastly developed dysphagia. According to her family, she still maintains her 
cognitive skills. Brain MRI scan at 7 years revealed bilateral symmetric high T2 signals 
and low T2 signals in the caudate and putamen (Figure 3.6). At 11 years, she was 
cachectic with dystonia and areflexia. She passed away soon after at the age of 11 years 
and 6 months. No mtDNA mutations were reported for Patient 7-I. 
Her younger brother, patient 7-II (MDC score: 5), is a 10 year-old male who had normal 
development until the age of 9 years when he changed his preferred writing hand from 
the right to the left hand and then developed problems moving his right arm. He later 
developed slurred speech and ataxia. MRI brain scan at 9 years revealed bilateral 
symmetric high T2 signals in the lentiform nuclei, signals in the right caudate head, and 
signals in the left medulla oblongata all with corresponding high FLAIR signals and low 
T1 signals. At 10 years, he developed dystonia with increased tone, decreased power in 
















Figure 3.6 Brain MRI neuroradiological image for patient 7-I 
Axial MRI image of Patient 7-I at 7 years showing bilateral symmetric high T2-FLAIR 




3.4.1.8 Family 8 
Patient 8 (MDC score: 7) is a 2 year-old Kuwaiti Arab Bedouin female who is a product 
of an IVF pregnancy to consanguineous distant cousin parents. Her maternal cousin is 
reported to be blind. She presented with nystagmus at 4 months and a brain MRI scan 
result suggested possible optic neuritis. She improved after she was started on 
prednisolone. She had motor developmental delay and her CSF lactate was slightly 
elevated when measured (2.8 mmol/l). She was noted to be ataxic at 6 months with a 
follow-up MRI brain scan at 10 months revealed new bilateral bright T2-FLAIR signals 
in the subthalamic regions (Figure 3.7). At 2 years, she was noted to have a convergent 













Figure 3.7 Brain MRI radiological images of Patient 8 
Axial (A) and coronal (B) MRI images of Patient 8 at the age of 10 months showing 







3.4.1.9 Family 9 
Patient 9 (MDC score: 9) is a 5 year-old Syrian Arab male patient born to consanguineous 
first cousin parents. He was born full term and was diagnosed antenatally to have 
intrauterine growth retardation (IUGR). At 5 months, his mother noticed his failure to 
thrive, and by 8 months he developed nystagmus and strabismus. MRI brain scan at 18 
months revealed abnormal areas of white matter signal intensity in periventricular white 
matter as well as cerebellar white matter (Figure 3.8). At 2 years, he had developmental 
delay, failure to thrive and walked at 27 months. He was only saying 2 words at that time 
and later was diagnosed with have moderate to severe hearing loss. His lactate levels 
increased to 9.7 mmol/l after a period of fasting in preparation for an audiometry test; this 
was normalised using sodium bicarbonate and he was started on thiamine, L-carnitine and 
coenzyme Q supplements. At 5 years, he was noted for having a thin build, short stature, 
wearing glasses to correct hypermetropia, had alternating strabismus, nystagmus, blue 
sclerae, was hypotonic with muscle weakness affecting his shoulder and hip girdles, 
experiences fatigue during the day, and has a broad-based gait. No mtDNA mutations 




























Figure 3.8 Brain MRI radiological findings in Patient 9 
Axial MRI images of Patient 9 at 18 months showing bilateral symmetric low T1 
signals (yellow arrows; A and C) and high T2 signals (yellow arrows; B and D) in the 





3.4.1.10 Family 10  
Patient 10 (MDC score: 5) is a 60 year-old Kuwaiti female with non-consanguineous 
parents. She presented at 34 years with bilateral ptosis and progressive external 
ophthalmoplegia; a surgery to correct her ptosis was done at the age of 40 years. She 
experienced post-operative pain in the left side of her face; thereafter, she reported 
impaired sensation in the same area. She reported difficulty chewing and choking at times 
which required her to adjust her diet. She had mildly spasticity in her lower limbs with a 
stiff (not ataxic) gait, experienced exercise intolerance and fatigue, had weak proximal 
muscles, and experienced constipation for which she took laxatives. 
3.4.1.11 Family 11  
Patient 11-I (MDC score: 8) is a 6 year-old Kuwaiti Arab Bedouin female born to 
consanguineous first cousin parents. Delivery was by caesarean section followed by an 
uneventful neonatal period with birth weight of 3.0 kg. She had an epileptic episode at 
age of 4 months and later presented with global developmental delay, hypotonia, epilepsy, 
and lactic acidosis. She is microcephalic and has micrognathia. She also has bilateral 
hearing loss; mild hearing loss in the right ear and moderate hearing loss in the left ear. 
MRI brain scan at 4 months reported severe cortical atrophy, hypomyelination of frontal, 
occipital and temporal lobes with calcification of basal ganglia. CT head scan 4 months 
reports multiple bilateral symmetrical foci of calcification in both basal ganglia and 
thalami and bilateral periventricular regions and left cerebellum suggestive of a metabolic 
disorder. No mtDNA mutations were reported for Patient 11-I 
The medical report of the Patient 11-I’s older sister, Patient 11-II (MDC score: 4), 
reported she was born after an uneventful pregnancy with birth weight 3.0 kg and was 
kept in the incubator for 1 day. At 5 months of age, she presented with microcephaly, 
dysmorphic features, developmental delay and hepatitis. She also presented with 
spasticity and brisk DTRs with clonus and had large ears. Patient 11-II passed away and 
the age and cause of death were not available. 
Patient 11-I has an affected 5 year-old female double first cousin, Patient 11-III (MDC 
score: 6), whose parents are also consanguineous first cousins; Patient 11-III's mother is 
the full-sister of Patient 11-I's mother and the cousin's father is the first cousin of both the 
Patient 11-I's mother and father. Patient 11-III was born at full term by caesarean section 
with no perinatal issues and birth weight of 3.0 kg. At the age of 2 years and 2 months, 
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for a period of 2-3 weeks, she presented with sudden jerky movements during her sleep 
which lasted 2-3 minutes and occurred 2-3 times a day. Frequency increased to 10 times 
a day accompanied by nystagmus both vertical and horizontal. Poor feeding and reduced 
activity reported by parents along with increased irritability. No fever, diarrhoea, 
vomiting, head trauma, cyanosis, or intake of medication reported. Blood test revealed 
mild increase in lactate (2.78 mmol/l) and CBC test showed lymphocytic leucocytosis. 
CT head scan reported prominent sulci and ventricular cyst and an MRI brain scan 
reported brain atrophy. 
3.4.1.12 Family 12: 
Patient 12 (MDC score: 7) is a 6 year-old Kuwaiti Arab male born to non-consanguineous 
parents. Delivery was at full term by caesarean section following an uneventful pregnancy 
with birth weight 3.71 kg and no neonatal issued reported. He developed progressive 
stiffness in his limbs, trunk and head from the age of 1 month. By 3 months, he had 
difficulties starting a feed, had poor social interaction as he did not make eye contact or 
smile to his mother or caretakers, and was crying excessively but without any reported 
seizures. He had generalised hypertonia and hyperreflexia and serum and CSF lactate 
levels were slightly elevated (3.1 mmol/l and 3.0 mmol/l respectively). MRI brain scan at 
3 months showed abnormal diffuse white matter signal. At 5 months, he was noted to 
start following with his eyes and smile, but he also became dystonic when irritable or 
crying. He was treated with Clonazepam and later commenced Baclofen; the dosage was 
gradually increased as he got older. At 11 months he started recognising and interacting 
with his parents and had stranger anxiety. Follow-up MRI brain scan at 3 years revealed 
diffuse high T2-FLAIR signal in the white matter and noted a thin corpus callosum 
(Figure 3.9). A muscle biopsy was taken at 19 months and showed mild histochemical 
changes not suggestive of mitochondrial disorder. Nonetheless, he was started on a 
mitochondrial cocktail including L-carnitine (300 mg, twice a day), coenzyme Q (5 mg 
twice a day), and vitamin C (100 mg twice a day). mtDNA analysis on DNA extracted 
from peripheral blood and muscle did not identify the m.3243A>G or m.8344A>G 
variants. At 3 years 5 months, the patient had a febrile seizure due to a respiratory 
infection and was started on Phenobarbitone. He had recurring generalised tonic-clonic 
seizures 6 months later prompting the increase in Phenobarbitone, yet he continued to 
have seizures at a rate of about once a month.  
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Figure 3.9 Brain MRI neuroradiological images for Patient 12 
MRI brain scan for Patient 12 at 3 years 
A Axial T2-FLAIR image showing high signal in the white matter near the ventricle 
horns (yellow arrows) 
B Sagittal T1 image highlights thinning of the corpus callosum (yellow arrow) 
 
 
3.4.1.13 Family 13 
Patient 13 (MDC score: 9) is a 15 year-old Kuwaiti Persian male born to consanguineous 
first cousin parents. He was born full term by caesarean section with birth weight 3.5 kg. 
Apgar scores were 2 at 1 minute and 5 at 5 minutes and he was ventilated for 9 hours after 
birth. He was found to have bilateral hydronephrosis and was diagnosed to have posterior 
urethral valve and was operated on when he was 2 weeks old. He had developmental 
delay since early infancy; he sat at the age of 1 year, walked at 6 years, exhibited delayed 
speech and a low IQ. He developed unilateral ptosis that was corrected at 6 years. At 15 
years, he was noted to have a short stature, synophrys, mild turricephaly, had bilateral 
cataracts which were removed, was generally weak and had an abnormal EMG disclosing 
non-irritative myopathy in his weak and wasted shoulder and hip girdle muscles. He also 
had secondary sexual characteristics such as facial and axillary hair and gynaecomastia. 






3.4.1.14 Family 14 
Patient 14-I (MDC: 8) is a 21 year-old Kuwaiti Arab Bedouin female patient and firstborn 
to consanguineous parents from the same tribe. Following a normal pregnancy, she was 
born at full term after a long labour and required resuscitation, but persistent ventilation 
was not required; her birth weight was 2.8 kg. At the age of 1 month, her parents became 
concerned reporting minimal movement of her limbs, but she was aware of her 
surroundings. At 5 months, she presented with global developmental delay, generalised 
hypotonia, and muscle wasting. An MRI at the age of 20 months revealed cerebral atrophy 
and an EEG at the age of 3 years showed abnormal background activity that was slow for 
her age. Auditory test results were unremarkable, and EMG and nerve conduction studies 
were unremarkable too. ECG and ECHO results were also unremarkable. 
The patient had slow development and by the age of 8 years she presented with 
microcephaly (<3rd centile), failure to thrive (weight <3rd centile), bilateral ptosis and 
ophthalmoplegia, myopathic face, generalised muscle wasting, diminished DTRs, and 
most notably developed choreoathetotic movements. Haematological and biochemical 
profiles including lactate, ammonia, and creatine kinase levels were within normal range. 
Furthermore, peroxisomal, lysosomal, blood and urine amino acids, and urine organic 
acid studies were all unremarkable.  
By the age of 13 years, choreoathetoid movements in her arms, hands, and fingers were 
clearly noted in addition to contractures in both her knees. Both horizontal and vertical 
gaze palsy were noted, and subsequent ophthalmological tests revealed bilateral tigroid 
fundi with a small halo to each disc, high myopia (>-20.00), and VEP results revealed 
macular pathway dysfunction suggesting the patient had moderate to poor levels of 
vision. Brain MRI at 13 years confirmed generalised reduction of cerebral white matter 
bulk and EEG showed a slow rhythm. Spinal curvature emerged over several years; likely 
a consequence of truncal hypotonia, continued growth and weakness to the extent that 
she was unable to support herself when sitting. She underwent surgery in the UK to 
correct the scoliosis with spinal rods. The patient lost her motor skills after the spinal 
surgery. 
Upon suspicion of underlying genetic disease by specialists in the UK, various genetic 
tests were performed including chromosomal karyotyping and targeted gene sequencing 
of POLG (on suspicion of Alpers-Huttenlocher syndrome) but all results were normal. A 
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muscle biopsy was obtained for analysis, and results showed myopathy with a mild 
generalised increase of lipids in muscle fibres while respiratory chain enzyme activities 
were normal. By the age of 19 years, the patient had developed epilepsy that was 
controlled by sodium valproate. 
The patient has 4 healthy siblings and one affected brother (Patient 14-II; MDC score: 5) 
who is 9 years old and was born at 36 weeks after an uncomplicated pregnancy with a 
birth weight of 2.3 kg. The mother noticed he was hypotonic with head lag and 
constipation from the first month of life. At the age of 13 months, he was noted to be 
developmentally delayed with microcephaly (2nd centile) and he presented with 
choreiform flicking movements which his mother noticed were increasing in frequency 
and severity. Hypotonia was noted in the neck, shoulders and trunk in addition to muscle 
weakness in the upper limbs. The patient had problems with all automatic reactions. EMG 
and nerve conduction studies were unremarkable. Blood sugar and lactate levels were 
within normal range. Brain MRI scans at 6 months and 14 months both revealed mild 
generalised reduction of white matter.  
A number of genetic tests were requested to rule out suspected genetic disorders. Patient 
results for karyotyping, Prader-Willi and Angelman syndrome methylation, Fragile X 
testing, SMN1 exons 7 and 8 deletions, and array-CGH were all normal. A muscle biopsy 
was obtained from the patient and respiratory chain enzyme test revealed a marginal loss 
of complex IV activity. Histological tests showed non-specific mild myopathic features 
with slow hypotrophy and increased fibre size variation. No evidence of structural 
congenital myopathy was identified. Upon suspicion of mitochondrial disease 
involvement, mtDNA analysis was undertaken for mutations associated with neuropathy, 
ataxia and retinitis pigmentosa/ maternally inherited Leigh Syndrome (NARP/MILS), 
MELAS and MERRF and results were unremarkable.  
Patient 14-II's carnitine profile and very long chain fatty acid levels in blood were normal. 
Blood sugar and lactate levels were normal, and CSF protein, sugar, and lactate levels 
were also normal. Other CSF tests assessed amino acid, monoamine metabolites, 
dihydrobiopterin, and 5-methlytetrahydrofolate on suspicion of which were all normal. 
Urinary glycosaminoglycan and reducing substance tests were normal, urine amino acid 
test showed an increase in taurine levels, and urine purine screen showed no 
sulphocysteine. Urine organic acids revealed ketosis with dicarboxylic aciduria, elevated 
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levels of homovanillic and vanillomandelic acids, with generalised tricarboxylic acid 
cycle stress.  
3.4.1.15 Family 15 
Patient 15 (MDC score: 8) was a Kuwaiti Arab Bedouin female born to consanguineous 
paternal first cousin parents, born at term following a normal pregnancy and birth weight 
3.2 kg. She was the third of six siblings. Her growth and development progressed 
normally, but at the age of 6 years and 6 months, she developed a febrile illness and was 
diagnosed with influenza H1N1 infection. She was treated with Tamiflu and improved, 
however shortly after she became lethargic and sleepy staying in bed most of the day for 
days at a time. 3 months later, while visiting Thailand for medical investigations, she 
developed seizures. EEG records and brain MRI scans were both unremarkable. She 
returned to Kuwait and her lethargy became exaggerated and she would sleep for 10 days 
and then function normally for a couple of days after which she would sleep for another 
group of days. At the age of 7 years, she collapsed while playing on a trampoline and was 
having trouble breathing and likely suffered a cardiac arrest. She was taken to the nearest 
hospital within approximately 25 minutes and was revived but later suffered four more 
episodes of cardiac arrest. A brain MRI scan showed evidence of hypoxic ischaemic 
damage with global cerebral and deep grey matter involvement with preserved brainstem 
and cerebellar function. She was boarded to Great Ormond Street Hospital (GOSH) in 
London, UK, for further management. Investigations identified she had cardiomyopathy 
and was suggested to have an underlying metabolic disorder. Neurological assessment 
confirmed she sustained severe hypoxic ischaemic brain damage and had severe visual 
impairment, but her hearing seemed intact. She developed dystonia, was fitted with a PEG 
due to her feeding problems and was noted have labile blood pressure. On examination, 
she had contractures affecting her arms (flexed at the elbows and wrists), her legs were 
extended, and she had scoliosis. Further assessment revealed she had significant GORD. 
A muscle biopsy was taken, and respiratory chain enzyme activity assay revealed low 
complex IV activity.  
3.4.1.16 Family 16 
Patient 16 (MDC score: 10) is a 10 year-old Kuwaiti female patient born to 
consanguineous first cousin Kuwaiti parents. She was born at 29 gestation weeks as one 
of triplet IVF pregnancy with a birth weight 1.340 kg and Apgar scores 9 at 1 minute and 
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10 at 5 minutes. She developed respiratory distress and was monitored in the NICU for 3 
days and treated with surfactants I and V. Her motor and cognitive skills development 
were delayed and a brain MRI scan at 9 months showed delayed myelination and 
prominent CSF spaces. She developed strabismus at the age of 1 year which was operated 
on and corrected. She did not achieve independent walking until the age of 3 years, a skill 
which she subsequently lost at the age of 5 years. In addition, she developed ptosis, 
dysphagia, and spastic diplegia. Blood lactate was repeatedly elevated (6-10 mM) and so 
were potassium levels. ECHO at 6 years was unremarkable, her dysphagia subsided, and 
her cognitive skills remain mildly delayed, but she has a very good memory. By the age 
of 10 years, she had developed bilateral ophthalmoplegia with minimal movement in any 
direction with no facial weakness, had truncal muscle weakness leading to her inability 
to rise from lying down to sitting without support and had increased tone in both legs with 
brisk DTRs in both lower limbs. No mtDNA mutations were reported for Patient 16. 
3.4.1.17 Family 17 
Patient 17 (MDC score: 4) is a 7 month-old Egyptian male, fourth of four children born 
to non-consanguineous parents. He was born by elective caesarean section due to 
maternal hypertension during pregnancy and his birth weight was 2.7 kg. At the age of 2 
months, he developed afebrile seizures in the form of generalised spasms, head nod, and 
flexion of trunk and hips which occurred in clusters 6 - 7 times per day; he was well in 
between episodes. Seizures were controlled by Levetiracetam and adrenocorticotropic 
hormone treatments for 20 days that was later switched to Vigabatrin for 20 days and then 
switched to Topiramate. His seizures continued into the age of 4 months reducing to 4 - 
5 clusters per day. A brain MRI scan was unremarkable, but EEG records showed 
multifocal epilepsy. Investigations revealed persistent elevated serum lactate (3.4 - 7.1 
mM), elevated pyruvate (255.1 µM), and lactic aciduria. Liver function and serum 
glucose levels were unremarkable. On examination at 7 months of age, he was noted to 
be well nourished with no dysmorphic facial features, but he had gross motor 
developmental delay and an exaggerated head lag. 
3.4.1.18 Family 18 
Patient 18-I (MDC score: 12) was a male patient born to consanguineous (distant 
relatives) Kuwaiti parents. No problems were reported during the pregnancy and he was 
born at full term with a birth weight of 3.75 kg. He was floppy and slow to respond at 
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birth and was later noted to be developmentally delayed as he did not fixate, nor follow 
and did not acquire a social smile. At 3 months of age, he had recurrent seizures in the 
form of up-rolling eyes and tonic-clonic movements of the upper limbs and was admitted 
to the hospital due to chest infections and seizures. Neurological findings showed he had 
spastic paraplegia with increased deep tendon reflexes (DTRs), and he was not following 
or responding to external stimuli. Laboratory test showed elevated CSF lactate (5.1 
mmol/L, normal range 0.6 - 2.2 mmol/L), persistent elevated serum lactate (4.0 - 15.0 
mmol/L, normal range 0.5 - 2.2 mmol/L), and elevated pyruvate (144 µmol/L, normal 
range 41 - 67 µmol/L). A brain MRI scan showed basal ganglia involvement and 
biochemical analysis of respiratory chain enzyme activity in a muscle biopsy showed 
complex I and IV activities were deficient. Patient 18-I passed away around the age of 1 
year with cause of death report available. 
Family history revealed Patient had 2 older brothers who presented with a similar 
phenotype (suggestive of Leigh syndrome) and passed away. One of the decease brothers 
was boarded to the UK where they investigated respiratory chain enzyme activity in a 
muscle biopsy and identified complex I and IV deficiency. They have 3 living sisters who 
developed similar symptoms having developmental delay, epilepsy, microcephaly and 
clasp knife rigidity. Brain MRI scan of one of the affected sisters revealed bilateral 
symmetric abnormal signals in the lateral aspect of the putamen. The affected siblings 
have 2 healthy sisters. 
Patient 18-II (MDC score: 7) was a male patient and the double first cousin of Patient 18-
I (their mothers are sisters, and their fathers are brothers). He was born at full term by 
normal delivery with a birth weight of 3.25 kg and he presented with mild jaundice but 
no other neonatal issues. He had a seizure at the age of 8 months and was noted to be 
developmentally delayed on examination. He was not following, presented with a head 
lag, mild hypertonia in the upper limbs with generalised hyperreflexia. A brain CT scan 
showed hypoattenuation involving the head of the caudate and anterior aspect of the 
putamen along with mild cerebral atrophy. He was prescribed phenobarbitone to control 
his seizures but sadly passed away around the age of 1 year with no record of cause of 
death available. Patient 18-II had an affected brother who presented with a febrile illness 
early in life and passed away around the age of 1 year. Brain MRI scan suggested post-
encephalitis brain atrophy and respiratory chain enzyme activity in a muscle biopsy 
showed complex IV deficiency. The deceased siblings have an older, affected sister (28 
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years old) who has had seizures since the age of 4 years, is developmentally delayed, had 
an ataxic gait, and developed kyphoscoliosis at the age of 10 years. Brain MRI scan 
showed she had diffuse minimal cerebral atrophy, and respiratory chain enzyme activity 
in muscle tissue showed no deficiency. The affected siblings have 3 healthy younger 
brothers. 
3.4.1.19 Family 19 
Patient 19 (MDC score: 5) is a 7 year-old Kuwaiti male born to non-consanguineous 
parents at full term by normal delivery after an uneventful pregnancy with birth weight 
3.0 kg. At 5 months, he had a ‘staring look’ when awakening and developed recurrent 
myoclonic jerks in his left leg. He was started on Phenobarbitone to treat the abnormal 
movements he developed. EEG records were abnormal, but a brain MRI scan was 
unremarkable. Auditory assessment reported bilateral impaired hearing for which he was 
fitted with hearing aids, and an ophthalmology assessment due to poor eye contact 
identified hypermetropia and he was prescribed glasses. At 16 months, his 
Phenobarbitone was halted and replaced by Sodium Valproate and had was noted to be 
global developmental delay. He developed intractable seizures at the age of 5 and a half 
years and his Sodium Valproate dose was increased. On examination, he was reported to 
be microcephalic, had a stereotypic movement of the head, had a spastic gait, and had 
increased tone in legs with brisk DTRs. Investigations into serum lactate, ammonia, 
electrolytes, thyroid function, and complete blood count revealed unremarkable results.  
He gradually developed autistic behaviours including self-mutilation (hand biting) and 
was prescribed Risperidone. At the age of 7 years, he was examined and was reported to 
be irritable, bilateral toe walking gait with support, and had left convergent strabismus. 
No mtDNA mutations were reported for Patient 19. 
3.4.1.20 Family 20 
Patient 20 (MDC score: 6) is an 8 year-old Omani male born to consanguineous parents 
(first cousins once removed). He was born with a low birth weight indicating intrauterine 
growth restriction. He has global developmental delay, failure to thrive, congenital 
cataracts, generalised hypotonia, and a brain MRI scan at 2 years revealed mild cerebral 
atrophy. Serum lactate (1.8 mM) and CK levels (82 mM) were within normal range. 
Family history revealed similarly affected relatives including a younger sibling presenting 
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with primary microcephaly, generalised hypotonia, congenital cataracts, and 
developmental delay with difficulty in learning. 
3.4.1.21 Family 21 
Patient 21-I (MDC score: 6) was a Yemeni female, second born to consanguineous first 
cousin parents, born at full term by caesarean section. Her birth weight was 4.0 kg and 
she had no reported neonatal issues. At the age of 21 months, she developed recurrent 
fever attacks associated with intractable seizures that later became afebrile seizures 
leading to status epilepticus. She was developmentally delayed, had general hypotonia, 
and investigations revealed elevated liver enzymes in the blood (AST and GGT). EEG 
results showed an abnormal record and a brain MRI scan revealed encephalitis suggestive 
of viral aetiology. The patient passed away at the age of 26 months with no known cause 
reported. 
Her younger sister, Patient 21-II (MDC score: 6) is 1 year-old and was born by normal 
delivery. At 6 months of age, she developed infantile spasms and a brain MRI scan was 
unremarkable. The patient's spasms were controlled until the age of 1 year when she 
developed an episode of severe infection and septic shock after which she developed 
uncontrollable epilepsy in the form of generalised tonic-clonic seizures and abnormal eye 
movements. She suffered from convulsive and non-convulsive status epilepticus. Brain 
MRI scan at 1 year revealed global cerebral atrophy and bilateral signal changes involving 
the thalami, caudate nuclei, globus pallidi, post-parietal cortical and subcortical regions, 
midbrain, pons, and cerebellum. Radiological findings were suggestive of a 
mitochondrial disease involvement. Investigations revealed normal findings for serum 
amino acid and acylcarnitine profiles, urine organic acids, and CSF lactate, protein and 
glucose. EEG results showed severely abnormal records. 
3.4.1.22 Family 22 
Patient 22-I (MDC score: 6) is a 17 year-old Kuwaiti female born to consanguineous 
maternal first cousin parents. She was born at full term by normal delivery with no 
pregnancy or neonatal issues reported and her birth weight was 2.5 kg. At the age of 9 
years, she developed an unsteady gait, tremor, and impaired communication skills. She 
developed scoliosis and myopia for which she was prescribed glasses. She was fitted with 
a brace for her scoliosis in the USA. EMG results were suggestive of an 
axonal/demyelinating neuropathy. Genetic analysis using microarray-CGH revealed 
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multiple duplication regions in chromosome Xq28 (75kb and 88kb) not previously 
reported in association with disease. Family history revealed multiple relatives with short 
stature.  
Her younger sister, Patient 22-II (MDC score: 4), is a 13 year-old female born at full term 
with a history of oligohydramnios near the end of pregnancy, and her birth weight was 
3.1 kg. At the age of 10 years, she became easily fatigued and on examination was noted 
to have a thin build with failure to thrive, but psychomotor development was normal for 
her age. ECHO revealed mild to moderate concentric left ventricular hypertrophy.  
 Summary of recruited families and cases 
The presentations and findings of all the patients were tabulated to help review and 
compare the available information amongst the selected and recruited patients. Clinical 
presentations of the patients are tabulated in Table 3.1, available investigation results are 




Table 3.1 Table of clinical presentations in patients recruited for the study  
(continued on next page). 
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1-I 5 F +  Birth + + - - - - - - - - - - + - - - - - - + - - - +  
1-II 11 M +  7 + + - - - + + - - + - - + - - - - - - + - - - + Constipation 
1-III 7 M +  4 + + - - - - - - - - - - - - - - - - - - - - - -  
2 10 F +  1 + + - - - - - - - - - -  - + - - - - - - - - -  
3 7 M - Birth + + - -  - - - - - - - +  + - - - - - - - - -  
4-I 8 F +  24 + - - - - + - - - + - - + - - - D - - - - - - -  
4-II 9 M +  2  + + - + + - + + - + - - - + - - - - - - - - - -  
4-III 7 M +  14 + + + + + - - - - + - - - + - - - - - - - - + -  
5-I 8 M +  Birth + + - - - + - - - - + - + - - - - - - - - - - - Short stature, GORD 
5-II 9 M +  3 + + - - - + - - - - + - + - + - - - - - - - - - Short stature, GORD 
5-III 5 F +  N/A + - - - - - - - - - + - + - - - - - - - - - - -  
6 6 M +  4 + + - - - + - - - - - - + - + - - - - + - - - - Myopia, 
7-I 8 F +  54 + - + - - - + - - + - - - + - - - + - - + - + -  
7-II 5 M +  108 + - - - - - - - - - - - - + - - - - - - - - + - Dysarthria 
8 7 F - 4 months + + - - - - - - - - - - + - - - - - - + - + + -  
9 9 M - N/A - + - - - - - - - + - - + - - - - - - + - - - - IUGR 
10 5 F - 34 years - - - + + - - + + - - - - - - - - - - - - - - -  
11-I 8 F +  4 + + - - - - - - - - - + + - + - - - - - - - - +- Micrognathia 
11-II 4 F + 5 + - + - - + - - - - - + + - - - B - - - - - - - Hepatitis 









































































12 7 M - 1 + + - - - - - - - - - - + - + - - - - - + + - -  
13 9 M +  Birth + + - + - + + - - - + - + - - - - - - - - - - - Hydroureteronephrosis 
14-I 8 F +  1 + + - + + + + - - + - + + + + - D - + - - - - - 
Scoliosis, myopia, pale 
optic discs, peripheral 
neuropathy 
14-II 5 M +  5 + + - - - - - - - + - + + - - + - + - - - - - -  
15 8 F - N/A + - - - - - - - - - - - - - - - - - - - - - - -  
16 19 F +  N/A + - + + + - - - - - - - + - - - D - - - + - - - Cerebral palsy 
17 4   3 - - - - - - - - - - - - - - - - - - - - - - - -  
18-I 12 M +  3 + - + - - - - - - - - + + - + - Ex - - - - + - -  
18-II 7 M +  8 + - - - - - - - - - - - + - + + - - - - - - - -  
19 5 M - 1 - - + - - - - - - - - - + - + - B - - - - - - -  
20 6 M +  N/A + + - - - - - - - + - + + - - - - - - - - - - - Cataracts 
21-I 6 F +  21 + + - - - - - - - - - - + - + - - - - - - - - -  
21-II 6 F +  6 + - - - - - - - - - - - - - + - - - - + - - - -  
22-I 6 F +  108 + - - - - - - - - - - - + - - - - - - - - + - - Tremor, scoliosis, myopia, F/H short stature 
22-II 4 F +  120 + - - - - - - - + + - - - - - - - - - - - - - -  
 
B: brisk ; CNS: central nervous system; D: diminished; DTR: deep tendon reflexes; Ex: exaggerated; MDC: Mitochondrial Disease Criteria; 
N/A: not available 
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Table 3.2 Table of investigation results of patients recruited for the study  
(continued on next page). 
































































1-I 5 F +  Birth + - - - + - - - - - - - -  
1-II 11 M +  7 + - - + - + - - - + - - CI, CII, CIII, CIV  
1-III 7 M +  4 + - - - + + - - - - - - -  
2 10 F +  1 + - - - - + + - + - + - -  
3 7 M - Birth + - - - - + + - + - + - -  
4-I 8 F +  24 + - - - - + - - - - - - -  
4-II 9 M +  2  + - - - - + - + - - - - -  
4-III 7 M +  14 + - - - - + + - - - - - - Elevated CK, creatinine 
5-I 8 M +  Birth + - + - - + - - - - - - -  
5-II 9 M +  3 + - + - - + - - - - + - -  
5-III 5 F +  N/A + - - - - + - - - - - - -  
6 6 M +  4 + + - + + + - - - - - - - hypoglycaemia, metabolic acidosis 
7-I 8 F +  54 + - - - - - - - - - - - -  
7-II 5 M +  108 + - - - - - - - - - - - -  
8 7 F - 4 + - - - - - - - + - - - -  
9 9 M - N/A - + - - - + - - - - - - -  
10 5 F - 34 years - - - - - - - - - - - - -  
11-I 8 F +  4 + - - - - - - - - - - - -  
11-II 4 F + 5 + - - - - - - - - - - - -  
11-III 6 F +  26 + - - - - + - - - - - - -  
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12 7 M - 1 - - - - - + - - + - - + -  
13 11 M +  Birth + - - + - - - - - - - + - Hydroureteronephrosis 
14-I 8 F +  1 + - - + - - - - - - + - CIV lactic aciduria 
14-II 5 M +  5 + - - - - - - - - + - - -  
15 8 F - N/A + - - - + - - - - - - - CIV  
16 19 F +  N/A + - - - - + + - - - - - - elevated anion gap 
17 4   3 - - - - - + + - - - - - -  
18-I 12 M +  3 + - - + - + + + - - - - CI, CIV  
18-II 7 M +  8 + - - + - + - + - - - - CI, CIV  
19 5 M - 1 - + - - - - - - - - - - -  
20 6 M +  N/A + - - - - - - - - - - - -  
21-I 6 F +  21 + - - - - - - - - - + - - Elevated AST/GGT 
21-II 6 F +  6 + - - - - - - - - - + - -  
22-I 6 F +  108 + - - - + - - - - - - + -  
22-II 4 F +  120 + - - - + - - - - - - - -  
 
CI: complex I; CIV: complex IV; CNS: Central Nervous System; CSF: cerebrospinal fluid; MDC: Mitochondrial Disease Criteria; N/A: not 
available; PNS: Peripheral Nervous System; SNHL: sensorineural hearing loss;  
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Table 3.3 Table of neuroradiological findings in patients recruited for the study  












































S lactate peak 
N
otes 
1-I F MRI - - + + - - - - - - - - - - - - - - +  
1-II M MRI - - - + + - - - - - - - - - - - - - -  
1-III M N/A                     
2 F MRI - - - - - + - - + + - - - - - - - - -  
3 M MRI - - + - - - + + - - - + + - - - - - + Involving left hemisphere 
4-I M MRI + - - - - - - - - - - - - - - - - - -  
4-II F MRI - - - - - + - - - - - + - + + - + + -  
4-III M MRI - + - + - - - - - - - - - + - + + - -  
5-I M N/A                     
5-II M N/A                     
5-III F N/A                     
6 M MRI - + - - - - - - - - - - - - - -  - -  
7-I F MRI - - - - - + - - - - - - - - - - - - +  
7-II M MRI - - - - - + - - - - - - - - - - - - -  
8 F MRI - - - - - - - - - + + - - - - + - - -  
9 M MRI - - - + - - - - - -  - - + - + - + -  
10                       





11-II F N/A                     













































S lactate peak 
N
otes 
12 M MRI + - + - - - - + - - - - - - - + - - -  
13 M MRI - - - - - - - - - - - - - - - - - + - Left side 
14-I F MRI - + - - - - - - - - - - - - - - - - -  
14-II M MRI - + - - - - - - - - - - - - - - - - -  




cerebral and grey 
matter 





18-I M MRI - - - - - + - - - - - - - - - - - - -  
18-II M MRI - + - - - + - - - - - - - - - - - - -  
20 M MRI - + - - - - - - - - - - - - - - - - -  




21-II F N/A                     
22-I F N/A                     




Mitochondrial disease cases have been poorly diagnosed in Kuwait in the past 10 years. 
The tool of choice to genetically analyse and diagnose cases suspected of mitochondrial 
disease is Sanger sequencing of patient DNA that was extracted from peripheral blood. 
In a highly consanguineous population such as in Kuwait autosomal recessive diseases 
are likely more prevalent (Skladal et al., 2003; Shawky et al., 2013). A new approach 
was required to improve the diagnosis rates of mitochondrial disease cases in Kuwait. 
This initiated a collaboration with the Wellcome Centre for Mitochondrial Research, 
based at Newcastle University, where clinical and research staff have a wealth of 
knowledge and expertise in this specialised field.  
For my PhD project, cases suspected of mitochondrial disease in Kuwait were recruited, 
reviewed and scored. The recruitment process required the review of many suspected 
cases, but many were excluded due to the lack of clinical history, lack of clinical follow-
up, or lack of investigation results. Clinical history and progress of disease in patients 
was important during the recruitment process but some medical reports only contained a 
summary of presentations and investigation results from a single patient visit with no 
clinical history or follow-up afterwards. In addition, investigations such as blood 
investigations and neuroradiological imaging that could reveal highly suggestive findings 
that would increase the likelihood of recruitment were not requested. Another issue that 
was faced was families of patients suspected of mitochondrial disease involvement were 
either unreachable for a follow-up appointment to request investigations or they declined 
to attend a follow-up appointment at KMGC.  
Cases from most recruited families had neuroradiological MRI findings that were either 
suggestive of mitochondrial disease involvement or showed cerebral atrophy or 
leukodystrophy. These findings played a major role in their recruitment since subjects 
who did not have neuroradiological findings were not prioritised and thus not recruited 
to the study. Blood and urine investigations also played a very important role in the 
recruitment process as their outcomes could be highly suggestive findings such as 
elevated blood lactate or elevated tricarboxylic acid cycle intermediates in urine. Results 
of CSF investigations are challenging to obtain, but elevated lactate in CSF is one of the 
key findings associated with mitochondrial disease. Only seven patients had a lumbar 
puncture performed and obtains results of CSF analyses including lactate levels. Even 
though muscle biopsies are a last resort to confirm mitochondrial disease involvement in 
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patients, muscle biopsies are not routinely obtained and analysed for mitochondrial 
disease in Kuwait which renders the fifth category of the utilised MDC of no use for 
almost all cases. Only a few cases had a muscle biopsy taken and analysed in the UK and 
findings supported their recruitment to the study.  
The scoring of patient presentations and investigation results using the MDC scale helped 
identify missing clinical details that can be requested to support the suspicion of 
mitochondrial disease involvement. Family history of disease also influenced the 
recruitment of families with a few consanguineous families having multiple affected 
siblings raising their chances of recruitment.  
The utilised MDC was developed using previously published criteria, but no extensive 
evaluation or validation of the MDC has been carried out. The utilised MDC could have 
been used to score published cases (be it of mitochondrial disease patients or known non-
mitochondrial disease patients) to evaluate how accurately it can predict the suspicion of 
mitochondrial disease. Given the criteria categories used in the MDC, it is likely that 
patient scores might be skewed to increasing the suspicion of mitochondrial disease 
involvement. These steps could be carried out to help improve the utilised MDC, however 
the involvement of expert clinicians in the selection process helped overcome such an 
effect by using the MDC and genuinely select cases that are suspected of mitochondrial 
disease. 
Diagnosing mitochondrial disease patient is a difficult task. Numerous studies attempted 
to utilise criteria in diagnosed mitochondrial disease cases to assess how successful they 
are in predicting diagnosis and assessed specificity and sensitivity of the criteria (Diogo 
et al., 2009; Puusepp et al., 2018; Witters et al., 2018). No specific mitochondrial disease 
criteria are defined as the universal standard thus far. Predicting mitochondrial disease in 
patients is challenging and requires tools and expertise to assess and evaluate available 
clinical data and investigation results. The review of high MDC scoring cases by a 
mitochondrial specialist (Prof Robert McFarland) assisted in excluding cases and 
prioritising patients for WES analysis. It is important to point out that the chronological 
order of cases investigated was dependant on the time of review and recruitment from 
KMGC. Prioritisation based on high scoring cases occurred when there were a number of 
cases awaiting analysis; the highest scoring cases were prioritised for WES analysis. The 
method of WES investigations and the results of variant filtration are outlined and 
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Chapter 4. Whole exome sequencing of paediatric 
patients from Kuwait suspected of mitochondrial disease 
 
 Introduction 
Consanguineous marriages are common practice in many parts of the world with this 
preference estimated in at least 20% of the global population and more than 8.5% of 
children worldwide born to consanguineous parents (Modell and Darr, 2002). 
Consanguinity rates reaching and exceeding 50% have been reported in many Arab 
countries with rates of first cousin marriages exceeding 20% (Tadmouri et al., 2009). 
Prevalence of inherited disorders among consanguineous populations is often higher than 
in non-consanguineous populations (Skladal et al., 2003; Shawky et al., 2013).. This has 
been observed in Kuwait where levels of consanguinity exceeding 50% have been 
reported (Al‐Awadi et al., 1985; Radovanovic et al., 1999; Tadmouri et al., 2009; Al-
Kandari and Crews, 2011). 
Genetic investigations into causative mutations in genetic disorders can be performed 
using a number of tools depending on available findings and history of disease in the 
family. Genetic analysis methods include the following: targeted gene sequencing of 
suspected genes; linkage analysis studies based on inheritance within a family; and 
homozygosity/autozygosity mapping within families of known consanguinity (Alkuraya, 
2010; Ott et al., 2015; Frazier et al., 2019). High-throughput NGS is a set of powerful 
tools that have been a driving factor in diagnosing genetic diseases (Shendure and Ji, 
2008). In human genetics, different NGS approaches that can be used to sequence 
specifically targeted genes (targeted gene panels), sequence the protein coding regions of 
the genome (WES and clinical exome sequencing), or sequence the full human genome 
(WGS) (Figure 4.1). NGS technology can sequence the 16.6 kb mitochondrial genome 
to identify mutations and targeted assessment of mtDNA heteroplasmy levels can also be 
determined using pyrosequencing. NGS technology amplifies the target DNA of choice 
(target gene panels, clinical exome sequencing, WES and WGS) and reads the sequenced 
in stretches of DNA 100-200 bp in length (Buermans and den Dunnen, 2014). These 
sequences are aligned to a reference human genome sequence, annotated with genetic 
information such as the location of the sequence within the genome, the location of a 
variant within a gene, and then analysed for in silico prediction of pathogenicity and 
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frequency of the variant within control databased such as gnomAD (Wadapurkar and 
Vyas, 2018). The NGS approach amplifies and sequences targeted regions of the genome 
multiple times (named read “depth”) to determine its zygosity and the quality of the 
variant call by reading the variant multiple times and sometimes exceeding 100x reads. 
The technology also attempts to read all the targeted regions of the genome (named read 
“coverage”) and advances in the technology have increased the percent coverage of WES 
from 80% to 95% (Lelieveld et al., 2015). The cost of gene sequencing has dropped in 
the past two decades due to the introduction of NGS technologies and thus have become 
a first-tier approach to diagnosing patients suspected of genetic disorders (Wadapurkar 
and Vyas, 2018). However, NGS has limitations within these parameters as variants 
might be located outside the covered regions or the depth and quality of the read may be 
rendered as poor, and thus not called.  
 
Figure 4.1 Genome regions targeted by different NGS techniques 
All protein coding regions of the human genome are targeted and sequenced by the 
WES approach (green). Specific genes of interest are targeted and sequenced when 
using the clinical exome sequencing and targeted gene panel approaches (purple). The 
whole human genome is sequenced when the WGS approach is used (orange). 
 
NGS tools have been utilised in diagnosing cases suspected of genetic disorders using 
targeted gene panel sequencing (Morgan et al., 2010), WES (Choi et al., 2009; Bolze et 
al., 2010; Ng et al., 2010), and WGS (Lupski et al., 2010). Later studies employed NGS 
on patient cohorts with various clinical presentations and resulted in varying successful 
diagnosis rates within each study (Saunders et al., 2012; Yang et al., 2013; Gilissen et 
al., 2014; Soden et al., 2014).  
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Mitochondrial disease patients have been initially associated with mutations in mtDNA 
mutations, rearrangements and deletions in DNA from muscle and blood samples (Holt 
et al., 1988; Wallace et al., 1988; Goto et al., 1990; Shoffner et al., 1990). However, 
mtDNA mutations are not the sole source of pathogenicity in mitochondrial disease 
patients since mutations in nuclear encoded genes were also associated with 
mitochondrial disease (Endo et al., 1989; Liu et al., 1993; Bourgeron et al., 1995). With 
1,158 proteins associated with mitochondrial function, mutations in over 300 nuclear 
genes have been associated with disease so far (Stenton and Prokisch, 2020; Thompson 
et al., 2020a). NGS methods, including WES and targeted gene panels, have been 
successful in identifying nDNA mutations in genes associated with mitochondrial 
function (Haack et al., 2010; Gotz et al., 2011; Calvo et al., 2012). Studies that used WES 
on patient cohorts suspected of mitochondrial disease yielded diagnosis rates higher than 
60% (Haack et al., 2012; Lieber et al., 2013; Taylor et al., 2014; Wortmann et al., 2015). 
NGS methods have a shorter turnover time for results compared to earlier approaches 
such as targeted gene sequencing, linkage analysis and homozygosity mapping since 
NGS methods identify the suspected mutations in each patient or family.  
There have been numerous studies based in countries neighbouring Kuwait that utilised 
NGS technology to diagnose patient cohorts suspected of genetic disorders (Dixon-
Salazar et al., 2012; Alazami et al., 2015; Yavarna et al., 2015; Alfares et al., 2017; Anazi 
et al., 2017; Monies et al., 2017). The cohorts of these studies were mostly from 
consanguineous families and the overall rate of diagnosis was 45% (Alahmad et al., 
2019). These cohort studies identified 178 novel candidate genes associated with disease 
including 14 gene associated with mitochondrial function most of which were identified 
in consanguineous families in the cohort. In addition, founder mutations in at least 10 
genes associated with mitochondrial disease were identified in unrelated families.  
 Aims 
The aim of this chapter is to describe the genetic analysis approach and outline the 
filtration of called variants in the recruited patients from 22 families. In cases with 
variants in previously reported genes, phenotype comparisons are performed to expand 
clinical spectrums of associated disease. Addressing aetiology of disease is also 
performed to elucidate pathogenicity in novel candidate genes as well and pathogenicity 
of novel variants identified.  
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 Methods  
4.3.1 Whole exome sequencing 
Whole exome sequencing was performed as outlines in Section 2.2.5. 
4.3.2 In silico analysis of candidate gene variants 
In silico analysis of the effect of detected variants were performed as outlines in Section 
2.2.6. 
4.3.3 Sanger Sequencing 
DNA for Sanger sequencing was extracted from peripheral blood of patients and their 
family members as described in Section 2.2.3.  
Sanger sequencing of the identified variants was performed as follows outlined in 
Sections 2.2.7, 2.2.8, 2.2.9, 2.2.10, 2.2.11, 2.2.12, 2.2.13 and 2.2.14 
4.3.4 Filtration of variants called in WES 
A flowchart of the following description of the filtration process is outlined in Figure 
4.2. 
4.3.4.1 Rare or novel homozygous variants 
Variants called in WES were filtered to identify protein coding variants that were novel 
or rare; rare variants have a minor allele frequency of less than 1% in the gnomAD and 
ESP6500 databases (Lek et al., 2016). Since the majority of families were 
consanguineous, variants were filtered for homozygous variants since autosomal 
recessive inheritance of variants was likely. Depending on the availability of an in-house 
exome variant database (consisting of results from 384 previous WES analysis results 
from a cohort of mitochondrial and neurological disease patients and controls that were 
analysed at Newcastle University), the results were filtered for variants that were not 
previously homozygous in the in-house exome database. This step helps narrow down the 
search for pathogenic variants in my cohort but can be omitted or modified to include 
variants with less than 4 reported homozygotes in the database due to presence of patients 
within the in-house exome database. The individuals in the in-house exome database are 
recruited in Newcastle and therefore will be of different ethnicity (likely European) 
compared to families in my recruited cohort. Due to high rates of consanguinity within 
the families, there might be polymorphic variants that have not been reported previously. 
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4.3.4.2 Mitochondrial proteins 
The list of identified genes was filtered for proteins localising to the mitochondria and is 
listed in the MitoCarta2.0 database of mitochondrial proteins (Calvo et al., 2015). The 
panel of WES results were then filtered to eliminate homozygous variants identified in 
other patients in the panel (excluding relatives of the patient).  
4.3.4.3 ‘In silico’ predictions of pathogenicity 
The resulting variants were prioritised based on genes previously associated with disease, 
previously reported pathogenic variants, loss-of-function variants (frameshift deletions or 
insertions or nonsense variants), in silico predictions of pathogenicity of missense 
variants, absence of homozygotes in gnomAD or ESP6500 databases, protein function 
and location of affected protein residue within the protein sequence. These filtrations 
steps help narrow down the scope of search for candidate variants and genes.  
4.3.4.4 Modifications to the prioritisation scheme 
Should the prior steps not suggest a clear variant to investigate, a few modifications to 
the filtration process can be done to include more variants and genes. The first suggested 
modification (Figure 4.2, A) is to omit the filtration of proteins localising to the 
mitochondria and look for variants in all genes. This might yield a candidate variant to 
investigate that so far has not been associated with mitochondrial function. The second 
modification (Figure 4.2, B) is to include heterozygous variants and continue the search 
for candidate bi-allelic (compound heterozygous) variants that might explain disease in 
the patient. The last suggested modification (Figure 4.2, C) would be to include splice-
site variants as they might be the causative variants in some cases and need to be 
investigated. A combination of the previous suggested modifications might lead to the 




Figure 4.2 Whole exome sequencing variant filtration flowchart 
Whole exome sequencing filtration pipeline utilised to search for variants in candidate 
disease causing genes in patients suspected of mitochondrial disease. Steps A, B, and C 
are different filtration steps that were used to identify candidate gene in non-
mitochondrial disease patients (e.g. steps A and B were used to filter for compound 




4.4.1 Average coverage and depth of utilised WES kits and platforms 
For patients from families 1-13 and families 15-17, the Nextera Rapid Exome Capture 
kits used on an Illumina NextSeq500 platform reported an average coverage at 50-80% 
of bases at 30x depth.  
For patients from family 14 and families 18-22, the Twist capture kit used on the Illumina 
NovaSeq 6000 platform reported an average coverage exceeding 95% of bases at 30x 
depth of more. 
4.4.2 LETM1 
4.4.2.1 Family 1 
Patient 1-I was a female patient born to consanguineous Kuwaiti Bedouin parents. She 
presented with hypertrophic cardiomyopathy, developmental delay, hypotonia, hearing 
impairment, and nystagmus ( Table 4.1). A brain MRI showed a thin corpus callosum. 
She had a family history of 2 brothers who passed away early in life. She passed away at 
the age of 1 year and 2 months. 
WES was carried out on DNA from Patient 1-I and results suggested she was homozygous 
for a novel codon deletion in exon 5 of the LETM1 (leucine zipper-EF-hand containing 
transmembrane protein 1) gene resulting in the deletion of the lysine residue at position 
252 of the protein (NM_012318.2; c.754_756delAAG; p.Lys252del). LETM1 is an IMM 
transmembrane protein that plays a crucial role in calcium homeostasis by acting as a 
Ca2+/H+ antiporter and plays an important role in maintaining mitochondrial morphology 
(Shao et al., 2016; Piao et al., 2009). In silico analysis of the effect of the codon deletion 
using the protein prediction tool PROVEAN suggested that the amino acid deletion was 
deleterious (Choi et al., 2012; Choi and Chan, 2015). A single individual, who was 
heterozygous for a missense mutation at the location of the deleted residue, was reported 
in the gnomAD database - the missense mutation had a minor allele frequency of     
4.6×10-6 - and in silico missense prediction tools Polyphen-2 and SIFT both predicted 
that the missense mutation was likely deleterious (Lek et al., 2016; Adzhubei et al., 2010; 
Ng and Henikoff, 2001; Kumar et al., 2009). However, a database dedicated to the 
reporting and analysis of background de novo mutations in humans analysed the missense 
mutation through 14 in silico protein damage predicting tools and concluded that the 
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variant was not damaging since not enough prediction tools reported the mutation as such 
(Jiang et al., 2017).  
Sanger sequencing confirmed that Patient 1-I was homozygous for the codon deletion. A 
segregation study confirmed both parents were heterozygous carriers of the codon 
deletion, all healthy brothers were wild-type, and all healthy sisters were heterozygous 
carriers (Figure 4.3). DNA extracted from a homogenised muscle sample from her older 
affected brother, Patient 1-II (muscle sample was taken during his visit to Great Ormond 
Street Hospital in London in 2007) confirmed that he was also homozygous for the codon 
deletion in LETM1 (Figure 4.3). No DNA was available for the younger affected brother 
who passed away. Since all affected siblings and the patient passed away, no muscle or 




Figure 4.3 Segregation of LETM1 deletion in Family 1. 
Pedigree showing the segregation of the LETM1 codon deletion (c.754_756delAAG; p.Lys252del) in Family 1 members. Genotyping of Patients 
P1-I and P1-II (P1-I and P1-II respectively), which are 2 of the 3 affected siblings that passed away, found them to be homozygous for the codon 
deletion. Sequencing chromatograms highlight the deleted nucleotides in the heterozygous individuals (black box).
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4.4.2.2 Family 6 
Patient 6 was a male born to consanguineous Egyptian parents. He presented with 
nystagmus, myopia, hypotonia, sensorineural hearing loss, cataracts, and hypertrophic 
cardiomyopathy ( Table 4.1). He experienced 2 separate seizure attacks and a brain 
MRI showed mild reduction in brain volume.  
WES analysis identified a rare homozygous LETM1 missense mutation in Patient 6 
(c.881G>A; p.Arg294Gln). The variant results in a non-synonymous change of a highly 
conserved residue and the database dedicated to in silico analysis of background de novo 
mutations in humans (mirDNMR) reported the variant as damaging in 10 various in silico 
protein damage predicting tools including PolyPhen-2, PROVEAN, CADD and 
MutationTaster (Kumar et al., 2009; Adzhubei et al., 2010; Choi et al., 2012; Schwarz 
2014; Choi and Chan, 2015; Jiang et al., 2017). The identified variant was reported in 4 
heterozygous controls of European ancestry by gnomAD database with a MAF of 1.6 ´ 
10-5 (Lek et al., 2016). Two other controls of European descent were heterozygous for 
another variant that affects the same residue (c.880C>T; p.Arg294Trp) and a European 
control was heterozygous for a frameshift deletion (c.880delC; p.Arg294Glyfs). The total 
MAF for all heterozygous variants reported is 2.8 ´ 10-5. This variant segregated in the 
family as Patient 6 was homozygous while parents and healthy siblings were 
heterozygous (Figure 4.4). This affected residue is located in a highly conserved region 
of the protein and homozygotes have not been previously reported making is an ideal 






Figure 4.4 Segregation of LETM1 variant in Family 6. 
A Pedigree showing the segregation of the rare missense LETM1 variant (c.881G>A; 
p.Arg294Gln) in Family 6 members. Patient 6 (P6) was homozygous for the missense 
mutation. Sequencing chromatograms of identified missense variant in Patient 6 
highlighting the nucleotide change (red arrow). 
B Clustal Omega alignment of LETM1 protein residues in model organisms showing 





 Table 4.1 Phenotypes of LETM1 patients 









Age of onset Birth 6 months Birth 30 months 

































 N/A: not available; SNHL: Sensorineural hearing loss 
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4.4.3 Family 8 
Patient 8 is a 2 year-old female born to consanguineous Kuwaiti Arab Bedouin parents 
following IVF. She presented with nystagmus, developmental delay, ataxia, hypotonia 
and convergent strabismus. Her CSF lactate levels were elevated, and a brain MRI 
revealed bilateral symmetric signals in the subthalamic regions. Family history revealed 
her maternal cousin was blind. 
WES was carried out on DNA from Patient 8 and results suggested she was homozygous 
for a novel truncating variant in exon 1 of the NDUFA13 (complex I structural subunit 
FA13, GRIM19) gene resulting in the premature truncation at position 8 of the protein 
(NM_015965; c.22C>T; p.Gln8*). Sanger sequencing confirmed that the proband was 
homozygous for the truncating variant and a segregation study identified both parents as 
unaffected heterozygous carriers (Figure 4.5). A younger brother was born after the 
segregation and was reported to be a heterozygous carrier by colleagues at KMGC. 
 
 
Figure 4.5 Segregation of NDUFA13 variant in Family 8 
Pedigree of Family 3 showing the segregation of the identified truncating NDUFA13 
mutation (c.22C>T; p.Gln8*). Sequencing chromatograms of identified homozygous 
missense variant in Patient 8 (P8) highlighting the nucleotide change (black arrow).  
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4.4.4 Family 5  
Patient 5-II is a 9 year-old male born to consanguineous Arab Bedouin parents. He 
presented with developmental delay, hypotonia, short stature, mild dysmorphic features, 
GORD, and persistently elevated serum lactic acid. DNA from Patient 5-II from family 
5 was selected for WES. 
WES analysis identified a novel homozygous MPC1 missense mutation in Patient 5-II 
(c.109C>T; p.Pro37Ser). MPC1 encodes the IMM protein Mitochondrial Pyruvate 
Carrier 1 that forms a heterodimer complex with its paralog Mitochondrial Pyruvate 
Carrier 2 (MPC2) to facilitate the uptake of pyruvate by mitochondria (Bricker et al., 
2012). The variant results in a non-synonymous change of a highly conserved residue 
located in a transmembrane domain of the protein and is the residue that follows the first 
residue of exon 6 (McCommis and Finck, 2015). In silico tools including PolyPhen-2, 
PROVEAN, CADD and MutationTaster predicted the change to be deleterious (Kumar 
et al., 2009; Adzhubei et al., 2010; Choi et al., 2012; Schwarz 2014; Choi and Chan, 
2015). The variant segregated in the family where the proband and his affected siblings 
were homozygous, parents were heterozygous and unaffected siblings were wild-type 







Figure 4.6 Segregation of MPC1 variant in Family 5 
A Pedigree of family 7 showing the segregation of the identified MPC1 missense 
mutation (c.109C>T; p.Pro37Ser). Sequencing chromatograms highlight the identified 
missense variant in Patients 5-1, 5-II and 5-III (P5-I, P5-II and P5-III respectively) 
highlighting the nucleotide change (black arrows). 
B Clustal Omega alignment of MPC1 protein residues in vertebrates showing high 




4.4.5 Family 7  
Patient 7-I was a female Syrian Arab patient born to consanguineous parents. She 
presented with developmental delay then lost her motor skills, developed progressive 
hypertonia, became ataxic, then wheelchair-bound and lastly developed dysphagia. A 
brain MRI scan revealed bilateral symmetric signals in the caudate and putamen. She 
passed away at the age of 11 years and 6 months.  
Patient 7-I has a younger brother (Patient 7-II) who developed slurred speech, ataxia 
dystonia, decreased muscle power in in shoulders and hips, and bradycardia at the age of 
10 years. A brain MRI scan revealed bilateral symmetric signals affecting the basal 
ganglia and brainstem. DNA from both Patient 7-I and Patient 7-II were selected for WES 
as a sibling duo.  
WES identified a truncating TTC19 frameshift deletion in both affected siblings, patients 
7-I and 7-II (c.779_780delAT; p.Tyr260*). TTC19 is a complex III assembly factor that 
colocalises with the respiratory chain protein in the IMM (Ghezzi et al., 2011). The 
deletion was segregated in the family where both patients were homozygous, parents and 
an unaffected sibling were heterozygous, and 3 unaffected siblings were wild-type 





Figure 4.7 Segregation of TTC19 deletion in Family 7 
This pedigree shows the segregation of the truncating TTC19 frameshift deletion 
(c.779_780delAT; p.Tyr260*) within Family 7. Sequencing chromatograms of the 
genotyped family members highlight the deleted nucleotides in heterozygous 
individuals such as the parents (black box). Patients 7-I and 7-II are labelled P7-I and 
P7-II respectively.   
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4.4.6 Family 2 
Patient 2 is a 5 year-old female born to consanguineous Jordanian Arab parents. She 
presented with seizures early in life and elevated lactate levels in CSF and serum with a 
high serum pyruvate and lactate/pyruvate ratio also reported. A head CT scan at 1 month 
showed a hypodensity in the central brainstem and thalami.  
WES was carried out on the DNA from Patient 2 and results suggested she was 
homozygous for a novel missense mutation in exon 3 of the transmembrane protein 
encoding gene SLC19A3 (solute carrier family 19 member 3) resulting in the substitution 
of the tryptophan residue at position 59 with an arginine residue (NM_025243; c.175T>C; 
p.Trp59Arg). The mutation was predicted to be damaging by almost all in silico 
prediction tool including Polyphen-2, SIFT and PROVEAN (Adzhubei et al., 2010; Ng 
and Henikoff, 2001; Kumar et al., 2009; Choi et al., 2012; Choi and Chan, 2015).  
Sanger sequencing confirmed that Patient 2 was homozygous for the suggested missense 
mutation and a segregation study showed both parents and her 2 siblings were all 






Figure 4.8 Segregation of novel missense SLC19A3 variant in Family 2. 
A Family 2 pedigree showing the segregation of the novel SLC19A3 missense 
mutation (c.175T>C, p.Trp59Arg) with the remaining unknown genotype of the 
patient’s sister. Sequencing chromatograms of identified missense variant in 
genotyped family members and highlighting the nucleotide change in Patient 2 
(P2) (black arrow). 
B Clustal Omega alignment of SLC19A3 protein residues in model organisms 
showing high conservation of the substituted Tryptophan 59 residue except in 




4.4.7 Family 4 
Patient 4-III was the youngest of the 3 affected siblings in Family 4. He was born to 
consanguineous first cousin Syrian parents. At the age of 14 months, he began to lose his 
acquired milestones, became spastic and had elevated serum lactate levels. A brain MRI 
scan showed bilateral symmetric signals in the cerebellum, and the brainstem. At 19 
months, he presented with ptosis, hypertonia in his limbs, and hypotonia in his axial 
muscles and microcephaly was noted . DNA from Patient 4-III was selected for WES. 
WES was carried out on the DNA from Patient 4-III and results suggested she was 
homozygous for a novel frameshift deletion in exon 5 of the transmembrane protein 
encoding gene SURF1 (surfeit-1) resulting in the premature truncation after 4 residues 
(NM_003172; c.367_368delAG; p.Arg123Glyfs*4). Sanger sequencing confirmed that 
Patient 4-III was homozygous for the novel frameshift mutation and a segregation study 
showed all affected siblings (Patients 4-I and 4-II) were homozygous while parents and 





Figure 4.9 Segregation of SURF1 deletion in Family 4. 
Pedigree of family 4 showing the segregation of the identified truncating SURF1 
deletion (c.367_368delAG). Sequencing chromatograms highlight the deleted 
nucleotides in heterozygous individuals (black box). Patients 4-I, 4-II and 4-III (P4-I, 
P4-II and P4-III respectively) were homozygous for the deletion. 
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4.4.8 Family 10 
Patient 10 is a 60 year-old adult female patient born to non-consanguineous Kuwaiti 
parents. She developed ptosis and progressive external ophthalmoplegia at the age of 34 
years. She developed difficulty chewing and choking when eating, experienced exercise-
intolerance, had weak proximal muscles and spastic lower limbs with a stiff gait, and 
experienced constipation.  
WES was carried out on DNA from Patient 10 and results suggested she was homozygous 
for a rare missense variant in exon 6 of the RRM2B (Ribonucleotide Reductase subunit 
M2B) gene resulting in the substitution of the leucine residue at position 64 of the protein 
with a proline (NM_015713; c.574G>A; p.Ala192Thr). Sanger sequencing confirmed 
that the proband was homozygous for the rare missense variant and a segregation study 
could not be carried out due to absence of parental DNA (Figure 4.10). Carrier status of 




Figure 4.10 Confirmation of missense RRM2B mutation in Patient 10. 
A Sequencing chromatogram highlighting the confirmed missense RRM2B variant 
(c.574G>A; p.Ala192Thr) in Patient 10 (black arrow). 
B Clustal Omega alignment of RRM2B protein residues in model organisms showing 







4.4.9 Family 9  
Patient 9 is a 5 year-old male patient born to consanguineous Syrian Arab parents. He 
presented at birth with IUGR and later presented with developmental delay, failure to 
thrive, short stature, hypermetropia, nystagmus, blue sclerae, strabismus, moderate 
hearing loss, fatigue, hypotonia, muscle weakness affecting shoulders and hip girdles, 
and a broad-based gait. A brain MRI scan revealed abnormal areas in the periventricular 
white matter and cerebellum. Serum lactate levels elevated following a period of fasting 
prior to an audiometry test. 
WES was carried out on DNA from Patient 9 and results suggested he was homozygous 
for a previously reported missense variant in exon 2 of the NDUFB9 (complex I structural 
subunit FB9) gene resulting in the substitution of the leucine residue at position 64 of the 
protein with a proline (NM_005005; c.191T>C; p.Leu64Pro). Sanger sequencing 
confirmed that the proband was homozygous for the missense NDUFB9 variant and a 
segregation study of identified parents and siblings as unaffected heterozygous carriers 




Figure 4.11 Segregation of NDUFB9 variant in Family 9 
Pedigree of family 9 showing the segregation of the identified NDUFB9 mutation in family members. Sequencing chromatograms show the 
heterozygous state of carriers and highlights the nucleotide change in Patient 9 (P9) (black arrow). 
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4.4.10 Family 3 
Patient 3 is a 10 year-old male patient born to consanguineous Syrian Arab parents. 
He presented with seizures and tachypnoea from birth accompanies by elevated 
lactate in serum and CSF and elevated pyruvate, alanine and creatine kinase in 
blood. He became hypotonic with persistent elevated serum lactate. He developed 
another seizure at the age of 5 years and a brain MRI revealed abnormal signals in 
the basal ganglia and brainstem along with a thin corpus callosum and dilatation of 
lateral and third ventricles. 
WES was performed on DNA from Patient 3 and this indicated he was homozygous 
for a previously reported nonsense mutation that terminated protein translation of 
the PDHX gene (Pyruvate Dehydrogenase Complex component X) in the middle of 
exon 6 resulting in protein truncation (NM_003477; c.742C>T; p.Gln248*). The 
reported MAF of this mutation in the gnomAD database is 1.22 × 10-5 with 3 
heterozygous individuals reported, one African and two European controls (Lek et 
al., 2016). Sanger sequencing confirmed Patient 3 was homozygous for the 
nonsense mutation. A segregation study revealed both parents, 1 brother, and 2 
healthy sisters were heterozygous carriers of the variant, a healthy brother and a 
healthy sister were wild-type, and an affected brother was found to be homozygous 














Figure 4.12 Segregation of PDHX truncating variant in Family 3. 
Pedigree showing the segregation of the truncating PDHX variant among family1. Patient 3 (P3) and an affected older brother were both 
homozygous for the nonsense mutation. Sequencing chromatograms highlight the identified homozygous PDHX truncating variant in Patient 3 
and his affected sibling (black arrow). 
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4.4.11 Family 11 
Patient 11-I is a 6 year-old female patient born to consanguineous Kuwaiti Arab parents. 
She presented with global developmental delay, hypotonia, epilepsy, microcephaly, 
micrognathia, bilateral hearing loss and lactic acidosis. A brain MRI revealed severe 
cortical atrophy, hypomyelination of the frontal, occipital and temporal lobes, and 
calcification of the basal ganglia. A head CT scan revealed multiple bilateral symmetric 
foci of calcification in the basal ganglia, thalami, periventricular regions and left 
cerebellum.  
Patient 11-III is the double first cousin of Patient 11-I. Patient 11-III is a 5 year-old female 
who presented with jerky movements during her sleep, nystagmus, poor feeding, reduced 
activity, irritability, and a mild increase in serum lactate. A brain MRI scan revealed brain 
atrophy. DNA from Patient 11-I and Patient 11-III were selected for WES analysis as first 
cousin duo. 
WES was carried out on the DNA from Patient 11-I and her affected double first cousin 
Patient 11-III with results suggesting that they were both homozygous for a novel 
missense variant in exon 2 of the RNASEH2C (Ribonuclease H2 subunit C) gene, 
resulting in the substitution of a leucine residue at position 68 with a valine residue 
(NM_032193; c.202C>G; p.Leu68Val). RNASEH2C is one of three subunits that 
comprise the endonuclease RNase H2 complex that is responsible for cleaving 
ribonucleotides from RNA:DNA and DNA:DNA duplexes (Crow et al., 2006). The 
mutation was predicted to be damaging by the in silico prediction tools Polyphen-2 and 
PROVEAN (Adzhubei et al., 2010; Kumar et al., 2009; Choi et al., 2012; Choi and Chan, 
2015). Sanger sequencing confirmed that Patients 11-I and 11-III were both homozygous 
for the suggested missense mutation and a segregation study showed parents of both 
patients were heterozygous carriers of the variant (Figure 4.13). Healthy siblings of both 







Figure 4.13 Segregation of RNASEH2C variant in Family 11. 
A Pedigree of family 11 showing the segregation of the identified RNASEH2C missense 
mutation (c.202C>G, p.Leu68Val). Sequencing chromatograms highlight the 
homozygous missense variant in Patients 11-I and 11-III (P11-I and P11-III 
respectively) (black arrow). 
B Clustal Omega alignment of RNASEH2C protein residues in model organisms 





4.4.12 Family 12 
Patient 12 is a 6 year-old male patient born to non-consanguineous Kuwaiti Arab parents. 
He presented with generalised hypertonia and hyperreflexia, mildly elevated serum and 
CSF lactate levels, became dystonic, irritable, and developed epilepsy. A brain MRI scan 
revealed diffuse signal in the white matter and a thin corpus callosum. 
WES was carried out on DNA from Patient 12 and results identified 2 variants in exon 2 
TREX1 (Three Prime Repair Exonuclease 1). One variant was a novel frameshift 
duplication (NM_033629; c.50dupT; p.Asp18Argfs) and the other heterozygous variant 
was a previously reported missense variant (NM_033629; c.341G>A; p.Arg114His) 
(Crow et al., 2006). Sanger sequencing confirmed that Patient 12 was compound 
heterozygous for the 2 identified variants and segregation study revealed that his father 
was heterozygous for the nucleotide duplication allele while his mother was heterozygous 




























Figure 4.14 Segregation of TREX1 variant in Family 12 
A Pedigree of family 12 showing the segregation of the identified TREX1 variant. 
B. Sequencing chromatograms of identified TREX1 frameshift duplication (c.50dupT) 
in Patient 12 highlighting the nucleotide insertion (black box). 
C. Sequencing chromatograms of identified TREX1 missense variant (c.341A>G) in 















4.4.13 Family 13  
Patient 13 is a 15 year-old male patient born to consanguineous Kuwaiti Persian parents. 
He presented with developmental delay, unilateral ptosis, short stature, synophrys, mild 
turricephaly, bilateral cataracts, general weakness, and EMG disclosing non-irritative 
myopathy wasted shoulder and hip girdle muscles. 
WES was carried out on DNA from Patient 13 and results suggested he was homozygous 
for a novel frameshift deletion in exon 11 of the VPS13B (COH1, Vacuolar Protein 
Sorting 13 homolog B) gene resulting in the substitution of the leucine residue at position 
64 of the protein with a proline (NM_152564.4; c.1512delA; p.Glu505Lysfs). VPS13B 
is a plasma membrane protein associated with vesicle-mediated transport and intracellular 
protein sorting (Kolehmainen et al., 2003). Sanger sequencing confirmed that the proband 
was homozygous for the frameshift deletion, but a segregation study was not performed 









Figure 4.15 Confirming identified VPS13B frameshift deletion in Patient 13 
Sequencing chromatograms of identified VPS13B frameshift deletion (c.1512delA) in 






4.4.14 Family 14 
Patient 14-I is a 21 year-old female patient born to consanguineous Kuwaiti Arab Bedouin 
parents from the same tribe. She presented with global developmental delay, failure to 
thrive, microcephaly, gaze palsy, myopia, bilateral ptosis and ophthalmoplegia, 
myopathic face, generalised hypotonia, generalised muscle wasting, scoliosis, and 
developed choreoathetotic movements. A brain MRI scan revealed cerebral atrophy and 
an EEG showed slow abnormal background activity. 
Patient 14-II is Patient 14-I’s 9 year-old brother. He presented with developmental delay, 
microcephaly, hypotonia, muscle weakness, constipation, and developed choreiform 
flicking movements. A brain MRI scan revealed mild generalised reduction of white 
matter. DNA from both Patient 14-I and 14-II were selected for WES. 
WES analysis was performed on DNA from both Patients 14-I and 14-II and filtering for 
protein coding homozygous and heterozygous variants in genes coding for mitochondrial 
and non-mitochondrial proteins suggested no variants. However, including splice-site 
variants in the filtration steps suggested both patients were homozygous for a novel 
splice-site altering variant in ATP8A2 (NM_016529; c.321+1G>T; p.?). The variant is 
predicted to result in the retention of intron 3. Sanger sequencing confirmed both sibling 
patients were homozygous for the splice-site variant, and a segregation study showed 
both parents were heterozygous carriers (Figure 4.16). DNA from the 4 healthy siblings 
were not available to complete the segregation due to the family not consenting to 
genotyping of healthy siblings. 
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Figure 4.16 Segregation of ATP8A2 variant in Family 14 
Pedigree of family 14 showing the segregation of the identified ATP8A2 variant (c.321+1G>T). Sequencing chromatograms of identified 
homozygous splice-site variant in Patient 14-I highlighting the nucleotide change (black arrow). 
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4.4.15 Undiagnosed cases 
No candidate variants were identified in 8 of the 22 recruited families. The various 
filtration modifications were applied as described in Section 4.3.4, but no candidate 
variants were confirmed in these families.  
4.4.15.1 Family 16 
WES analysis revealed Patient 16 was heterozygous for a previously reported truncating 
MGME1 variant (c.456G>A; p.Trp152*) (Kornblum et al., 2013). MGME1 is a 
mitochondrial nuclease that plays a role in DNA maintenance during mtDNA replication. 
Sanger sequencing of the truncating variant confirmed the patient was homozygous while 
sequencing of an exon with low read depth coverage identified no variants within it. 
Reanalysis of WES variants did not identify any other candidate variants. 
 Summary of findings 
4.5.1 Variants in patients from consanguineous unions 
Since the majority of recruited patients were born in consanguineous families, 
homozygous variants were the main focus of the WES variants filtration process. Of the 
14 diagnosed families, 12 patients had consanguineous and 2 had non-consanguineous 
parents. All diagnosed patients from consanguineous families harboured homozygous 
genetic mutations, while one of the non-consanguineous families harboured a 
homozygous mutation and the other harboured compound heterozygous mutations (Table 
4.2). 
4.5.2 Rate of candidate variants identified  
Of the 22 recruited families, 14 genetic diagnoses have been reached (63.6%). This is an 
expected yield as this was a similar diagnosis rate in previous research involving WES of 
patients suspected of mitochondrial disease (Taylor et al., 2014; Wortmann et al., 2015; 
Pronicka et al., 2016). Of the 14 diagnosed families, 10 families (71%) were diagnosed 
with or suspected of mitochondrial disease involvement, and 4 families (29%) were 
diagnosed with phenocopies of mitochondrial disease such as AGS and Cohen syndrome.  
A total of 15 variants were identified in 13 genes. Of the 15 variants, 10 were novel 
variants (LETM1, SLC19A3, SURF1, MPC1, NDUFA13, TTC19, RNASEH2C, VPS13B, 
TREX1, ATP8A2), 2 were rare variants previously reported in a heterozygous state in 
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controls (RRM2B, LETM1), 3 were previously reported in patients (PDHX, NDUFB9, 
TREX1). Categories of the mutations are as follows: 7 missense mutations (SLC19A3, 
MPC1, NDUFB9, LETM1, RRM2B, RNASEH2C, TREX1), 2 truncating mutations 
(PDHX, NDUFA13), 3 frameshift deletions (SURF1, TTC19, VPS13B), 1 non-frameshift 
deletion (LETM1), 1 duplication (TREX1), 1 splice-site variant (ATP8A2). Of the 13 
identified genes, 12 were previously reported as associated with disease in patients, and 
only LETM1 was a novel candidate gene with mitochondrial localisation and function.  
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Table 4.2 Summary of variants identified using WES in recruited patients showing in silico predictions of pathogenicity in missense 
mutations  
(continued on next page).  







Variant MAF PPh2 SIFT Mutationtaster CADD 
1 LETM1 NM_12318.2 Exon 5 c.754_756del p.Lys252del Novel candidate gene - - - - - 
2 SLC19A3 NM_025243 Exon 3 c.175T>C p.Trp59Arg Novel variant - 0.998 0.15 0.99999 24.5 
3 PDHX NM_003477 Exon 6 c.742C>T p.Gln248* Reported pathogenic variant 1.22 ´ 10
-5 NA 0.81 - 35 
4 SURF1 NM_003172 Exon 5 c.367_368del p.Arg123Glyfs*4 Novel frameshift deletion - - - - - 
5 MPC1 NM_016098 Exon 3 c.109C>T p.Pro37Ser Novel variant - 0.991 0.27 0.9999 27 
6 LETM1 NM_12318 Exon 6 c.881G>A p.Arg294Gln Novel candidate gene; rare variant -         
7 TTC19 NM_017775 Exon 8 c.779_780del p.Tyr260* Novel frameshift deletion - - - - - 
8 NDUFA13 NM_015965 Exon 1 c.22C>T p.Gln8* Novel truncating variant - - - - 38 
9 NDUFB9 NM_005005 Exon 2 c.191T>C p.Leu64Pro Reported pathogenic variant 1.6 ´ 10
-5 0.999 0.02 0.99999 26.3 
10 RRM2B NM_015713 Exon 6 c.574G>A p.Ala192Thr Rare missense variant 4.0 ´ 10
-6       31 
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Variant MAF PPh2 SIFT Mutationtaster CADD 
11 RNASEH2C NM_032193 Exon 2 c.202C>G p.Leu68Val Novel variant - - - - 25 


















13 VPS13B NM_015243 Exon 11 c.1512del p.Glu505Lysfs 
Novel frameshift 
deletion - - - - - 




variant - - - - - 
 
CADD: Combined Annotation Dependent Depletion; MAF: gnomAD minor allele frequency; PPh2: PolyPhen2; RefSeq: Reference Sequence; 




4.6.1 Mitochondrial disease diagnoses 
4.6.1.1 LETM1 
LETM1 is a hexameric transmembrane protein, embedded in the mitochondrial inner 
membrane that plays a crucial role in calcium homeostasis by acting as a Ca2+/H+ 
antiporter (Shao et al., 2016). The protein also helps maintain mitochondrial morphology 
since overexpression of the protein leads to the fragmenting of mitochondria and 
knockdown results in the swelling of mitochondrial cristae and necrotic cell death 
(Nowikovsky et al., 2004; Tamai et al., 2008; Piao et al., 2009). The protein was 
determined to have one transmembrane domain with the C-terminus located in the matrix 
(Shao et al., 2016), but a more recent study identified another transmembrane domain of 
the protein with both the N and C-termini locating to the matrix (Lee et al., 2017).  
The LETM1 gene was first reported as a deleted gene in Wolf-Hirschhorn Syndrome 
(WHS) patients (Endele et al., 1999). It is one of several genes in the WHS critical region, 
located on the p arm of chromosome 4, that is hemizygously deleted in WHS patients. 
Symptoms of WHS include a characteristic facial dysmorphology, microcephaly, 
developmental delay, cardiac defects, epilepsy and hypotonia (Hirschhorn et al., 1965; 
Wolf et al., 1965; Hart et al., 2014). Many of these phenotypes are present in patients 
with mitochondrial disease as well as other neurological disorders.  
Patient 1-I and both her affected brothers (Patients 1-II and 1-III) presented with 
developmental delay and hypotonia, but cardiomyopathy was only observed in the patient 
and her younger brother while its presence was speculated in her older brother as it was 
not investigated or reported; all these clinical features fall under WHS and mitochondrial 
disorder symptoms. However, Patient 1-I and her older, affected brother presented with 
ophthalmological and auditory issues, both her brothers had elevated serum lactate levels 
and a muscle biopsy from her older brother showed reduced overall respiratory chain 
defect in all OXPHOS complexes. Observation of these accompanying clinical symptoms 
strongly supports a diagnosis of mitochondrial disorder in this family rather than WHS. 
This is further supported by the absence of the facial dysmorphic features of WHS and 
the absence of seizures in any of the siblings. Since WHS is associated with the 
hemizygous deletion in chromosome 4, the finding of a homozygous deletion in 2 of the 
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3 affected siblings with unaffected heterozygous parents is the final indicator that 
haploinsufficiency does not result in clinical presentation in this family (Hart et al., 2014).  
The LETM1 amino acid residues affected in the 2 families are located in the C-terminal 
domain (CTD) that protrudes from the IMM into the matrix with the LETM1 protein 
having a single transmembrane domain (Shao et al., 2016). Residues 252 and 294 are 
predicted to be part of a coiled-coil domain but the UniProt knowledge base reports the 
residue 252 to be the first residue in the ribosome binding domain (Endele et al., 1999; 
Prasad et al., 2009; The UniProt Consortium, 2017). Using this determined model, the 
mitoribosomal protein L36 (MRPL36) binds to LETM1 and localises to the IMM (Piao 
et al., 2009). MRPL36 plays a key role in binding the large ribosomal subunit to the small 
ribosomal subunit (Prestele et al., 2009). The deletion of the MRPL36 gene results in an 
overall respiratory chain complex defect since it contributes to the insertion of OXPHOS 
complex subunits by anchoring the mitoribosome close to the IMM where the expressed 
proteins are inserted by the IMM transmembrane protein OXA1 (Prestele et al., 2009; 
Bauerschmitt et al., 2010). It is likely that the deletion of the residue disrupted the binding 
of MRPL36 to LETM1 resulting in OXPHOS complex defects like those observed as a 
result of the C-terminal extension (CE) domain of the MRPL36 protein (Prestele et al., 
2009). This defect was reported in the OXPHOS complex activity carried out on the 
muscle biopsy from the Patient 1-I's older brother further supporting this hypothesis. The 
Ca2+ binding domain of the LETM1 polypeptide is located near the C-terminal of the 
LETM1 protein leading to the dismissal of the effect of the homozygous on the protein's 
calcium antiporter activity.  
The conflicting model presented by Lee et al. (2017) places the residues in the IMS with 
a proposed coiled-coil region for binding ribosomal proteins. This might suggest that a 
reaction might be taking place in the IMS that could explain the observed swelling of the 
mitochondria in knockdown cell lines. It is unfortunate that no biopsy may be obtained 
to further research the effect of this variant on mitochondrial function and how it may 
have contributed to their clinical symptoms. 
A submission of the identified LETM1 variants in GeneMatcher (Sobreira et al., 2015) 
matched us with a cohort of patients with variants in the same gene that are being 
compiled into a collaborative study that can highlight tissue result from surviving 
patients. A total of 7 families so far, including the 2 families from this study, have been 
assessed. One of the patients harboured the same rare homozygous mutation identified in 
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Patient 6 (c.881G>A; p.Arg294Gln) in a 34 year-old female patient born to 
consanguineous Italian parents. The patient presented with developmental delay, 
myopathy, hypotonia, ataxia, nystagmus, divergent strabismus, ptosis, bilateral cataracts, 
and lactic acidosis. A brain MRI scan at the age of 8 years revealed cerebral atrophy and 
cerebellar hypoplasia. Histochemical analysis of muscle biopsy revealed ragged red fibres 
and COX-deficient fibres, and respiratory chain enzyme activity assessment revealed 
combined OXPHOS deficiency of complexes I, III and IV. The patient’s presentations 
match those identified in Patient 1-II with both presenting with hypotonia, myopathy, 
nystagmus, lactic acidosis, and combined OXPHOS enzymes deficiency in muscle. 
Another family with two sibling patients who have compound heterozygous LETM1 
variants with one variant affecting a residue neighbouring the mutation identified in 
Patient 6 [c.878T>A; p.Ile293Asn] while the other was a frameshift deletion [c.2094del; 
p.Asp699Metfs]. Both affected siblings presented with developmental delay, diabetes, 
epilepsy, deafness, and facial dysmorphism. Other varying presentations were spasticity 
and clonus in one sibling while the other had neuropathy and MRI brain revealed 
hypoplasia in the pons and cerebellum. Interestingly, no elevated lactate was reported in 
either siblings. 
The collaborative work on LETM1 patients will provide a clinical spectrum of 
presentations that helps diagnose similar patients, while available tissue samples will help 
shed light on the aetiology of disease in the patients. It is surprising that 2 unrelated 
patients in this cohort who were from different ethnicities harboured mutations in a single 
novel candidate gene (LETM1). This was a promising finding; however, all the patients 
were deceased, and no tissue samples were available to pursue functional studies; only 
genotyping and segregation studies were possible.  
4.6.1.2 NDUFA13 
The identified NDUFA13 nonsense mutation is located very early on in the translated 
polypeptide and the synthesised protein is likely degraded due to non-sense mediated 
decay. NDUFA13 encodes a supernumerary complex I subunit located on the membrane 
arm of the inner mitochondrial membrane protein complex (Zhu et al., 2016; Guo et al., 
2017). The protein was previously identified as GRIM19 due to its function in inducing 
cell death by interferon-β and all-trans-retinoic acid (Angell et al., 2000). Mutations in 
NDUFA13 were first identified in thyroid Hurthle cell carcinomas and in other organ 
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cancers suggesting its function as a tumour (Máximo et al., 2005; Pinto and Màximo, 
2018). Knocking out NDUFA13 expression in HEK293T cells, using TALENs tools, 
results in the disruption of complex I assembly (Stroud et al., 2016).  
The first identified inherited pathological mutation in NDUFA13 was reported in patient 
siblings suspected of mitochondrial disease where both presented with developmental 
delay, hypotonia, lower limb spasticity, lactic acidosis, optic atrophy, abnormal eye 
movements, and complex I deficiency in muscle (Angebault et al., 2015). Additionally, 
one of the siblings presented with epilepsy, choreoathetotic movements, auditory 
neuropathy, and global akinesia; the other presented with truncal ataxia, distal dyskinesia, 
and bradykinesia. Radiological MRI findings in both affected siblings revealed high 
signal in the dentate nucleus in addition to an elevated lactate peak in the basal ganglia 
on MRS. Functional analysis of skin fibroblasts from both patients revealed decreased 
levels of CI subunit proteins including NDUFA13, NDUFA9 and NDUFB8, decreased 
levels of assembled CI and OXPHOS supercomplexes, and lower oxygen consumption 
rates compared to controls. 
Bi-allelic compound heterozygous NDUFA13 variants were reported in another patient 
who presented with early-onset Leigh syndrome (Gonzalez-Quintana et al., 2020). This 
patient presented before the age of 2 years with nystagmus, hypotonia, lactic acidosis, 
moderate neurological symptoms and bilateral lesions in the basal ganglia. By the age of 
16 years, he had developed spastic tetraparesis, difficulty swallowing, low weight and 
mild hypertrophic cardiomyopathy. Biochemical OXPHOS enzyme analysis in patient 
biopsy revealed isolated CI activity. In addition, functional analysis of patient skin 
fibroblasts showed decreased levels of NDUFA13 and NDUFA9 proteins, decreased 
levels of assembled respirasomes, a slower growth rate, and lower oxygen consumption 
rates compared to controls. 
The identified homozygous NDUFA13 mutation in this study is the third identified family 
thus far. Progression of Patient 8's clinical presentations is similar that of the NDUFA13 
affected siblings reported by Angebault et al. (2015). Radiological MRI findings are 
consistent with a mitochondrial disease diagnosis and also overlap with regards to the 
involvement of the optic nerve (Figure 3.7). The early presentation of the NDUFA13 
patient reported by Gonzalez-Quintana et al. (2020) is similar to Patient 8 regarding 
developmental delay, nystagmus, hypotonia and lactic acidosis. The variation in clinical 
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presentations and findings show clinical heterogeneity with regards to mutations 
identified within a single gene associated with mitochondrial function. 
The identified NDUFA13 variant results in an early termination of protein translation 
likely meaning there is no protein expression. A skin biopsy from Patient 8 was requested 
to run functional studies to confirm variant pathogenicity and support the genetic 
diagnosis that this patient is complex I deficient. 
4.6.1.3 MPC1 
MPC1 encodes the IMM protein Mitochondrial Pyruvate Carrier 1 that forms a 
heterodimer complex with its paralog Mitochondrial Pyruvate Carrier 2 (MPC2) to 
facilitate the uptake of pyruvate by mitochondria (Bricker et al., 2012; Vanderperre et al., 
2015). Both paralogs are required to form the complex and facilitate pyruvate 
transportation into the matrix.  
Patients from three families suspected of mitochondrial disease were genetically 
investigated and 2 missense mutations in MPC1 were identified (Brivet et al., 2003; 
Bricker et al., 2012). The patients presented with developmental delay, lactic acidosis, 
microcephaly, facial dysmorphism, hypotonia, nystagmus, hepatomegaly, and 
hypoglycaemia. Investigations revealed elevated plasma pyruvate and lactate, and Kreb's 
cycle intermediates in urine. Radiological brain MRI revealed cerebral atrophy, slight 
ventricular dilatation, and periventricular leukomalacia and calcification in addition to 
high lactate peak in caudate ganglia on MRS. Oxygen consumption in pyruvate driven 
respiration conditions was decreased in patient fibroblasts compared to control fibroblasts 
indicating the cells’ dependence on anaerobic glycolysis to generate energy. Transfection 
of the patient fibroblasts with a vector carrying a wild-type human MPC1 gene rescued 
the oxygen consumption supporting the genetic diagnosis of both MPC1 mutations.  
Patients 5-I and 5-II presented with clinical phenotypes similar to those reported in the 
MPC1 patients. Some of the similar phenotypes are developmental delay, lactic acidosis, 
microcephaly/brachycephaly, and facial dysmorphism. Their younger sister (Patient 5-
III) also presented with these features with the exception of the facial dysmorphism.  
The novel MPC1 missense mutation these patients harbour is the third reported mutation 
in MPC1. Skin biopsies from Patients 5-I and 5-II have been requested to functionally 
investigate the effect of the novel variant on MPC1 activity and expression in fibroblasts. 
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4.6.1.4 TTC19 
TTC19 is a complex III assembly factor that colocalises with the respiratory chain protein 
in the IMM (Ghezzi et al., 2011). Bi-allelic mutations in TTC19 are associated with a 
group of heterogeneous phenotypes in both paediatric and adult patients; presentations 
include progressive neurodegenerative disease, psychosis, ataxia, and occasionally 
elevated lactate reported in patients (Ghezzi et al., 2011; Nogueira et al., 2013; Atwal, 
2014; Melchionda et al., 2014; Morino et al., 2014; Ardissone et al., 2015; Koch et al., 
2015; Kunii et al., 2015; Mordaunt et al., 2015). Radiological findings in patients 
commonly show involvement of the basal ganglia and the cerebellum. Most identified 
mutations are truncating, or frameshift indels that result in the loss of TTC19 protein 
expression in patient muscle and fibroblasts. Complex III enzyme activity is reduced in 
patient muscle and in fibroblasts grown in galactose, however immunoblotting and blue 
native gel electrophoresis (BNGE) do not show any reduction in the expression of 
complex III subunits and protein complex intermediates.  
Recent research revealed that TTC19 is responsible for cleaving the N-terminal chain of 
the ubiquinol:cytochrome c reductase, Rieske iron-sulphur polypeptide (UQCRFS1) in 
the fully assembled protein complex (Bottani et al., 2017). The accumulation of these N-
terminus chains results in an inactive fully assembled complex III protein. The clinical 
progression of symptoms in Patient 7-I and her brother along with the lack of reported 
plasma lactate elevation and radiological findings involving the caudate and putamen 
(Figure 3.6) reflect a similar phenotype to that reported by Mordaunt et al. (2015) in an 
Iraqi patient. Skin biopsies from both affected siblings has been requested to functionally 
investigate the expression of TTC19 protein in fibroblast cell lines using immunoblotting, 
BN-PAGE and possibly respiratory chain enzyme activity. Findings will support the 
diagnosis of complex III deficiency and reinforce the phenotype-genotype relationship 
between TTC19 mutations and clinical and functional finding in previously reported 
patients. 
4.6.1.5 SLC19A3 
SLC19A3 encodes a thiamine/H+ antiporter that is a member of the SLC19 
folate/thiamine transporter family found in the plasma membrane that takes up thiamine 
while simultaneously expelling protons (Rajgopal et al., 2001; Ganapathy et al., 2004). 
Bi-allelic mutations in its gene are associated with biotin-thiamine responsive basal 
 189 
ganglia disease (BTRBGD) (Ferreira et al., 2017). BTRBGD is an autosomal recessive 
disorder that presents initially as encephalopathy with seizures and is accompanied by 
development delay or regression often leading to hypotonia and muscle fatigue (Aljabri 
et al., 2016; Algahtani et al., 2017). Lactic acidosis was also reported in some cases and 
was treated with thiamine and biotin (Pérez-Dueñas et al., 2013). However, treatment at 
late stages of BTRBGD does not reverse the effects leading to long-term symptoms that 
eventually lead to death (Algahtani et al., 2017). 
The clinical presentations of Patient 2 sit well with the BTRBGD diagnosis and she has 
been treated with thiamine and other supplements but there is no report of any biotin 
being administered. The homozygous mutation in exon 3 of the SLC19A3 gene results in 
the non-synonymous substitution of a non-polar tryptophan residue at position 59 with a 
basic arginine residue in a transmembrane domain of the SLC19A3 protein (Prasad et al., 
2009; The UniProt Consortium, 2017). This substitution likely disrupts the secondary 
folding of the transmembrane protein leading to a reduction in thiamine/H+ antiporter 
activity resulting in the development of BTRBGD. Thiamine (also known as vitamin B1) 
has an active phosphorylated form thiamine pyrophosphate (TPP) which is an important 
cofactor in cellular metabolism including pyruvate dehydrogenase (PDH) activity 
(Depeint et al., 2006). 
Alaskan Husky Encephalopathy (AHE) is an animal disorder that presents with brain 
lesions similar to Leigh syndrome (Vernau et al., 2013) AHE is caused by the truncation 
of the SLC19A3.1 paralog of the SLC19A3 protein due to compound heterozygous 
variants involving a 4bp insertion and a single nucleotide polymorphism in the gene 
(c.624insTTGC, c.625C>A) (Vernau et al., 2015). The SLC19A3.1 paralog is expressed 
in the brain and spinal cord of Alaskan Huskies. Functional analysis of brain tissue from 
affected Huskies showed thiamine deficiency, reduction in OXPHOS activity and an 
increase in oxidative stress. These results do not reflect what happens in humans since 
SLC19A3 gene is expressed ubiquitously in humans (Vernau et al., 2013). 
No functional study has been reported in the literature to investigate the effects of 
SLC19A3 mutations on mitochondrial function in patients. Obtaining a biopsy sample and 
performing protein and mitochondrial functional analyses would expand our knowledge 
on the aetiology of this disease. 
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4.6.1.6 SURF1 
SURF1 encodes a complex IV assembly factor that is embedded in the inner 
mitochondrial membrane (Zhu et al., 1998). In addition to its role in assembly, SURF1 is 
also suggested to play an important role in the incorporation of heme a as part of the 
complex IV biogenesis pathway (Hannappel et al., 2012). Bi-allelic SURF1 mutations 
were first identified in Leigh syndrome patients with associated complex IV deficiency 
in 1998 (Tiranti et al., 1998; Zhu et al., 1998; Wedatilake et al., 2013).  
Leigh syndrome was reported by Denis Leigh in 1951 and is now considered the most 
common diagnosis in paediatric mitochondrial disease patients (Leigh, 1951; Lake et al., 
2015). Radiological MRI findings of symmetrical lesions involving the basal ganglia and 
brainstem are the most consistent features in Leigh syndrome. Genetic mutations 
associated with Leigh syndrome were first reported in 1991; since then, mutations in more 
than 75 genes (mitochondrial and nuclear) have been associated with Leigh syndrome 
(Hammans et al., 1991; Lake et al., 2016). SURF1 is one of these genes and is commonly 
linked with complex IV deficiency associated with Leigh syndrome; cases with other 
SURF1 mutations are associated with leukodystrophy (Rahman et al., 2001; Wedatilake 
et al., 2013).  
Patients 4-I, 4-II and 4-III all presented with clinical phenotypes suggestive of 
mitochondrial disorder. Radiological brain MRI findings in all 3 patients were supportive 
of the diagnosis. For example, brain MRI findings for patient 4-III showed lesions 
involving the brainstem consistent with the radiological findings of Leigh syndrome 
patients (Figure 3.5). Patient 4-I also presented with hypertrichosis which is frequently 
reported in patients with SURF1 mutations (Kleist-Retzow et al., 2001; Østergaard et al., 
2005; Yüksel et al., 2006; Baertling et al., 2013). 
No functional studies to support the SURF1 mutation can be carried out due to the lack 
of skin and muscle biopsies or a cell line for any of the patients. Nonetheless, clinical and 
radiological findings support the genetic diagnosis of the three siblings having a 
pathogenic frameshift SURF1 deletion. 
4.6.1.7 RRM2B 
RRM2B encodes the cytosolic protein Ribonucleotide Reductase regulatory TP53 
inducible subunit M2B, which is a part of the ribonucleotide reductase complex 
responsible for the reduction of ribonucleoside diphosphates to deoxyribonucleoside 
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diphosphates (Bourdon et al., 2007). which is a crucial step in replenishing cellular 
deoxyribonucleoside triphosphate levels for DNA synthesis, most importantly mtDNA 
synthesis. RRM2B mutations have been associated with mtDNA depletion and multiple 
mtDNA deletions in patients (Pitceathly et al., 2012; Keshavan et al., 2020). Patients with 
RRM2B mutations either present early in life or in adulthood with the most commonly 
reported phenotypes in adults being ptosis and progressive external ophthalmoplegia 
(PEO).  
Patient 10’s presentation and age at onset fit well with the genetic diagnosis of bi-allelic 
RRM2B mutations. Even though her MDC score was only suggestive of probable 
mitochondrial disease involvement, as the only adult in the cohort, her presentations of 
ptosis, PEO, and exercise intolerance and fatigue were highly suggestive of mitochondrial 
disease. The MDC used in the study was specified for use with paediatric cases rendering 
it unreliable in this case. Furthermore, the lack of medical reports and investigation results 
likely depleted the MDC score. The decision to recruit was based on Prof McFarland's 
expertise and assessment of her clinical presentation during his visit to Kuwait. As the 
only adult patient, her parents were deceased, and no segregation study was possible. 
4.6.1.8 NDUFB9 
The identified variant is the only NDUFB9 reported in patients who were homozygous 
and their fibroblasts revealed a defect in complex I activity that was rescued when wild-
type NDUFB9 cDNA was expressed (Haack et al., 2012). NDUFB9 encodes a 
supernumerary complex I subunit located within the membrane arm of the protein 
embedded in the inner mitochondrial membrane (Zhu et al., 2016; Guo et al., 2017). 
NDUFB9 plays a role in the interaction between complexes I and III when forming 
supercomplexes (Wu et al., 2016a). Knocking out NDUFB9 expression in HEK293T 
cells, using TALENs and CRISPR/Cas9 methods, results in the disruption of complex I 
assembly (Stroud et al., 2016). The first reported pathogenic mutation in NDUFB9 was 
associated with reduced expression of NDUFB9 and other complex I subunits in 
fibroblasts in addition to reduced complex I activity (Haack et al., 2012). One of the 
affected siblings presented before the age of 6 months with progressive hypotonia and 
lactic acidosis. 
Patient 9 is homozygous for the same mutation reported and his symptoms occurred 
before the age of 6 months. His elevated lactate and hypotonia are also consistent yet the 
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ophthalmologic and auditory presentations are additional clinical presentations not 
reported before. Since no up-to-date clinical data is available for the reported patient's 
symptoms, the additional symptoms could be considered as clinical variations in patients 
with NDUFB9 mutations.  
4.6.1.9 PDHX 
Pyruvate dehydrogenase complex (PDHc) is a protein that localises in the mitochondrial 
matrix and catalyses the final step of glycolysis by converting pyruvate to acetyl-CoA 
(Brown et al., 2006). The PDHX gene codes for the E3 binding protein (E3BP), also 
known as PDHc component X, which binds to the protein’s catalytic subunit E2 to the 
E3 subunit of the PDHc. Mutations in the PDHX gene are predominantly associated with 
patients exhibiting lactic acidosis, due to pyruvate dehydrogenase deficiency, mostly 
accompanied by symptoms of developmental delay, encephalopathy, and occasionally 
reported seizures, or hypotonia (Barnerias et al., 2010; Tajir et al., 2012; Ivanov et al., 
2014). Patient 3's presentation with episodic lactic acidosis, developmental delay, 
hypotonia, epilepsy and encephalopathy are clearly associated with PDHc deficiency. 
In Kuwait, two previously reported patients that were homozygous for protein truncating 
mutations in PDHX presented with similar symptoms including the reported thinning of 
the corpus callosum (Ramadan et al., 2004). One of them was homozygous for a mutation 
that led to the termination of translation in exon 6 at residue position 248 (c.742C>T, 
p.Gln248*) and the other was a nonsense mutation that terminated translation in exon 1 
at the 5th residue position (c.14A>G, p.Typ5*). Pyruvate dehydrogenase activity was 
reduced in both patient and histochemical analysis showed both patients were deficient 
for E3BP. Truncating mutations were reported elsewhere in the literature with similar 
reported symptoms and deficiencies as previously described (Brown et al., 2006; Tajir et 
al., 2012). 
More importantly, the genotyped homozygous mutation in Patient 3 was reported in a 
case that was compound heterozygous for the truncating variant plus the insertion of a 
long-interspersed element-1 that resulted in the deletion of exons 3 to 9 of the PDHX gene 
(Miné et al., 2007). Reported clinical symptoms overlapped with Patient 3 pyruvate 
dehydrogenase activity was reduced and the E3BP deficiency was reported. 
Even though the truncating mutation was previously reported in the literature, this is the 
first time it is present in a homozygous state. Repeating biochemical and histochemical 
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and confirming the effects of the mutation on pyruvate dehydrogenase activity and E3BP 
expression will provide further support to the effects of truncating mutations in the PDHX 
gene. 
4.6.2 Non-mitochondrial diagnoses 
4.6.2.1 RNASEH2C 
Cleavage of ribonucleotides from RNA:DNA and DNA:DNA duplexes is performed by 
the endonuclease RNase H2 (Crow et al., 2006b). Three subunits (RNASEH2A, 
RNASEH2B and RNASEH2C) comprise the fully functioning enzyme. Mutations in 
genes coding for these subunits are associated with Aicardi-Goutières syndrome (AGS) 
an autosomal recessive disorder that usually presents in childhood with microcephaly and 
an encephalitic-like syndrome that leads to psychomotor delay, irritability, hypotonia, 
abnormal movements and many develop epilepsy (Rice et al., 2007b; Crow et al., 2015). 
Calcification of the basal ganglia and white matter abnormalities in MRI brain scans are 
also characteristic of AGS. 
In the RNASEH2C gene, a homozygous missense mutation (c.205C>T; p.Arg69Trp) 
directly neighbouring the genotyped variant found in Patient 11-I and her cousin Patient 
11-III (c.202C>G; p.Leu68Val) was reported in at least 24 families with AGS (Crow et 
al., 2015). The presentation of developmental delay, hypotonia, microcephaly, epilepsy 
and MRI scans showing calcification of the basal ganglia in Patient 11-I points towards 
a diagnosis of AGS. The reported symptoms of Patient 11-II in addition to Patient 11-III's 
presentation with jerky movements, irritability and reported encephalopathy further 
support the AGS diagnosis. However, elevated lactate reported in both affected cousins, 
hearing loss in Patient 12-I and nystagmus in Patient 11-III suggest the possible 
involvement of mitochondrial dysfunction. Analysis of biopsy samples from both 
affected cousins could uncover any mitochondrial involvement in this AGS suggested 
diagnosis. 
4.6.2.2 TREX1 
TREX1 was the first gene associated with AGS and is also associated with adult-onset 
autosomal dominant retinal vasculopathy with cerebral leukodystrophy (RVCL) 
(Richards et al., 2007; DiFrancesco et al., 2015). TREX1 encodes a 3’-5’ DNA 
exonuclease that degrades single stranded DNA during DNA damage repair and in a 
cellular apoptosis pathway (Höss et al., 1999; Lee-Kirsch et al., 2007). AGS patients with 
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TREX1 mutations were the most severely affected compared to patients with variants in 
other associated genes (ADAR, IFIH1, RNASEH2B, and SAMHD1) (Adang et al., 2020). 
RVCL patients with heterozygous mutations in the C-terminal of TREX1  
Patient 12 presented with leukodystrophy, epilepsy, spasticity, developmental delay, and 
elevated serum and CSF lactate; no interferon alpha levels were measured in the patient’s 
serum or CSF. The patient’s phenotype, notably the elevated serum and CSF lactate, was 
highly suggestive of mitochondrial disease or other neurological disorders, but AGS was 
not suspected. The lack of thorough clinical investigations such as cranial CT scan and 
assessment of serum a-interferon levels in the TREX1 patient resulted in the 
misinterpretation of the phenotype. The elevated lactate levels reported might be a result 
of distress at the time of sample collection. Leukodystrophy is another finding that has 
been reported in mitochondrial disease patients adding to the suggestiveness of the 
phenotype. Although not yet measured, the patient’s serum interferon alpha levels might 
have been suggestive of AGS; this should be followed-up and confirmed in the patient. 
4.6.2.3 VPS13B 
VPS13B encodes vacuolar protein sorting 13 homolog B, a transmembrane protein of the 
plasma membrane associated with vesicle-mediated transport and intracellular protein 
sorting (Kolehmainen et al., 2003). The VPS13B gene spans 864 kb with 4 protein coding 
transcripts identified the largest containing 62 exons. The VPS13B protein localises to 
the Golgi apparatus and siRNA knockdown of VPS13B resulted in Golgi fragmentation, 
defects in endosome and lysosome formation, and defects in Golgi glycosylation 
indicating VPS13B is required to maintain Golgi morphology and glycosylation and plays 
a role in the endosomal - lysosomal pathway (Seifert et al., 2011; Duplomb et al., 2014). 
Furthermore, siRNA knockdown of the rat homolog Coh1 in rat hippocampal neurons 
reduced the length of neurites formed compared to siRNA scramble knockdown 
suggesting the protein in involved in neuritogenesis (Seifert et al., 2015).  
Mutations in VPS13B are associated with Cohen syndrome, an autosomal recessive 
disorder with variable clinical presentations patients (Kolehmainen et al., 2003). More 
than 200 patients diagnosed with Cohen syndrome from different parts of the world 
including Finland, Italy, Greece, Iran, Pakistan, India, Japan, and China (Bugiani et al., 
2008; Seifert et al., 2009; Douzgou and Petersen, 2011; Rafiq et al., 2015; Zhao et al., 
2019; Alipour et al., 2020; Kaushik et al., 2020). Most reported mutations result in loss 
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of protein function (i.e., frameshift deletions and truncating mutations). Patients typically 
present with microcephaly, infantile hypotonia, non-progressive developmental delay, 
typical craniofacial features (in the form of short philtrum, high arched or wave shaped 
eyelids, thick hair, and low hairline), hyperextensibility of the joints, slender extremities, 
motor incoordination, intermittent neutropenia, and a cheerful disposition (Kivitie‐Kallio 
and Norio, 2001; El Chehadeh-Djebbar et al., 2013). Variable reported presentations 
include abnormal truncal fat distribution (observed in mid-childhood), typical facial 
characteristics, retinitis pigmentosa, myopia, cataract, and chorioretinal dystrophy 
(Douzgou and Petersen, 2011; Douzgou et al., 2011).  
Patient 13's clinical presentations fit well with this genetic diagnosis as he presented with 
developmental delay, facial dysmorphic features, mild turricephaly, bilateral cataract 
(which was treated), generalised muscle weakness, wasted shoulder and hip muscles 
supported by an abnormal EMG indicating myopathy and a brain MRI revealing mild 
cerebellar atrophy. The MRI findings were previously highlighted as a key finding in 
some patients with bilateral cerebellar hypoplasia, but Patient 13 only had unilateral (left) 
hypoplasia (Waite et al., 2010). No blood investigation results were available to report 
on lactate levels and neutrophil levels which would further support a clinical Cohen 
syndrome. Patient 13 had a high MDC score of 9 meaning he was a good candidate for 
the study as a suspected mitochondrial disease patient born to first cousin parents with 
family history of an affected paternal aunt. The lack of clinical history regarding disease 
progression did not prompt the exclusion of the patient from recruitment highlighting a 
limitation of the recruitment process. The patient's family did not provide DNA samples 
to perform a segregation study therefore we could not confirm segregation of the 
identified deletion and genotype the affected aunt. 
4.6.2.4 ATP8A2 
ATP8A2 encodes a P4-type ATPase, a plasma membrane protein that translocates the 
aminophospholipid phosphatidylserine across the membrane's lipid bilayer from the 
exocytoplasmic to the cytoplasmic leaflet; ATP8A2 is expressed in the retina, testes and 
brain where it is mostly expressed in the cerebellum (Coleman et al., 2009; Cacciagli et 
al., 2010). The translocation of aminophospholipids maintains lipid bilayer asymmetry 
which is crucial for maintaining the curvature of cellular membranes and is associated 
with numerous cellular functions including cell division, vesicle formation, membrane 
permeability, and apoptosis.  
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A number of patients with ATP8A2 mutations have been reported and presented with 
cerebellar ataxia, mental retardation and dysequilibrium syndrome 4 (CAMRQ4) and 
manifested severe neuromuscular phenotypes (Cacciagli et al., 2010; Onat et al., 2013). 
The first reported case presented with severe mental retardation and hypotonia and had a 
balanced chromosomal translocation between chromosomes 10 and 13 resulting in the 
splitting of the ATP8A2 gene. The second family were primarily diagnosed with Unertan 
syndrome, a syndrome characterised by mental retardation, primitive language and 
quadrupedal gait. Patients from the second family presented with mental retardation, 
truncal ataxia, mild atrophy of cerebral cortex, cerebellum and corpus callosum, and most 
had quadrupedal gait. A missense ATP8A2 mutation involving a highly conserved residue 
(Ile376Met) was identified and segregated in the affected individuals.  
Patients 14-I and 14-II presented with similar phenotypes to those reported in the Unertan 
family, but no quadrupedal gait was noted. The presence of ptosis and ophthalmoplegia 
along with lactic aciduria in Patient 14-I raises the question of whether metabolic or 
mitochondrial function is involved in the disease aetiology. This is supported by the 
presence of metabolic findings in Patient 14-II. Unfortunately, no patient cell line was 
available to run cDNA analysis to assess the effect of the splice-site variant on mRNA 
splicing. 
 Summary 
The aim of my study was to recruit paediatric patients residing in Kuwait who are highly 
suspected of mitochondrial disease involvement. With this in mind, my selected cohort 
was from a highly consanguineous population with a focus on diagnosing mitochondrial 
disease resulted in a rate of diagnosis that reflects the high proficiency of the implemented 
recruitment scheme and adapted MDC scoring criteria. The clinical phenotypes of 
patients were not suggestive of any specific genes to be targeted initially since the 
majority of patients did not have biochemical or histological results from muscle biopsies. 
Utilisation of WES resulted in the diagnosis of 14 out of 22 families without the need for 
linkage analysis or homozygosity mapping. The rate of diagnosis (63.6%) was similar to 
diagnosis rate reported in cohorts of suspected mitochondrial disease patients investigated 
using WES (Haack et al., 2012; Taylor et al., 2014; Wortmann et al., 2015; Pronicka et 
al., 2016).  
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 Conclusion 
The use of agnostic WES had an advantage over targeted gene sequencing of genes 
associated with mitochondrial function since WES allowed for the diagnosis of 4 families 
with disorders that were phenocopies of mitochondrial disease (Lieber et al., 2013). 
Nonetheless, there were limitations to the WES method since coverage and depth of 
variant calls varied between patients (see Section 4.4.1) which could have resulted in 
reduced capture of some genes associated with mitochondrial function (Sims et al., 2014). 
Moreover, WES is not reliable in identifying translocations and inversions in 
chromosomes, identifying copy number variants (CNVs), sequencing repeat regions and 
GC-rich regions, identifying methylation patterns due to epigenetics or unipaternal 
disomy, or identify deep intronic variants that could result in cryptic splicing or affect 
microRNA function (Seaby et al., 2015; Sheppard et al., 2018). These limitations are 
expected when using WES as a first-tier diagnostic tool to diagnose patients suspected of 
a genetic disorder, but the resulting diagnostic rates keep it as a promising diagnostic tool. 
Another limitation was the databases of control genotypes used in determining variant 
frequencies in the world population (such as gnomAD); these databases do not include 
Arabs as an exclusive subgroup. There are no databases with Arab population genotypes 
available publicly, however a number of databases are being developed in Saudi Arabia 
and Qatar (Team, 2015; Zayed, 2016). The disadvantage of using gnomAD as a reference 
database for controls is that some common variants in the Arab population might be 
under-reported in the database and thus could lead to a false-positive classification of a 
variant that has a higher frequency in the population than reported. Nonetheless, the 
availability of variants from over 60,000 sequenced individuals is a great starting point 
and a resource to rule out variants that are already identified. 
The input from clinical experts in Kuwait and Newcastle along with the use of the 
developed MDC played a major role in increasing the rate of mitochondrial disease 
diagnoses within my study cohort. Such input and analysis of patients could help diagnose 
patients without the need for invasive muscle biopsies to confirm mitochondrial disease. 
Although the MDC has limited sensitivity in its analysis, its high specificity enables 
patients with mitochondrial disease to be recruited for WES analysis. However, the 
utilised MDC was not thoroughly evaluated and validated using known mitochondrial 
and non-mitochondrial disease cases. The result of these scores was the identification of 
variants associated with non-mitochondrial diseases in 4 families. This finding suggests 
 198 
a limitation of the MDC that can suggest a case to be suspected of mitochondrial disease 
due its scoring methods. The utilisation of the MDC scoring system helped establish a 
comparison between the recruited cases, but its specificity needs to be re-evaluation to 
help identify patients suspected mitochondrial disorders more accurately. 
It was surprising to see patients from 2 unrelated families with mutations affecting the 
same gene (LETM1), a novel candidate gene associated with mitochondrial function. 
Studies involving understudied populations such as the Middle East can help identify 
novel candidate genes due to the high consanguinity rate within the population leading to 
high rates of recessive genetic disorders. It was unfortunate that patients from both 
families were not available 
The remaining 8 undiagnosed cases were investigated for variants that might explain their 
phenotypes using WES, but no clear candidates were identified; these included mtDNA 
variant that were sequenced in the process. Due to the presence of consanguinity within 
the population and the lack of a clear phenotype associated with mtDNA mutations, no 
mtDNA variants were identified in these patients. Further investigations are required to 
help identify the cause of disease in the patients but the lack of access to skin biopsies 
and functional analysis hinders the progress of diagnosis in these patients.  
For interesting cases in my cohort with novel variants identified, we were able to obtain 
skin biopsies to establish fibroblast cell lines and functionally investigate the steady-state 
levels of protein subunits and OXPHOS complex assemblies which are highlighted and 
discussed in the following chapter (Chapter 5).  
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Chapter 5. The functional validation of genetic variants 
identified by whole exome sequencing 
 
 Introduction 
Traditional mitochondrial disease investigations have depended on functional findings in 
patient biopsies suggestive of impaired mitochondrial function prior to initiating, and 
guiding, diagnostic genetic analyses (Wortmann et al., 2017). This has routinely involved 
the acquisition of a muscle biopsy from the patient and analysing OXPHOS complex 
enzyme activities histochemically and biochemically. With the introduction of NGS 
methods in the forms of WES/WGS and/or large gene panels, improved diagnostic rates 
have prompted a shift in the approach to diagnosis to a “genetics-first” approach. Genetic 
diagnoses in mitochondrial disease patients using NGS technologies may result in a 
number of scenarios that might prompt further investigations to validate the identified 
variants as causative. A range of functional analysis methods are utilised for this purpose 
and multiple factors influence the selected methods of validation. A flowchart outlining 
the process of functional investigations has recently been proposed by our group and is 
found in Figure 5.1 (Thompson et al., 2020a).  
If the identified variants are known, validated pathogenic variants in a gene previously 
associated with mitochondrial disease and the clinical phenotype correlates with 
previously reported patients with the same genotype, no investigation beyond the 
segregation study within the patients’ families is warranted. If the identified variant is a 
novel variant in a known mitochondrial disease gene, investigating steady-state protein 
levels of the protein and related proteins (e.g. OXPHOS subunits) in patient tissue (e.g. 
muscle biopsy) or fibroblast cell lines using SDS-PAGE and immunoblotting will 
highlight the effect of the variant on the expression of the protein of interest and related 
proteins (Schägger, 2006), while investigating the assembly of OXPHOS complexes 
using BN-PAGE will assess the effect of the variant on complex assembly (Wittig et al., 
2006). In addition, assessment of gene transcription via qPCR of cDNA generated from 
patient mRNA can highlight the effect of the identified variant on gene expression (Wong 
and Medrano, 2005). Furthermore, splice-site variants can be investigated by sequencing 
cDNA to conclude how the variant affects splicing and if it results in intron retention or 
exon skipping (Anna and Monika, 2018). 
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If the variant is identified in a novel candidate gene of known mitochondrial function, 
SDS-PAGE and BN-PAGE phenotypes were assessed in patient tissue and/or cell lines 
to evaluate the effect of the variant on protein levels and, when necessary, OXPHOS 
complex assembly and protein levels. Assessment of respiratory chain complex enzyme 
activities can support SDS-PAGE and BN-PAGE findings (Schägger, 2006; Wittig et al., 
2006; Frazier et al., 2020). If the novel candidate gene plays a role in mtDNA expression, 
analysis of the incorporation of [35S] labelled methionine and cysteine can assess the 
synthesis rates of newly transcribed mtDNA encoded proteins in patient cell lines 
compared to control cell lines (Richter et al., 2013). Furthermore, a rescue experiment 
expressing a wild-type copy of the protein in the patient cell lines and assessing the effect 
on previously established phenotype helps validate that the identified variant is 
pathogenic (Murphy et al., 2016). GeneMatcher (https://genematcher.org/) is a platform 
that matches researchers that have identified variants in the same novel candidate genes 
fostering collaboration to build larger patient cohorts, something that is a constant 
challenge in the study of rare disease (Sobreira et al., 2015). This can lead to parallel 
functional studies on multiple variants and provide functional evidence validating the 
pathogenicity of the variants in novel candidate genes and establishing an association 
with mitochondrial disorders and/or other genetic disorders. 
The previously mentioned functional methods depend on the availability of cell lines, 
typically skin fibroblasts, from patients. In circumstances where patient tissues and cell 
lines are not available (e.g., the affected individual may be deceased or parental consent 
has not allowed the collection of tissues or cells for functional testing), other tissue culture 
models and animal models may be studied. Cellular phenotypes can be assessed in human 
cell lines using a number of methods: knocking down gene expression using RNA 
interference methods (Han, 2018); knocking out gene expression using gene editing 
methods such as TALENs and Crispr-Cas9 (Stroud et al., 2016); knocking in mutations 
in homologs of the gene in other organisms such as yeast (Bricker et al., 2012); or using 
mouse knock-in or knock-out models (Agostino et al., 2003; Yatsuga and Suomalainen, 
2012; Li et al., 2014). An example of this is the generation of knock-out Slc19a3 mice 
which showed decreased uptake of thiamine compared to wild-type mice (Reidling et al., 
2010). This is an excellent model with regards to SLC19A3 mutations in LS patients that 
revealed the consequence of the mutations on protein function. However, the outcomes 
of model experiments are not always representative of human knock-out experiments or 
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present with phenotypes similar to human phenotypes. For example, mutations in SURF1 
are associated with LS due to complex IV deficiency, but Surf1 knock-out mice presented 
with a mild decrease in complex IV activity upon tissue analysis, absence of 
neurodegeneration, and increased lifespans compared to controls (Dell'Agnello et al., 
2007). The phenotype observed in this mouse model is not representative of the 
phenotypes observed in SURF1 LS patients. Therefore, caution needs to be observed 
when generating and investigating these models. 
At KMGC, the only functional analysis tool available is a tandem mass spectrometer used 
as part of Kuwait’s national new-born screening programme. It assesses acylcarnitine and 
amino acid levels in dried blood spots optimally acquired on day 3 of life. These screening 
results can identify neonates with treatable metabolic disorders including disorders 
related to the fatty acid oxidation and amino acid metabolism pathways. However, as a 
screening step, follow-up validation of possible metabolic disease is carried out on 
peripheral blood at a specialised biochemistry lab and genetic investigation is not 
necessarily performed to elucidate the cause of the disease phenotype. However, in cases 
that do have follow-up genetic analyses (e.g., very-long-chain acyl-CoA dehydrogenase 
deficiency, phenylketonuria and biotinidase deficiency), Sanger sequencing is performed 
on ACADVL, PAH and BTD genes, respectively, in search of known founder mutations 
in the populations or novel variants in these genes due to the high phenotype-genotype 
correlations. This approach has been utilised for the past 5 years and has identified a large 
number of patients with these disorders and genotyped and segregated variants in 
families. Genetic counselling services are provided to families with such results (highly 
likely with consanguineous parents). This process utilises a “function first” approach to 
diagnosing neonates and is an optimal follow-up for the new-born screening programme 
results. 
In patients with suspected genetic disease, genetic results may be carried out at a 
commercial facility that carries out NGS analyses most commonly WES. Segregation 
studies are carried out at KMGC using Sanger sequencing, but novel variants or variants 
of unknown significance (VUS) are not followed up with functional analyses when 
required for validation and are assumed to be causative. This lack of functional 
investigations is concerning and establishing a functional lab that utilises methods to 
validate pathogenicity of genetic variants is critical in Kuwait and KMGC requires such 
facilities to expand its service and provide support for its genetic findings. 
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 Aims 
The Aim of this chapter is to validate the genetic findings in patients from 4 families 
recruited from Kuwait using functional analysis techniques available. This chapter 
includes patients from 3 additional families that were referred from the King Saud 
University, Riyadh, Kingdom of Saudi Arabia, and the NHS Highly Specialised Service 
for Rare Mitochondrial Disorders in Newcastle upon Tyne, UK. These additional cases 
harboured novel variants in known mitochondrial disease genes that required validation. 
Evidence of pathogenicity in these cases with novel or rare variants allows for a definitive 
diagnosis to be made and feedback to the treating clinicians can provide support to patient 
families through genetic counselling. Functional findings can also inform about new 





Figure 5.1 An overview of workflow utilised in identifying variants and validating 
their pathogenicity in association with mitochondrial disease. 
(Legend on next page)  
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Figure 5.1 An overview of workflow utilised in identifying variants and validating 
their pathogenicity in association with mitochondrial disease. 
Genetic investigations are initiated upon suspicion of mitochondrial disease. Methods 
include preliminary sequencing of mtDNA in search of possible mutations. Upon 
identification, follow-up functional techniques can be used to validate pathogenicity of 
the variant and elucidate aetiology of disease.  
The following are examples of additional investigations used to validate and assess the 
consequence of identified variants:  
Cell-lines and Models: a yeast model was used to validate the pathogenicity of MPC1 
mutations identified by expressing the mutant MPC1 genes in mpc1-knockout yeast 
which did not restore yeast growth rates and did not restore rates of oxygen 
consumption to control levels (Bricker et al., 2012).  
Protein/RNA Analyses: complexome profiling of OXPHOS complex assembly was 
assessed in patients with NDUFA6 mutations and highlighted stalled complex I 
assembly and the absence of complex I’s N-module (Alston et al., 2018). 
Imaging: Transmission electron microscopy (TEM) of fibroblasts from a Leigh 
syndrome patient homozygous for SLC25A46 mutations revealed reduced numbers and 
lengths of cristae in mitochondria suggesting SLC25A46 plays a role in mitochondrial 
dynamics (Janer et al., 2016). 
Transport and Protein Import: Inhibition of complex I resulted in impaired protein 
import into the mitochondrial which was assessed by expressing a gene tagged with a 
mitochondrial target sequence and assessing protein localisation and mitochondrial 
import (Franco-Iborra et al., 2018). 
Transcription and mtDNA Maintenance: A northern blot assessing the expression of 
MT-ATP6 in fibroblasts of a patient with a dinucleotide deletion revealed a reduction in 
the mRNA expression of MT-ATP6 (JeŠIna et al., 2004). 
Translation: Following on from the aforementioned reduction in mRNA expression of 
MT-ATP6, JeŠIna et al. (2004) performed a [35S] methionine mitochondrial protein 
synthesis which confirmed the reduction in ATP6 protein synthesis in the mitochondria 
(Thompson et al., 2020a).  
 205 
 Methods 
5.3.1 Recruitment of Patients 
Patients were recruited via my research cohort from the Kuwait Medical Genetics Centre 
as outlined in Section 3.3.1. Additional patients were referred from the King Saud 
University, Riyadh, Kingdom of Saudi Arabia, and from the NHS Highly Specialised 
Service for Rare Mitochondrial Disorders in Newcastle upon Tyne, UK. Clinical 
summaries and growing fibroblast cell lines were provided by the respective centres. 
5.3.2 Acquiring patient fibroblast cell lines from skin biopsies 
Surviving patients living in Kuwait with novel variants of interest had a skin biopsy 
obtained by Ahmad Alaqeel, a clinical colleague at the KMGC. An outline of how 
samples were acquired is provided in Section 2.2.15. The biopsy samples were sent to the 
NHS Highly Specialised Service for Rare Mitochondrial Disorders in Newcastle upon 
Tyne, UK.  
5.3.3 Establishing primary cell lines from skin biopsies 
Gavin Falkous established the primary fibroblast cell line from the obtained patient skin 
biopsies by explanting the samples in T25 flasks. They were treated as outlined in Section 
2.2.16. The established fibroblast cell lines were split once they reached 80% confluency. 
5.3.4 Cell culture 
Cultured fibroblast cell lines of patients were performed as outlined in Sections 2.2.17, 
2.2.18, 2.2.19 and 2.2.20. 
Cells were expanded once they reached 60-80% confluency. Larger flasks were used 
when necessary to obtain larger numbers of cells for analysis. 
5.3.5 Cell lysing in preparation for protein steady-state analysis using western 
blotting 
Fibroblasts from control were harvested and lysed as outlined in Section 2.2.21.1 and the 
protein concentrations were determined as described in Section 2.2.21.2.  
5.3.6 Assessment of protein steady-state levels using western blotting 
An outline of the Western blotting method is provided in Section 2.2.21.3 and a 
description of the immunoblotting technique is outlined in Section 2.2.23. 
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5.3.7 Enrichment of mitochondria 
Mitochondrial enrichment was performed on harvested patient fibroblasts to provide a 
higher quantity and concentration of mitochondrial proteins for analysis of OXPHOS 
complex assembly. An outline of the mitochondrial enrichment method is provided in 
Section 2.2.22.1. 
5.3.8 Solubilisation of enriched mitochondria  
Enriched mitochondria were solubilised using 1% DDM as outlined in Section 2.2.22.2. 
5.3.9 Assessment of OXPHOS complex assembly using BN-PAGE 
An outline of the BN-PAGE method is provided in Section 2.2.22.4 and a description of 
the immunoblotting technique is outlined in Section 2.2.23. 
5.3.10 Analysis of respiratory chain complex activity 
These studies were performed by Langping He at the NHS Highly Specialised Service 
for Rare Mitochondrial Disorders in Newcastle upon Tyne, UK. A description of the 
methods is outlined in Section 2.2.24.  
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 Results 
5.4.1 Clinical summaries of investigated patients  
The following are clinical and genetic summaries of patients investigated and diagnosed 
at indicated centres or at the NHS Highly Specialised Service for Rare Mitochondrial 
Disorders in Newcastle upon Tyne, UK. 
5.4.1.1 Patient 23 
Patient 23 was investigated and diagnosed by the NHS Highly Specialised Service for 
Rare Mitochondrial Disorders in Newcastle upon Tyne, UK.  
Patient 23 was born in 1991 and presented with seizures and myoclonus with brain MRI 
reporting basal ganglia calcification. mtDNA and POLG mutations were investigated and 
excluded. WES identified a rare homozygous COX15 variant: NM_078470; c.1019T>C; 
p.Leu340Pro. In silico predictions tools including PolyPhen2, PROVEAN, CADD and 
Mutationtaster predict the mutation to be deleterious (Kumar et al., 2009; Adzhubei et 
al., 2010; Choi et al., 2012; Schwarz et al., 2014; Choi and Chan, 2015). The variant was 
reported in a single control from South Asia in the gnomAD database with MAF of 4.0 
 ´ 10-6 (Lek et al., 2016). The variant affects a residue that is embedded in a 
transmembrane domain of COX15 and could possibly disrupt the structure of the protein 
(Figure 5.2). 
COX15 codes for Heme A Synthase, a protein that catalyses the conversion of Heme O 
to Heme A. Heme A is an important Complex IV cofactor that is incorporated into COX1 
by SURF1. It has been shown that COX15 plays an important role in Complex IV 
assembly and binds COX1 (Bareth et al., 2013). A small number of patients with clinical 
presentations consistent with mitochondrial disease and skeletal muscle biopsy results 
indicating complex IV deficiency were subsequently found to harbour COX15 mutations 
(Antonicka et al., 2003; Oquendo et al., 2004; Bugiani et al., 2005; Alfadhel et al., 2011; 
Miryounesi et al., 2016).  
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Figure 5.2 Locations and consequences of identified and previously reported COX15 variants. 
Structural scheme of transmembrane COX15 protein highlighting the locations of previously reported mutations: missense mutations (red 
circles); truncating variant: red cross; splicing variant predicted to result in exon skipping (yellow segment), and missense variant reported in this 
project (black and yellow circle). 
IMS: Mitochondrial intermembrane space; IMM: inner mitochondrial membrane. 
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5.4.1.2 Patients 24-I and 24-II 
Patients 24-I and 24-II were referred by Malak Alghamdi, a Saudi Arabian paediatrician 
at King Saud University, Riyadh, Kingdom of Saudi Arabia.  
Patient 24-I is a 16 year-old female born to consanguineous Saudi Arabian parents. She 
was the third pregnancy and born at full term after an uneventful pregnancy. She 
presented with language delay and said her first word at the age of 3 years with a mild 
learning disability resulting in a limited vocabulary. She developed a progressive ataxic 
gait since the age of 12 years, experienced recurrent falls and was noted to have gaze 
evoked nystagmus. A brain MRI scan revealed bilateral symmetrical hyperintense signals 
in the brainstem, hypothalamic structures and deep grey matter with moderate diffuse 
cerebellar and vermin atrophy. She was suspected of having Wernicke’s encephalopathy 
and was started on Vitamin B1 therapy. After 2 years, brain MRI scans showed resolution 
of medial thalami, mammillary bodies, periaqueductal grey matter in midbrain, head of 
caudate and right globus pallidus, plus moderate cerebellar atrophy (Figure 5.4). MRS in 
the basal ganglia showed lactate peaks, and decreased NAA and creatine peaks, which 
suggested underlying mitochondrial disease. At the age of 16 years, she cannot walk, is 
wheelchair bound, mute, and completely dependent on her mother. Plasma amino acid 
analysis showed elevated alanine/lysine ratio, and urine sample analysis revealed lactic 
aciduria. 
Patient 24-I’s younger brother (Patient 23-II) is a 7 year-old male patient born at full term 
after an uneventful pregnancy. At the age of 6 years, he developed ataxia associated with 
recurrent falls. His serum lactate levels were elevated (3.1 mmol/L) and plasma amino 
acid analysis showed elevated alanine/lysine ratio, suggestive of mitochondrial 
dysfunction. 
Commercial NGS services provided by CentoGene (Germany) were used to perform 
WES analysis on DNA from Patients 24-I and 24-II. WES analysis identified the 
following non-frameshift TTC19 deletion in both patients that resulted in the deletion of 
10 protein residues: NM_017775; c.680_709del; p.Glu227_Leu236del. Sanger 
sequencing of the variant in the family identified both parents and 3 unaffected siblings 
to be heterozygous and confirmed both Patients 24-I and 24-II were homozygous for the 
identified variant (Figure 5.3). The function of TTC19 has been previously described in 
Section 4.6.1.4.  
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Fibroblast cell lines were obtained from both patients and sent for functional investigation 
to the NHS Highly Specialised Service for Rare Mitochondrial Disorders in Newcastle 
upon Tyne, UK. 
These patients were investigated with Patient 7-II (a TTC19 patient from my cohort) to 
functionally assess the expression of TTC19 and its effect on OXPHOS complex subunit 
expression, assembly and activity. Clinical and genetic findings for Patient 7-II are 
described in Sections 3.4.1.7 and 4.4.6 respectively. 
 
 
Figure 5.3 Family pedigree of Patients 24-I and 24-II 
A family pedigree of Patients 24-I and 24-II (labelled P24-I and P24-II respectively) 
showing the segregation of the identified TTC19 non-frameshift deletion 




Figure 5.4 Brain MRI Neuroradiological Images of Patient 24-I 
T2 weighted brain MRI scans of Patient 24-I showing: 
A At age of 12 years, bilateral symmetric lesions in the medial thalami (yellow arrows), 
caudate head (blue arrows), right putamen (pink arrow) and right globus pallidus. 
At 14 years after 2 years of vitamin B1 therapy: 
B Bilateral symmetric lesions in pontomedullary junction (orange arrows) 
C Resolution of basal ganglia and medial thalami lesions seen in panel A. 







5.4.1.3 Patient 25 
Patient 25 was investigated and diagnosed by the NHS Highly Specialised Service for 
Rare Mitochondrial Disorders in Newcastle upon Tyne, UK.  
Patient 25 was born to consanguineous parents and presented with tachypnoea and 
metabolic acidosis. The patient’s blood lactate levels were highly elevated (8.0 mmol/L). 
WES analysis identified a rare homozygous NDUFAF3 variant: NM_199069.2; 
c.335T>G; p.Ile112Arg. In silico predictions tools including PolyPhen2, PROVEAN, 
CADD and Mutationtaster predict the mutation to be deleterious (Kumar et al., 2009; 
Adzhubei et al., 2010; Choi et al., 2012; Schwarz et al., 2014; Choi and Chan, 2015). 
Furthermore, the variant resides near a splice-site and could possibly affect the splicing 
of the transcribed gene. The variant was reported in a single control from Africa in the 
gnomAD database with MAF of 4.0 ´ 10-6 (Lek et al., 2016). 
NDUFAF3 is a complex I assembly factor that is plays a role in the assembly of complex 
I’s Q module alongside the complex I assembly factor NDUFAF4 (Guerrero-Castillo et 
al., 2017). A number of patients presenting with Leigh syndrome and complex I 
deficiency have previously been reported with bi-allelic NDUFAF3 mutations (Saada et 
al., 2009; Baertling et al., 2017b; Ishiyama et al., 2018).  
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5.4.2 Functional analysis results 
The following are functional analysis results of investigated patient cell lines from the 
recruited patients. 
5.4.2.1 NDUFA13 
Clinical and genetic findings for Patient 8 are described in Sections 3.4.1.8 and 4.4.4 
respectively. Patient 8 was homozygous for a novel truncating NDUFA13 variant 
(NM_015965; c.22C>T; p.Gln8*). Immunoblotting of the NDUFA13 protein in the 
Patient 8 showed a clear defect in protein expression (Figure 5.5A). Immunoblotting of 
OXPHOS subunits showed a defect of NDUFB8 related to the NDUFA13 defect. 
Immunoblotting of BN-PAGE showed a clear complex I defect in the patient (Figure 
5.5B). 
5.4.2.2 COX15 
Patient 23 was homozygous for a rare missense COX15 variant (NM_078470; 
c.1019T>C; p.Leu340Pro; MAF = 4.0  ´ 10-6). Immunoblotting of OXPHOS protein 
subunits in the Patient 23 showed a clear defect in protein expression of complex IV 
subunits COX1 and COX2 (Figure 5.6A). Immunoblotting of the COX15 protein was 
attempted using a number of antibodies but results were inconclusive due to no bands 
showing or an array of unspecific bands appeared. Immunoblotting of BN-PAGE showed 


























Figure 5.5 Investigating NDUFA13 expression and Complex I assembly in Patient 8 
fibroblasts 
A Immunoblotting of OXPHOS subunits in NDUFA13 patient (P8) and age-matched 
control fibroblasts (C1 and C2) showing a defect in the 2 complex I subunits NDUFA13 
and NDUFB8 in the patient (red). These results represent finding of 3 biological 
repeats. 
B Immunoblotting OXPHOS complexes in NDUFA13 patient (P8) and age-matched 
control fibroblasts (C1 and C2) showing a complex I defect in the patient. This was the 




























Figure 5.6 Steady-state analysis of OXPHOS subunits and complex assembly 
analysis of OXPHOS complexes in Patient 23. 
A Steady-state analysis of OXPHOS subunits in Patient 23 (P23) using Western blotting 
shows a deficiency in COX I and COX II protein expression compared to age-matched 
control fibroblasts. These results represent findings of 4 biological repeats. 
B BN-PAGE analysis of OXPHOS complex assembly shows a defect in fully 
assembled complex IV in Patient 23 (P23) compared to age-matched control fibroblasts. 





Patient 25 was homozygous for a rare NDUFAF3 variant (NM_199069.2; c.335T>G; 
p.Ile112Arg; MAF = 4.0  ´ 10-6). Immunoblotting of the NDUFAF3 protein in the Patient 
25 showed a clear defect in protein expression (Figure 5.7). Immunoblotting of OXPHOS 
subunits showed a defect in the expression of complex I subunits NDUFA9, NDUFB8 




Figure 5.7 Investigating protein steady-state in Patient 25 
Immunoblotting of OXPHOS subunits Patient 25 (P25) and age-matched control 
fibroblasts showing a defect in expression of the complex I assembly factor NDUFAF3 




Two recruited families harboured novel homozygous TTC19 deletions. Patients 7-I and 
7-II harboured a truncating deletion (NM_017775; c.779_780del; p.Tyr260*) and 
Patients 24-I and 24-II harboured a non-frameshift deletion that resulted in the deletion 
of 10 protein residues (c.680_709del; p.Glu227_Leu236del).Fibroblasts were obtained 
for Patients 7-II, 24-I and 24-II, however Patient 24-II fibroblast cell line could not be 
expanded and therefore was not assessed. Immunoblotting of the TTC19 protein in 
Patient 7-II from Kuwait (P7-II) and Saudi Arabia (Patient 24-I) showed no clear defect 
in protein expression nor a defect in complex III subunits CORE2 and UQCRFS1 (Figure 
5.8A). Immunoblotting of BN-PAGE showed no OXPHOS defect in Patient 7-II (Figure 
5.8B); the fibroblasts cell line from Patient 24-I did not expand to the amount required 
for complex assembly analysis and therefore OXPHOS assembly could not be assessed 
using BN-PAGE. Residual OXPHOS enzyme activity did not show any defect in complex 
III enzyme activity in either cell lines which supports the immunoblotting results 

























Figure 5.8 Investigating TTC19 expression and Complex III assembly in fibroblasts 
of TTC19 patients 
A Immunoblotting of OXPHOS subunits and TTC19 in Patients 7-II and 24-I (P7-II and 
P24-I respectively) and age-matched control fibroblasts showing TTC19 defect in 
patients (red) but no complex III defect (CORE2 and UQCRFS1). These results 
represent findings of 3 biological repeats for both patients. 
B. Immunoblotting of OXPHOS complexes in TTC19 patient 7-II (P7-II) and control 
fibroblasts showing no complex III (CORE2) defect in patient. These results represent 






Clinical and genetic findings for Patients 5-I and 5-II are described in Sections 3.4.1.5 
and 4.4.5 respectively. Patients 5-I and 5-II harboured a novel MPC1 missense variant 
(NM_016098; c.109C>T; p.Pro37Ser). Immunoblotting of the MPC1 protein in the 
diagnosed siblings (patients 5-I and 5-II) showed a clear defect in protein expression 
(Figure 5.9). Immunoblotting of OXPHOS subunits does not show any effect on protein 
expression due to MPC1 defect. 
 
 
Figure 5.9 Investigating protein steady-state in Family 5 
Immunoblotting of OXPHOS subunits and MPC1 in MPC1 patients (5-I and 5-II) and 
age-matched control fibroblasts showing an MPC1 defect in patients (red). These results 




Clinical and genetic findings for Patient 12 are described in Sections 3.4.1.12 and 4.4.13 
respectively. Patient 12 harboured compound heterozygous TREX1 mutations. One 
mutation is a pathogenic missense variant that was previously reported in Aicardi-
Goutières syndrome patient (NM_033629; c.341G>A; p.Arg114His) while the other is a 
novel frameshift duplication (c.50dupT; p.Asp18Argfs). Immunoblotting of the TREX1 
protein in Patient 12 showed a clear defect in protein expression (Figure 5.10). 
Immunoblotting of OXPHOS subunits does not show any functional defects. 
 
 
Figure 5.10 Investigating protein steady-state in Patient 12 
Immunoblotting of OXPHOS subunits and TREX1 in Patient 12 (P12) and age-matched 
control fibroblasts showing a TREX1 defect in patient (red). These results represent 




Discovering genetic variants associated with disease is the first step to establishing a 
cause for suspected genetic disease in patients. If the identified variant has been 
previously associated with disease, and a clear phenotype-genotype correlation is 
established and observed, then no validation is required. However, if a novel variant has 
been identified in a gene that is already associated with disease, pathogenicity of the 
variant requires functional validation. To pursue this, patient tissue and cell lines are 
required to assess the functional consequences of the putative pathogenic variant. In cases 
genotyped with possible mitochondrial disease, steady-state protein levels of the affected 
protein and related proteins provide insight into the effect of the identified variant on 
cellular biology and assessment of OXPHOS complex assembly and activity further 
support these findings.  
Clinical and functional phenotypes of patients can be compared to previously reported 
patients and help expand clinical and functional phenotype in the scope of the effected 
gene and protein. Furthermore, functional findings help researchers understand 
mitochondrial biology by providing evidence of mitochondrial dysfunction related to the 
mutated protein.  
5.5.1 NDUFA13 
The identified NDUFA13 variant (NM_015965; c.22C>T; p.Gln8*) in Patient 8 is a novel 
truncating mutation that is associated with a defect in complex I assembly in Patient 8. 
The functional analysis results support a diagnosis of complex I deficiency and assessing 
respiratory chain enzyme activity is not necessary to confirm the findings. A single family 
with and identified NDUFA13 mutation were previously reported where functional 
analysis results revealed decreased expression of NDUFA13 and other complex I subunits 
in addition to showing a defect in complex I assembly in the investigated patients 
(Angebault et al., 2015). The study silenced the NDUFA13 gene expression using siRNA 
in control fibroblasts and functional analysis results showed a similar phenotype to that 
observed in patient fibroblasts. Another study knocked out NDUFA13 expression using 
the TALENs technique in HEK293T cells and analysis of complex I assembly revealed a 
clear absence of assembled complex I (Stroud et al., 2016). These findings support the 
pathogenicity of the truncating NDUFA13 in patient 8. 
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5.5.2 COX15 
The identified COX15 mutation in Patient 23 (NM_078470; c.1019T>C; p.Leu340Pro; 
MAF = 4.0  ´ 10-6) is a rare mutation that has not been previously reported in a 
homozygous state in controls. As a complex IV assembly factor, functional analysis on 
fibroblast cells and muscle biopsies from patients previously reported with bi-allelic 
COX15 mutations showed a deficiency in complex IV activity in addition to decreased 
complex IV assembly (Antonicka et al., 2003; Oquendo et al., 2004; Bugiani et al., 2005; 
Alfadhel et al., 2011). Clinical findings in these studies reported heterogeneous clinical 
presentations and findings that are suggestive of mitochondrial disease involvement 
including developmental delay, failure to thrive, nystagmus, tremor, hypotonia, muscle 
wasting, elevated CSF and serum levels, and lesions in the basal ganglia and cerebral 
white matter. The reported presentation and clinical findings in patient 23 fit with those 
of mitochondrial disease including the presence of seizures, myoclonus, and basal ganglia 
calcification. However, this is an expansion of the spectrum of presentations associated 
with COX15 mutations in mitochondrial disease patients. 
Assessment of steady-state levels of COX15 in some of these patients revealed varying 
effects on protein expression but unfortunately no COX15 antibody presented reliable 
results to assess the levels of COX15 in patient 23 (Swenson et al., 2016). The 
introduction of a proline in a transmembrane domain helix introduces a “kink” into the 
structure which will likely affect the final structure of the inner membrane bound COX15 
protein (Law et al., 2016). This is a possible explanation for the reduced complex IV 
subunits and a reduced complex IV assembly observed in Patient 23 fibroblasts and 
supports a diagnosis of complex IV deficiency. 
5.5.3 NDUFAF3 
The identified NDUFAF3 mutation in Patient 25 (NM_199069.2; c.335T>G; 
p.Ile112Arg; MAF = 4.0  ´ 10-6) is a rare mutation that has not been previously reported 
in a homozygous state in controls. As a complex I assembly factor, functional analysis on 
fibroblast cells and muscle biopsies from patients previously reported with bi-allelic 
NDUFAF3 mutations showed a deficiency in complex I activity in addition to decreased 
complex I assembly and decreased expression of complex I subunits (Saada et al., 2009; 
Baertling et al., 2017b; Ishiyama et al., 2018). Further investigations included the 
silencing of NDUFAF3 in HeLa cells using small interfering RNA (siRNA) which 
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resulted in a functional phenotype similar to that observed in NDUFAF3 patient cell lines 
(Saada et al., 2009), and complementation experiment using lentiviral transduction of 
NDUFAF3 patient cell lines which rescued the observed phenotype in the patient cell 
lines (Baertling et al., 2017b). None of the previously mentioned studies assessed the 
steady-state protein levels of NDUFAF3 in their patients. Patient 25 had a defect in 
steady-state levels of NDUFAF3 and other complex I subunits which support the 
diagnosis of complex I deficiency.  
5.5.4 TTC19 
The TTC19 deletions identified in Family 7 (NM_017775; c.779_780del; p.Tyr260*) and 
Patients 24-I and 24-II (c.680_709del; p.Glu227_Leu236del) are novel and have not been 
previously reported. A total of 19 patients harbouring TTC19 mutations have been 
reported previously (Ghezzi et al., 2011; Nogueira et al., 2013; Melchionda et al., 2014; 
Morino et al., 2014; Ardissone et al., 2015; Koch et al., 2015; Kunii et al., 2015; 
Mordaunt et al., 2015; Conboy et al., 2018; Habibzadeh et al., 2019). As a complex III 
assembly factor, functional analyses were performed on some TTC19 patients which 
revealed varying deficiencies in complex III activity in patients’ muscles (Ardissone et 
al., 2015) and no defect in steady-state levels of complex III subunits in patient fibroblasts 
or muscle samples (Ghezzi et al., 2011; Nogueira et al., 2013; Koch et al., 2015). The 
role of TTC19 is to cleave the N-terminus of UQCRFS1 after the assembly of complex 
III homodimer (Bottani et al., 2017). The defect in TTC19 expression does not necessarily 
result in a defect in complex III assembly (Nogueira et al., 2013; Melchionda et al., 2014; 
Koch et al., 2015). The functional findings in Patient 7-II and Patient 24-I show a defect 
the steady-state of TTC19, while complex III assembly in not affected in Patient 7-II. 
This is similar to functional findings observed in cell lines of previously reported TTC19 
patients. The unaffected complex III activity in fibroblasts of Patients 7-II and 24-I might 
be due to the fact that the defect in complex III assembly was observed in patient muscle 
samples. The functional analyses provide evidence that support a diagnosis of 
mitochondrial disease due to complex III deficiency.  
5.5.5 MPC1 
The identified MPC1 variant in Family 5 (NM_016098; c.109C>T; p.Pro37Ser) is novel 
and has not been previously reported. Patients with MPC1 mutations have been reported 
and their mutations were investigated using a yeast model to assess the effect of the 
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mutations on protein expression (Bricker et al., 2012). Further investigations into the 
expression of MPC1 steady-state levels showed a decrease in MPC1 expression in 
addition to a decrease in MPC2 (Oonthonpan et al., 2019). Patient phenotypes of reported 
MPC1 patients included facial dysmorphism, developmental delay, hypotonia and lactic 
acidosis all of which were observed in patients from Family 5. The defect in steady-state 
MPC1 levels in Patients 5-I and 5-II in addition to their observed clinical phenotypes fit 
with a diagnosis of MPC1 deficiency as reported previously in patients.  
5.5.6 TREX1 
One of the TREX1 variants identified in Patient 12 was previously reported in patients 
with AGS (NM_033629; c.341G>A; p.Arg114His) (Crow et al., 2006a), while the other 
variant was a novel frameshift duplication (c.50dupT; p.Asp18Argfs). Patient 12 
presented at the age of 1 month with progressive stiffness of neck, limb and trunk muscles 
and by 3 months he was noted to be irritable with excessive crying. By the age of 5 months 
4 limb dystonia was evident. CSF and serum lactate levels were elevated. Similar clinical 
presentations were observed in a cohort of genetically diagnosed AGS patients including 
patients with TREX1 mutations (Rice et al., 2007a; Crow et al., 2015; Livingston and 
Crow, 2016). Brain MRI scans of patient 12 at 3 years of age revealed high intensity T2 
signals in white matter regions near the ventricle horns and a thin corpus callosum which 
also fits with the spectrum radiological findings in AGS patients. Furthermore, patient 12 
had a febrile seizure at the age of 3 years and 5 months due to a respiratory infection and 
6 months later he had recurring general tonic-clonic seizures which is also reported in 
AGS patients. The elevated CSF and serum lactate levels in addition to other observed 
clinical presentations in patient 12 greatly overlap with presentations of mitochondrial 
disease patients which led to an MDC score of 7 suggesting mitochondrial disease 
involvement.  
Crow et al. (2006a) functionally investigated the effect of the identified TREX1 variant 
(p.Arg114His) in a number of AGS patients by assessing the activity of the 3’-5’ 
endonuclease which TREX1 encodes 
Rice et al. (2007a) suggest that the identified variant (p.Arg114His) is an ancient founder 
mutation and have investigated the variant functionally by assessing the activity of the 
3’-5’ endonuclease which TREX1 encodes and by assessing the expression of interferon 
genes due to the reported elevation of interferon alpha levels in AGS patients (Crow et 
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al., 2006a; Rice et al., 2007a; Silva et al., 2007; Ellyard et al., 2014). Steady-state levels 
were never assessed or reported in these patients. The steady-state level of TREX1 protein 
in Patient 12 was severely decreased. Since this diagnosis was not of a mitochondrial 
disorder, the finding of TREX1 deficiency in Patient 12’s fibroblast cell line due a known 
reported TREX1 variant and a loss-of-function frameshift duplication variant, it is 
indicative of an Aicardi-Goutières syndrome diagnosis which is a phenocopy disorder of 
mitochondrial disease.  
 Summary 
A summary of the functional findings described in the aforementioned Results section is 
tabulated in Table 5.1. 
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Table 5.1 Summary of functional results in patient fibroblasts  





5-II Kuwait MPC1 NM_016098 c.109C>T p.Pro37Ser Novel variant MPC1 deficiency N/A N/A 
7-II Kuwait TTC19 NM_017775 c.779_780del p.Tyr260* Novel frameshift deletion TTC19 deficiency Normal Normal 
8 Kuwait NDUFA13 NM_015965 c.22C>T p.Gln8* Novel truncating variant 
NDUFA13 and 












TREX1 deficiency N/A N/A 
23 Newcastle COX15 NM_078470 c.1019T>C p.Leu340Pro Rare missense variant COX-1 and COX-2 deficiency 
Complex IV 
deficiency N/A 
24-I Saudi Arabia TTC19 NM_017775 c.680_709del p.Glu227_Leu236del 
Novel non-frameshift 
deletion TTC19 deficiency N/A Normal 
25 Newcastle NDUFAF3 NM_199069 c.335T>G p.Ile112Arg Rare missense variant NDUFAF3 and complex I deficiency N/A N/A 
BN-PAGE: Blue native polyacrylamide gel electrophoresis; N/A: Not available; OXPHOS; oxidative phosphorylation; WB: Western blot. 
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 Final discussion 
My research cohort is comprised of 22 patients living in Kuwait who were recruited based 
upon clinical suspicion of a diagnosis of mitochondrial disease. Of the 22 recruited 
patients, 10 harboured bi-homozygous variants in genes associated with mitochondrial 
disease or function, and 4 harboured bi-allelic variants in genes associated with diseases 
that are phenocopies of mitochondrial disease. Skin biopsies were acquired from patients 
from 4 of the Kuwait cohort families with segregated novel variants, 3 were associated 
with mitochondrial disease and 1 was associated with a phenocopy of mitochondrial 
disease. The acquisition of skin biopsies depended on a number of factors including the 
exclusion of patients with previously reported variants (PDHX and NDUFB9 variants in 
families 3 and 9 respectively), the lack of samples from patients who were deceased (such 
as patients from families 1, 4, 6 and 7), and the absence of consent from patients or their 
guardians (families 2 and 10). In cases where variants segregated in the families, 
phenotype-genotype correlations in patients between mutations in the affected gene and 
previously reported cases supported the genetic diagnoses reached. This includes cases 
with phenocopies of mitochondrial disease that were diagnosed using WES (families 11, 
12, 13 and 14). In addition to the Kuwait cohort, patients from 3 families who harboured 
homozygous novel variants in mitochondrial disease genes were referred to our research 
project for functional validation of pathogenicity from King Saud University, Riyadh, 
Kingdom of Saudi Arabia, and the NHS Highly Specialised Service for Rare 
Mitochondrial Disorders in Newcastle upon Tyne, UK.  
As demonstrated in the study’s cohort, many patients in Kuwait harbour novel variants 
or variants in novel candidate genes with associated cellular functions. Reporting of these 
variants as possibly pathogenic, or variants of unknown significance, is practiced at 
KMGC without functional evidence supporting variant pathogenicity which should be 
accessible within the centre. Expanding the laboratories at KMGC would provide 
functional support of genetic diagnoses and this requires setting up a functional laboratory 
that follows up patients with identified novel mitochondrial disease variants and novel 
candidate genes associated with mitochondrial function. This would require an 
independent tissue culture laboratory and a functional laboratory to perform functional 
studies including western blotting and BN-PAGE. Where consent is available, skin 
biopsies would be obtained to establish and expand fibroblast cell lines from patients. 
These fibroblasts would be primarily analysed using western blotting and BN-PAGE to 
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investigate steady-state protein levels and OXPHOS complex assembly where required 
to provide functional evidence for the effects of the identified variants affecting 
mitochondrial function and other cellular functions. Furthermore, fibroblasts can be used 
to assess gene expression by measuring mRNA transcript levels using quantitative PCR 
techniques, while mRNA analysis can also identify alternative splicing transcripts due to 
splice-site variants using PCR amplification, agarose gel electrophoresis and Sanger 
sequencing. To further validate pathogenicity of the identified variants, the availability 
of fibroblast cell lines would also provide material for biochemical assessment of 
OXPHOS complex activities in patients. These would be the first steps towards 
functionally validating novel mitochondrial disease variants and novel candidate gene 
variants at associated with mitochondrial function at KMGC. These functional analyses 
can be expanded to include the validation of many other genetic disorders when 
functional validation of variants is required. 
Functional investigations provide support for pathogenicity of a certain variant. But the 
effect of the variant is only limitedly assessing to the expression of the effected protein 
and any associated proteins such as the OXPHOS subunits. The tissue source (skin or 
muscle) can also affect the observed phenotype since some proteins are expressed at 
varying levels depending on the tissue. For example, the MPC1 variant identified in 
family 5 is associated a reduction in MPC1 expression, but no other functional or 
biochemical assessments of pyruvate import were performed that might have provided 
further support to pathogenicity. Another example is the extremely modifying TTC19 
variants identified in a family from Kuwait and a family from Saudi Arabia. Since the 
function of the complex III assembly factor is the cleaving of UQCRFS1 at the end of 
complex assembly, no clear changes were observed in the levels of assembled complex 
III or complex III subunits. The availability of muscle biopsies might’ve provided more 
accurate evidence of pathogenicity since muscle is more energy dependant than skin and 
could show deficiencies in the biochemical enzyme activity of complex III and provide 
better evidence of functional pathogenicity. Although clear deficiencies are observed 
using the available tools, further assessment of pathogenicity is sometimes required to 
solidify findings. Due to the heterogeneity of clinical phenotypes in mitochondrial disease 
patients, causative association of variants, functional findings, and observed phenotypes 
are important to establish and are strongly supported with a larger number of cases 
reported.  
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Limitations to this study include the difficulty in accessing patient tissue samples (skin 
biopsies) until late in the study. This limited the time available to establish the fibroblast 
cell line and later functionally analyse the cell lines using the available functional analysis 
methods. Other analysis methods such as oxygen consumption rate and cell growth rate 
could have been performed to further support pathogenicity of the identified variants, but 
time was limited and thus these analyses were not carried out. Furthermore, maintaining 
cell line growth was a challenge that limited the ability to run OXPHOS complex 
assembly analysis using BN-PAGE on cell lines from the NDUFAF3 patient (Patient 25) 
and one of the TTC19 patients (Patient 24-I). Nonetheless, western blotting and BN-
PAGE results provided evidence supporting the pathogenicity of the identified variants. 
In light of these challenges, a “genetics-first” approach has resulted in rapid identification 
of novel candidate variants that were validated using functional analysis methods. 
Chapter 6 outlines a thorough investigation of a novel mitochondrial disease in patients 
from 2 unrelated families and how patient cell lines were assessed and investigated to 
determine aetiology of disease and to expand our understanding of mitochondrial biology. 
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Chapter 6. NDUFC2 mutations are a novel cause of 
Complex I deficiency in Leigh syndrome patients. 
 
 Introduction 
Leigh syndrome is the most common neurodegenerative disorder reported in paediatric 
mitochondrial disease patients (Rahman et al., 2017). Mutations in more than 90 genes 
including examples from both the nuclear and mitochondrial genomes have been 
associated with Leigh syndrome so far (Lake et al., 2019). Clinical heterogeneity in Leigh 
syndrome patients is observed with commonly reported presentations including 
developmental delay, loss of acquired skills, hypotonia, elevated CSF lactate levels, and 
multisystem involvement. Typical radiological findings in patients reveal bilateral and 
symmetric involvement of the basal ganglia and/or brainstem (Rahman et al., 1996).  
Complex I deficiency is a common biochemical phenotype affecting paediatric 
mitochondrial disease patients; more than a third of reported Leigh syndrome patients 
have complex I deficiency (Lake et al., 2016; Lake et al., 2017; Rahman et al., 2017). 
Complex I is the largest of the mitochondrial respiratory chain enzymes, is comprised of 
44 different subunits and requires at least 14 assembly factors for its biosynthesis (Stroud 
et al., 2016; Zhu et al., 2016; Guerrero-Castillo et al., 2017; Formosa et al., 2020). 
Knocking out complex I subunits resulted in defective or stalled complex I assembly and 
supported the modular assembly of complex I previously established (Stroud et al., 2016).  
Complexome profiling is a method that helps elucidate the pattern of assembly in protein 
complexes by combining BN-PAGE and mass spectrometry to analyse proteins present 
in intermediate subassemblies of complex assembly. This method has been used in cell 
lines from several mitochondrial disease patients with pathogenic variants in complex I 
subunits and has furthered our understanding of the assembly and stability of complex I 
(Alston et al., 2016a; Alston et al., 2018; Alston et al., 2020).  
There have so far been 42 different genes encoding either subunits or assembly factors of 
complex I associated with mitochondrial disorders; 29 of these genes are associated with 
Leigh syndrome patients (Figure 6.1) (Rahman et al., 2017; Rouzier et al., 2019; Alston 
et al., 2020; Thompson et al., 2020a). Genetic diagnoses of mitochondrial disease are 
challenging due to the genetic heterogeneity, with more than 330 genes already associated 
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with disease, including those associated with Leigh syndrome (Lake et al., 2019; Stenton 
and Prokisch, 2020; Thompson et al., 2020a). NGS in the form of targeted gene panels 
(Legati et al., 2016; Plutino et al., 2018) and unbiased WES (Taylor et al., 2014; 
Wortmann et al., 2015; Pronicka et al., 2016; Theunissen et al., 2018) has resulted in 
diagnostic rates of cohorts mitochondrial disease patients exceeding 60% (notably when 
using WES) and identified novel candidate genes associated with mitochondrial disease 
in patients.  
 Aims 
The aim of this chapter is to describe the clinical, biochemical and molecular findings of 
patients from two unrelated consanguineous families who presented with Leigh syndrome 
due to variants in NDUFC2, which encodes a complex I structural subunit. These 
unrelated patients were identified independently in Saudi Arabia and Italy and were 
referred as part of a collaboration. I will discuss investigations carried out to assess the 
effect of the NDUFC2 variants on gene expression, protein expression, complex I 
assembly and respiratory enzyme activity. Furthermore, complexome profiling was 
utilised to characterise the effect of the variants on complex I assembly and variant 
pathogenicity was validated further by expressing wild-type NDUFC2 in patient cell lines 




Figure 6.1 Complex I subunits and factors categorised based on association with disease. 
Venn diagram of all currently known complex I subunits and assembly factors grouped into 3 categories: green: not currently associated with 
disease; yellow: associated with mitochondrial disease; orange: associated with Leigh syndrome. Proteins in bold are assembly factors.  
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 Methods 
6.3.1 Patient consent 
Informed consent for diagnostic and research studies was obtained for all subjects in 
accordance with the Declaration of Helsinki protocols and approved by local institutional 
review boards at King Saud bin Abdulaziz University for Health Sciences in Jeddah, 
Kingdom of Saudi Arabia, and at the Fondazione IRCCS Istituto Neurologico Carlo Besta 
Milan, Italy. 
6.3.2 Next-generation sequencing 
6.3.2.1 Patient A-1 
Commercial NGS services provided by CentoGene (Germany) were used to perform 
WES analysis on DNA from Patient A-1.  
6.3.2.2 Patient B 
Genetic studies were performed on Patient B using a custom 300 gene targeted gene-
panel of nuclear genes previously associated with mitochondrial disease, candidate genes 
that take part in the same molecular pathway, and included all genes encoding complex I 
subunits. Library capture and enrichment were performed using a custom panel 
(SureSelectXT Custom library, Agilent, US) and sequencing was performed on an 
Illumina MiSeq platform according to the manufacturer’s protocol. Bioinformatic 
analysis was performed as previously described (Legati et al., 2016). 
6.3.3 Sanger Sequencing 
DNA for Sanger sequencing was extracted from peripheral blood of patients and their 
family members. The used primers targeting the identified NDUFC2 (NM_004549.6) 
deletion in Patient A-1 were as follows: 
Forward: 5’-ACATGAACATTCAGACCACAGC-3’ 
Reverse: 5’-CAAGGTGTCAACATACAGATTAGCA-3’ 
Sanger sequencing of the identified variants was performed on Family A as follows: 
A 25μl PCR reaction mixture consisted of 13.3μl nuclease free water, 5.0μl GoTaq X5 
reaction buffer (Promega), 2.5μl 2mM dNTPs (Promega), 3.0μl 10μM mixture of forward 
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and reverse primers (IDT), 0.2μl GoTaq polymerase (Promega) and 1.0 μl of the patient’s 
DNA.  
The PCR reaction heating steps were as follows: an initiation step at 94°C for 4 minutes, 
then 30 cycles of denaturation step at 94°C for 45 seconds, and annealing step at 62°C 
for 45 seconds and an extension step at 72°C for 45 seconds, and a final extension step at 
72°C for 5 minutes concluding with a hold step at 4°C.  
Sanger sequencing of Family B was performed by collaborators at the Fondazione IRCCS 
Istituto Neurologico Carlo Besta in Milan, Italy.  
6.3.4 RNA transcript levels 
This method was performed by collaborators at the Fondazione IRCCS Istituto 
Neurologico Carlo Besta in Milan, Italy.  
RNA purification and cDNA retrotranscription were performed using RNeasy mini kit 
(QIAGEN) and GoTaq 2-Step RT-qPCR System (Promega), respectively, according to 
the manufacturers’ protocols. RNA was extracted from skin fibroblasts, and 1 µg was 
used as template for RT-PCR, with the following oligonucleotides sequences: q-
NDUFC2-F 232_251 and q-NDUFC2-R 358_377 for NDUFC2 (NM_004549.6); q-
ACTB-F 425_442 and q-ACTB-R 502_521 for ACTB (NM_001101.5), used for 
normalisation. 
6.3.5 Cell culture 
Fibroblast cell lines of patients were cultured as outlined in Sections 2.2.17, 2.2.18, 2.2.19 
and 2.2.20. During the lentiviral rescue experiment, HEK293T cells and skin fibroblasts 
were initially cultured in Growth Media substituting FBS with dialysed FBS (Gibco, 
26400044) for 3 to 4 weeks.  
6.3.6 Oxygen consumption 
This method was performed by collaborators at the Fondazione IRCCS Istituto 
Neurologico Carlo Besta in Milan, Italy. Alessia Nasca, Andrea Legati, Eleonora 
Lamantea, Menuela Spagnolo, Danielle Ghezzi). 
Mitochondrial respiration of intact cells was measured using high-resolution respirometry 
(Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria) with DatLab software 7.1.0.21 
(Oroboros Instruments, Innsbruck, Austria) (Pesta and Gnaiger, 2011). Measurements 
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were performed at 37°C in Growth Media (Section 2.1.4.3). Basal respiration was 
measured for 20 minutes followed by titration of Oligomycin (2.5 µM final concentration; 
f.c.) to measure oligomycin-inhibited LEAK respiration. Subsequently, the respiratory 
uncoupler carbonyl cyanide-4-phenylhydrazone (FCCP) (Sigma Aldrich, Munich, 
Germany) was titrated stepwise until maximal uncoupled respiration (ETS) was reached. 
Residual oxygen consumption (ROX) was determined after sequential inhibition of 
complex I with Rotenone and complex III with Antimycin A. Absolute respiration rates 
were corrected for ROX and normalised for cell number.  
6.3.7 Respiratory chain enzyme activities 
These studies were performed by Langping He at the NHS Highly Specialised Service 
for Rare Mitochondrial Disorders in Newcastle upon Tyne, UK. A description of the 
methods is outlined in Section 2.2.24. 
6.3.8 Blue native PAGE and in gel activity stains 
These experiments were performed by collaborators at Goethe-Universität in Frankfurt, 
Germany (Juliana Heidler, Jana Meisterknecht and Ilka Wittig). 
Sample preparation and BN-PAGE of cultured cell pellets were essentially performed as 
previously described (Wittig et al., 2006). Equal protein amounts of samples were loaded 
on top of a 3 to 18% acrylamide gradient gel (dimension 14x14 cm). After native 
electrophoresis in a cold chamber, blue-native gels were fixed in 50% (v/v) methanol, 
10% (v/v) acetic acid, 10 mM ammonium acetate for 30 min and stained with Coomassie 
(0.025% Serva Blue G, 10% (v/v) acetic acid). In gel activity stains were performed as 
described in (Wittig et al. 2007). 
6.3.9 Western blotting & blue native-PAGE 
An outline of the western blotting method is provided in Section 2.2.21 and an outline of 
the BN-PAGE method is provided in Section 2.2.22. A description of the immunoblotting 
technique is outlined in Section 2.2.23. 
6.3.10 Complexome profiling 
These analyses were undertaken by collaborators at Goethe-Universität in Frankfurt, 
Germany. 
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Complexome profiling was performed on fibroblasts from Patient A-1 and Patient B and 
an age-matched control cell line as previously described (Heide et al., 2012; Fuhrmann 
et al., 2018).Sample preparation, mass spectrometry, data processing and raw data have 
been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 
(https://www.ebi.ac.uk/pride/archive/) (Vizcaíno et al., 2013) with the dataset identifier 
<PXD014936>." Complexome data were further analysed using NOVA (Giese et al., 
2015). Complex I and identified assembly intermediates were visualised using the Cryo-
EM structure of murine complex I (PDB: 6g2j) (Agip et al., 2018) and PyMOL (The 
PyMOL Molecular Graphics System, Version 2.3.3. Schrödinger, LLC.). 
6.3.11 Lentiviral rescue  
Wild-type NDUFC2 was expressed in patient fibroblasts using the Lenti-X TetOne 
Inducible Expression System with the pLVX-TetOne-Puro vector. Wild-type NDUFC2 
insert was generated by PCR using cDNA from control fibroblasts and the following 
primers containing EcoRI and BamHI restriction sites respectively (underlined sections 
are part of the pLVX-TetOne-Puro vector, bold nucleotides are restriction enzyme sites 
followed by nucleotides from the wild-type NDUFC2):  
Forward: pLVX-TetOne-Puro-2537_2522-NDUFC2-1_21: 
5'-CCCTCGTAAAGAATTCATGATCGCACGGCGGAACCCA-3' 
Reverse: pLVX-TetOne-Puro-2486_2501-NDUFC2-360_327:  
5'-GAGGTGGTCTGGATCCTCAACGTATTGGATGGAATTTTTCAAAAATTTCA-3' 
The insert was cloned into the linearised pLVX-TetOne-Puro plasmid vector (Takara Bio 
/ Clonetech) using the In-Fusion HD Cloning Kit (Takara Bio / Clonetech). The NDUFC2 
containing vector was packaged into infectious lentiviral particles using Lenti-X 
Packaging Single Shots (Takara Bio / Clonetech) to transfect HEK293T cultured in 
Growth Media containing dialysed FBS according to manufacturer’s guidelines. The 
presence of doxycycline/tetracycline in FBS could induce gene expression of the 
doxycycline induced vector, therefore Growth Media containing dialysed FBS (dialysed 
Growth Media) was used according to manufacturer’s guidelines. Dialysed Growth 
Media containing infectious lentivirus was harvested after 48 hours, centrifuged at 500 g 
for 10 minutes to remove cellular debris and the supernatant was retained. This virus 
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containing supernatant was used to transduce patient fibroblast cell lines at a ratio of 1:2 
with fresh dialysed Growth Media and 4  µg/ml polybrene overnight. The dialysed 
Growth Media was replaced and puromycin (2 µg/ml) added to select for successfully 
transduced cells. Transduced cells were cultured in puromycin for at least 7 days by which 
time all patient fibroblasts used as non-transduced controls had died. Expression of wild-
type NDUFC2 was induced by adding doxycycline (Takara Bio / Clonetech; 100 - 200 
µg/ml) to the media and incubating for 48 - 96 hours. The cultured cells were then 
harvested and analysed using the SDS-PAGE and western blotting (Section 2.2.21) or 
subjected to mitochondrial enrichment and subsequent BN-PAGE analysis (Section 
2.2.22). Fibroblast cell lines were later maintained in regular Growth Media after 




6.4.1 Clinical presentations of patients 
6.4.1.1 Family A 
Patient A-1, a female infant, is the second child born to healthy consanguineous first 
cousin Saudi parents (Family 1). She was born by normal vaginal delivery at 37 weeks 
gestation (birth weight 2.0 kg, 2nd – 9th centile) with no antenatal issues. Developmental 
delay was noted at 2 years when she was unable to walk. At 6 years, her height and weight 
remained below the 5th centile and clinical examination revealed facial dysmorphic 
features, spasticity and brisk deep tendon reflexes. She was unable to stand without 
support and unable to speak. A hearing assessment was unremarkable, but an 
ophthalmological examination revealed bilateral optic disc pallor. She did not develop 
seizures and had no cardiac, renal, or hepatic abnormalities. Serum lactate ranged from 
3.6 to 7.6 mmol/L (normal range 0.7–2.2 mmol/L), while ammonia, blood glucose and 
thyroid function were unremarkable. Plasma amino acid analysis detected elevated 
alanine (724 μmol/L, normal range 143–439 μmol/L) and elevated proline (366 μmol/L, 
normal range 52–298 μmol/L). Urine organic acid analysis showed increased fumaric 
acid excretion (151 mM/M creatinine, normal range < 20 mM/M). Leukocyte enzyme 
assay for arylsulfatase A, arylsulfatase B and galactocerebrosidase was unremarkable, as 
was abdominal ultrasound and array comparative genomic hybridisation (aCGH) testing. 
Brain MRI at 21 months showed bilateral areas of abnormal high signal intensity at the 
corticospinal tract level of the corona radiata with loss of white matter volume at these 
areas. This was associated with irregularity in the outline of the lateral ventricles 
suggestive of periventricular leukomalacia. Bilateral symmetrical abnormal T2 high 
signals of the medial aspect of the thalami, substantia nigra and posterior tract of the 




Figure 6.2 Neuroimaging of Patient A-1 
(Left) Axial T2-weighted imaging of Patient A-1 at 21 months showed bilateral 
hyperintense signals in the pons (arrows). 
(Right) Coronal T2-weighted imaging of Patient A-1 at 21 months showed bilateral 




Patient A-2 was the younger brother of Patient A-1; foetal echocardiogram showed mild 
cardiomegaly, dilated superior vena cava and a small ventricular septal defect (VSD). 
Antenatal ultrasound showed dilated cisterna magna and ventriculomegaly. He was born 
by normal vaginal delivery at 36 weeks gestation (birth weight 2.020 kg, 2nd centile). 
Postnatal echocardiography revealed a perimembranous VSD with left pulmonary artery 
stenosis. Following birth, he was noted to have persistently elevated serum lactate (4.0–
10.0 mmol/L; normal range 0.7–2.2 mmol/L). He exhibited global developmental delay 
and poor growth with his weight and length remaining below the 3rd centile. Brain MRI 
at the age of 10 days demonstrated bilateral abnormal high T2 signal intensity of the 
frontal periventricular area within the regions of caudo-thalamic grooves and associated 
irregularity of the outline of the lateral ventricles. Also noted were the foci of abnormal 
T2 signal in the lentiform nuclei with paucity of periventricular white matter and oedema. 
The MRI also revealed a Dandy-Walker malformation with partial agenesis of the corpus 
callosum (Figure 6.3). At 5 months of age, there was a rapid increase in head size. Brain 
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CT scan detected acute hydrocephalus with significant dilatation of the third and lateral 
ventricles. He underwent urgent ventriculoperitoneal shunt insertion. At the age of 19 
months, he developed a severe respiratory infection requiring paediatric intensive care 
unit support and lactate levels were elevated in excess of 20.0 mmol/L (normal range 0.7–
2.2 mmol/L). With this intercurrent illness, he developed seizures, regressed and lost all 
of his previously acquired developmental skills. Recurrent chest infections and 
pulmonary aspirations suggested an unsafe swallow and he was placed on nasogastric 
tube feeding. His clinical course was dominated by progressive spasticity, muscle atrophy 
development of a left hydronephrosis and a persistent lactic acidosis. Serum ammonia, 
creatine kinase, liver function, thyroid function, plasma amino acids, urinary organic 
acids, and newborn screening results were all unremarkable. He passed away at the age 




Figure 6.3 Neuroimaging of Patient A-2 
(Left) Axial T2-weighted imaging of Patient A-2 at 10 days of age showed bilateral 
hyperintense signals in the basal ganglia (yellow arrows). 
(Right) Sagittal T2 imaging of Patient A-2 at 10 days of age showed Dandy-Walker 
malformation (white arrow) and thinning of the corpus callosum (red arrow). 
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6.4.1.2 Family B 
Patient B, a male infant, was the third child from healthy consanguineous (first cousin) 
parents of Moroccan origin with an unremarkable family history. He was born at term 
after an uneventful pregnancy. Vomiting, failure to thrive, psychomotor delay and poor 
eye contact were reported from the first months of life. Clinical evaluation performed at 
5 months showed impaired growth (weight and length < 3rd centile), microcephaly (< 3rd 
centile), poor eye contact, non-paralytic strabismus, truncal hypotonia with limb 
hypertonia, paucity of spontaneous movements and lack of postural control. Brain MRI 
revealed bilateral abnormal high T2 signal intensity within the thalami (Figure 6.4), the 
basal ganglia and brainstem, though spinal cord MRI was normal. EEG and peripheral 
nerve conduction studies were unremarkable, but brainstem auditory and visual evoked 
potentials showed severe central conduction abnormalities. Epilepsy was not reported, 
however when under anaesthesia to perform MRI, he developed intermittent clonic 
seizures of both upper limbs which were successfully treated with midazolam. Routine 
blood investigations including plasma amino acid levels were reported normal, but serum 
lactate and pyruvate levels were elevated (3.2 mmol/L, normal range 0.8–2.1 mmol/L, 
and 194 µmol/L, normal range 55–145 µmol/L, respectively). Following severe 
respiratory deterioration, the patient died at 8 months of age.  
 
 
Figure 6.4 Neuroimaging of Patient B 
Axial (left) and coronal (right) T2-weighted imaging of Patient B at 5 months of age 
showed bilateral hyperintense signals in the thalami (arrows).  
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6.4.2 Genetic investigations 
6.4.2.1 Family A 
Patient A-1 was initially investigated using commercially available WES that prioritised 
identification of variants in known disease genes in their analysis. No candidate variants 
were identified using this NGS method. Subsequent unbiased WGS identified a 
homozygous 22-nucleotide deletion within the last exon of NDUFC2 predicting a stop 
loss mutation in the NDUFC2 protein (GenBank: NM_004549.6; c.346_*7del; 
p.His116_Arg119delins21). Segregation analysis using Sanger sequencing found both 
parents and a healthy brother were heterozygous for the c.346_*7del variant; DNA was 
not available from Patient A-2 (affected sibling) to confirm his genotype (Figure 6.5). 
The identified c.346_*7del variant is absent in variant databases and no healthy controls 
were homozygous for any loss-of-function NDUFC2 variants within the gnomAD 
database (Lek et al., 2016) 
6.4.2.2 Family B 
Biochemical investigation in Patient B’s muscle biopsy revealed an isolated complex I 
deficiency. This prompted genetic studies in the form of targeted gene-panel analysis 
which targeted 299 genes associated with mitochondrial function and disease including 
54 genes related to complex I assembly and previously associated with complex I 
deficiency (Appendix C). which identified a homozygous c.173A>T p.(His58Leu) 
NDUFC2 variant affecting a highly conserved histidine residue (Figure 6.6A). Three 
healthy controls in gnomAD were heterozygous for a rare variant affecting the same 
residue (c.172C>T, p.(His58Tyr), MAF = 1.21×10-5) (Lek et al., 2016). The residue 
change was assessed using numerous in silico prediction tools and all tools predict it to 
be pathogenic (PolyPhen2: 1.000 [probably damaging]; SIFT: 0.000 [deleterious]; 
PROVEAN: -6.733 [deleterious]; raw CADD: 3.99; scaled CADD: 27.9) (Ng and 
Henikoff, 2001; Kumar et al., 2009; Adzhubei et al., 2010; Choi et al., 2012; Choi and 
Chan, 2015; Rentzsch et al., 2018). Sanger sequencing confirmed that both parents were 
heterozygous carriers for the c.173A>T variant; the healthy siblings of Patient B were not 
















Figure 6.5 Identification and segregation of NDUFC2 deletion in Family A 
A Sequencing chromatograms depicting the identified 22 nucleotide deletion 
(c.346_*7del) identified in Patient A-1 (A-1), the heterozygous state of the deletion in the 
father, and the wild-type NDUFC2 sequence in Control DNA. 
B Pedigree showing segregation of variant in Family A. Patient A-2 was not genotyped 
























Figure 6.6 Identification and segregation of NDUFC2 missense variant in Family B 
A Clustal Omega sequence alignment shows evolutionary conservation of the p.His58 
residue (highlighted) along with its neighbouring residues (human NDUFC2: 
NP_004540.1). 
B Sequencing chromatograms depicting the identified missense variant (c.173A>T; 
p.(His58Leu)) in Patient B and the wild-type NDUFC2 sequence in Control DNA. 
C Pedigree of Family confirming carrier status of both parent for the identified missense 





6.4.3 Assessment of NDUFC2 mRNA gene expression in patients’ fibroblasts 
Quantitative real-time PCR (qRT-PCR) analysis of mRNA transcript levels derived from 
patient fibroblasts revealed a decrease in NDUFC2 mRNA expression in Patient A-1 
fibroblasts (43% of controls), while mRNA levels in Patient B were similar to controls 
(Figure 6.7). 
6.4.4 Assessment of respiratory chain enzyme activity in patients’ tissue and cell 
lines 
Mitochondrial respiratory chain enzyme analysis revealed isolated complex I deficiency 
in Patient A-1’s fibroblasts (16% residual activity compared to controls) and Patient B’s 
fibroblasts and muscle (19% and 48% residual activity compared to controls, 
respectively) (Error! Reference source not found.A and B). High-resolution respirometry a
nalysis on both patients’ fibroblast cell lines revealed a severe decrease in oxygen 
consumption rates (Error! Reference source not found.C). 
 
 
Figure 6.7 NDUFC2 mRNA transcript levels in NDUFC2 patients’ fibroblasts 
NDUFC2 mRNA transcript levels in fibroblast cell lines of controls (white), Patient A-1 
(grey) and Patient B (black). Quantification of NDUFC2 mRNA transcript levels 
(normalised to ACTB) showed diminished transcript levels in Patient A-1 while transcript 
levels were unaffected in Patient B. Bars correspond to standard deviations of two 










Figure 6.8 Analysis of respiratory chain complex activities in NDUFC2 patients’ fibroblasts 
A Assessment of respiratory chain enzyme activities, normalised to citrate synthase (CS), in fibroblast cell lines from controls (white), Patient A-
1 (grey) and Patient B (black). Mean residual enzyme activities of control fibroblasts (n = 8) are set at 100% and error bars represent 1 standard 
deviation of control activities. Asterisks (*) denote enzyme activity below control range.  
B Assessment of respiratory chain enzyme activities, normalised to citrate synthase (CS), in skeletal muscle from controls (white) and Patient B 
(black). Mean residual enzyme activities of control skeletal muscle (n>100 samples) are set at 100% and bars are 1 standard deviation of control 
activities. Asterisks (*) denote enzyme activity below control range. 
C Respiration of Patient B and Patient A-1 derived fibroblasts (black and grey, respectively) compared to control fibroblasts (white) using high-
resolution respirometry. ROX-corrected analysis of basal respiration, Oligomycin inhibited LEAK respiration and maximum uncoupled respiration 
(ETS). Both patient fibroblasts exhibited a severe mitochondrial respiration defect as measured by oxygen consumption. Data are mean ± SD from 
at least 3 experiments. **p<0.01, ***p<0.001. 
A B C 
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6.4.5 Steady-state protein levels of complex I subunits in patient cell lines 
SDS-PAGE was utilised to assess steady-state protein levels of complex I subunits in 
fibroblast lysates from patients and controls. Immunoblotting using antibodies against 
various complex I structural subunits (NDUFC2, NDUFB8, NDUFA9) revealed an 
overall decrease in steady-state levels of complex I subunits in both patients compared to 
controls (Error! Reference source not found.) 
6.4.6 Complex I assembly in patient cell lines 
BN-PAGE was utilised to assess the assembly of respiratory chain complexes in enriched 
mitochondria from patient and control fibroblast cell lines that were solubilised using 
DDM. Immunoblotting using antibodies against a subunit from each of the five 
respiratory chain enzymes (Complex I: NDUFB8; Complex II: SDHA; Complex III: 
UQCRC2; Complex IV: MT-CO1; Complex V: ATP5A) showed an absence of fully 
assembled complex I in Patient A-1 and a severe decrease in assembled complex I in 
Patient B compared to controls (Figure 6.10). Assessment of supercomplex formation in 
enriched mitochondria from patient and control fibroblast cell lines that were solubilised 
using digitonin showed a severe decrease in complex I-containing supercomplexes 





Figure 6.9 Western blot analysis of complex I subunits in NDUFC2 patient 
fibroblasts. 
Western blot analysis of various structural subunits of complex I in fibroblasts from 
Patient A-1 and Patient B (A-1 and B respectively) with three age-matched controls 




Figure 6.10 Assessment of OXPHOS complex assembly in NDUFC2 patients’ 
fibroblasts using BN-PAGE. 
BN-PAGE analysis of OXPHOS complex assembly in enriched mitochondria from 
patients and control fibroblasts solubilised using DDM. Immunoblotting was performed 
using antibodies to structural subunits from each OXPHOS complex (CI [NDUFB8], CII 
[SDHA], CIII [UQCRC2], CIV [MT-CO1], and CV [ATP5A]) (results are representative 





Figure 6.11 Assessment of assembly of complex I containing supercomplexes in 
Patient B 
Coomassie stain (left panel) and an in-gel complex I assay (right panel) in BN-PAGE 
showed decreased complex I-containing supercomplexes in subject mitochondria. 
Analysis of complex assembly and stability detected a drastic deficiency of complex I-
containing supercomplexes. 
S1, supercomplex containing complex I, dimer of complex III and 1 copy of complex 
IV; V, ATP synthase; I-III-IV, complexes I-III-IV. BHM, Bovine heart mitochondria 
solubilised with digitonin as native mass ladder. 
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6.4.7 Doxycycline inducible lentiviral rescue experiment 
To support the pathogenicity of the identified variants and assess the effect of expressing 
wild-type NDUFC2 in the patients’ fibroblast cell lines, a lentiviral rescue experiment 
was carried out. This involved lentiviral transduction of each patient fibroblast cell line 
with a doxycycline-inducible pLVX-TetOne-Puro vector containing wild-type NDUFC2.  
6.4.7.1 Optimisation of doxycycline dosage by assessing steady-state protein levels of 
NDUFC2 and other complex I subunits in transduced patient cell lines 
To optimise doxycycline induction, various doxycycline concentrations and periods of 
incubation were used to determine the optimal conditions for the rescue experiment by 
assessing the effect of induction on the steady-state levels of NDUFC2 and other complex 
I subunits. Initially, incubation of transduced patient cell lines in a gradient of doxycycline 
concentrations (25, 50, 100 and 200 ng/ml) for 96 hours showed increased steady-state 
protein levels of NDUFC2 and other complex I subunits (NDUFB8 and NDUFA9) with 
200 ng/ml having the highest levels as expected (Figure 6.12A). NDUFC2 protein levels 
in the induced Patient A-1 cell line showed a gradual increase in expression but did not 
reach levels comparable to controls; in contrast, the induced Patient B cell line did reach 
NDUFC2 levels comparable to controls but there was not an obvious difference in steady-
state protein levels between the doses of doxycycline tested (25-200 ng/ml) (Figure 
6.12A). NDUFB8 protein levels in the induced Patient A-1 cell line also did not show a 
gradual increase in protein levels corresponding to the doxycycline concentration. 
Subsequently, induction of transduced patient fibroblast cell lines with doxycycline 
concentrations of 100 ng/ml for 48 hours was compared to those induced with 200 ng/ml 
for 96 hours and showed an increase in complex I subunit expression in both conditions 
(Figure 6.12B). There was only a slight increase in NDUFC2 and NDUFB8 levels 
between the samples induced with 200 ng/ml doxycycline for 96 hours compared to 100 
ng/ml doxycycline for 48 hours demonstrating that 48 hours is sufficient to allow for 
NDUFC2 expression and subsequent complex I assembly. Again, steady state levels of 
complex I subunits including NDUFC2 were not comparable to controls in Patient A-1, 












Figure 6.12 Assessing the effect of lentiviral transduction of wild-type NDUFC2 
cDNA on steady-state complex I subunit levels in patient cell lines. 
A Western blot analysis of whole cell lysates from controls (C1 and C2) and patient cell 
lines (Patient A-1 and B) that were either untransduced (-) or transduced with the 
lentiviral vector (pLVX) containing wild-type NDUFC2 (+). Transduced cell lines were 
either uninduced or induced using a sequence of doxycycline concentrations of 25, 50, 
100 or 200 ng/ml for 96 hours where indicated (results are representative of 1 experiment; 
n=1).  
B Western blot analysis of whole cell lysates from controls (C1 and C2) and patient cell 
lines (Patient A-1 and B) that were either untransduced (-) or transduced with the 
lentiviral vector (pLVX) containing wild-type NDUFC2 (+). Transduced cell lines were 
either uninduced or induced with 100 ng/ml doxycycline for 48 hours or 200 ng/ml 
doxycycline for 96 hours where indicated (results are representative of 2 biological 





6.4.7.2 Assessment of Complex I assembly in induced patient cell lines 
The optimisation of doxycycline induction conditions described above showed that 
induction using 100 ng/ml doxycycline for at least 48 hours (Figure 6.12) was sufficient 
to increase steady-state protein levels of NDUFC2 and other complex I subunits in both 
transduced patients’ fibroblast cell lines to close to maximal levels within this system, 
though using 200 ng/ml did increase the expression slightly. Thus, due to the minimum 
requirement of 72 hours for fibroblasts to reach optimal confluency for harvesting for 
mitochondrial enrichment and subsequent BN-PAGE analysis, the induction was 
performed using 200 ng/ml doxycycline for 72 hours. Enriched mitochondria from 
induced patient cell lines were assessed using BN-PAGE and revealed an increase in 
complex I assembly compared to controls and their respective uninduced and 
untransduced cell lines (Figure 6.13). These results mirror the SDS-PAGE results with 
levels of fully assembled complex I in induced Patient B cell lines increased more than 
that observed in Patient A-1 cell lines but complex I levels in neither induced patient cell 
line reached levels similar to controls. 
 
 
Figure 6.13 Assessing the effect of lentiviral transduction of wild-type NDUFC2 
cDNA on complex I assembly in patient cell lines 
BN-PAGE analysis of OXPHOS complex assembly in enriched mitochondria isolated 
from controls (C1 and C2) and patient cell lines that were either untransduced (-) or 
transduced with the lentiviral vector (pLVX) containing wild-type NDUFC2 (+). 
Transduced cell lines were either uninduced or induced with 200 ng/ml doxycycline for 
72 hours (results are representative of 2 biological repeats; n=2).  
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6.4.8 Complexome profiling of patient fibroblast cell lines 
Complexome profiling was performed on fibroblast cell lines of both patients and an age 
matched control to investigate the role of NDUFC2 in complex I assembly and stability. 
In support of previous functional findings, there was a severe decrease in complex I-
containing supercomplexes (S) ( 
Figure 6.14 and Figure 6.15A-C). In addition, no NDUFC2 was detected in patient A-1 
and only a small amount was detected in Patient B ( 
Figure 6.14, grey horizontal line). Complex III and IV levels were unaffected compared 
to the control, however they formed smaller supercomplexes lacking complex I and 
remained as individual complexes (Figure 6.15B-C, black arrows). Close analysis of 
complex I assembly intermediates in the patients reveal the important role of NDUFC2 
in complex I biosynthesis. Assembly of the Q module appears unaffected by the variants 
identified in both patients. The Q module subunits (NDUFA5, NDUFS2, NDUFS3, 
NDUFS7 and NDUFS8) were detected with its assembly factors (NDUFAF3 and 
NDUFAF4) bound to it (Figure 6.16A-B). In contrast to the control profile, Q-module is 
shown to form an intermediate binding with the NDUFA13 subunit and the assembly 
factor TIMMDC1 (Q*~300 kDa,  
Figure 6.14, orange dashed boxes; Figure 6.16A) in both patients indicating that the 
identified intermediate is bound to the membrane. A larger Q intermediate with the 
NDUFA13 and TIMMDC1 is formed with components of the mitochondrial complex I 
assembly complex (MCIA) ACAD9, ECSIT, NDUFAF1 and the transmembrane protein 
TMEM126B resulting in a 715-800 kDA complex I intermediate (Figure 6.16A). In 
addition, a preassembled intermediate comprised of the ND4 module and the assembly 
factors TMEM70 and FOXRED1 was detected in both patients (Figure 6.16B). No 
intermediates of the N, ND2 and ND5 modules were detected in either patients. The 
complexome profiling findings suggest that in the absence of the NDUFC2 subunit 




Figure 6.14 Complexome profiling of fibroblasts from patients A-1 and B confirm 
complex I deficiency  
Complexome profiling identified assembly intermediates in patient cells with NDUFC2 
mutations. Complexes from mitochondrial membranes of Control, Patient A-1 and Patient 
B fibroblasts were separated by BN-PAGE (Figure 6.11) and analysed by complexome 
profiling. Assignment of complexes: III, complex III; IV, complex IV; III/IV, 
supercomplex containing dimer of complex III and 1-2 copies of complex IV; S, 
supercomplex containing complex I, dimer of complex III and 1-4 copies of complex IV. 
Assembly intermediates are highlighted in dashed boxes indicating stalled complex I 
assembly. In patient complexomes, various stalled complex I intermediates are 
assembled: ND4 module (blue dashed box); Q-TIMMDC1-NDUFA13 complex I 
intermediate (orange dashed box); and Q-TIMMDC1-NDUFA13-MCIA (green dashed 
box). In control complexome, the Q module (orange dashed box) is assembled without 
TIMMDC1 or NDUFA13. Complex I modules are denoted according to Stroud and 




Figure 6.15 Complexome Profiling of Fibroblasts from Patients A-1 and B confirm 
deficiency in supercomplex formation. 
A Abundance data for all the subunits of complex I were averaged to plot an abundance 
profile of complex I. Heatmap (upper panel) and profile plot (lower panel) compare 
complex I between control (black), Patient A-1 (red) and Patient B (blue). 
B Profile plot of complex III (average of all subunits). Black arrows indicate shifted 
complex III to the position of the individual complex and small supercomplex (III/IV) in 
Patient A-1 and B. 
C Profile plot of complex IV (average of all subunits) indicate less complex IV at the 
position of the supercomplexes for Patient A-1 and Patient B, but higher amounts of 








Figure 6.16 Complexome Profiling of Fibroblasts from Patient B demonstrate 
modular assembly of complex I. 
A Details of Q module-containing assembly intermediates of Patient B. Intensity based 
absolute quantification (iBAQ) values of assembly factors, single subunit and averaged 
Q-module subunits were plotted to show abundance profiles. The cartoon (lower panel) 
indicates assembled intermediate complexes relative to coloured boxes in the plot.  
B Details about ND4 module assembly intermediate of Patient B. Abundance profile of 
averaged iBAQ values of ND4 subunits and assembly factors show accumulation of a 





Biochemical investigations assessing the functional effect of the confirmed NDUFC2 
variants showed similar findings in Patients A-1 and B even though one patient was 
homozygous for a loss-of-function variant and the other was homozygous for a missense 
variant that affects a highly conserved residue. No homozygous loss-of-function 
NDUFC2 variants were reported in the gnomAD database and only two protein-coding 
variants were reported as homozygous in healthy controls: p.Leu46Val (n=4270 
homozygotes; MAF=0.197) and p.Arg119His (n=1 homozygote; MAF=2.77×10-4); 
neither substitution was predicted to change the biochemical properties of the affected 
residues (Lek et al., 2016). Recent work including NDUFC2-knockout HEK293T cells 
showed a defect in the expression of ND2, ND5 and N module subunits, but ND4 module 
subunits were unaffected (Stroud et al., 2016). In addition, ND1 module subunits were 
unaffected, however that is not the case in our NDUFC2 patients where both had a defect 
in ND1 module assembly (or stability) and only the NDUFA13 subunit was detected ( 
Figure 6.14 and Figure 6.16). The observed loss of the ND2 module (where NDUFC2 
is incorporated) in Patient B asserts that the conserved His58 residue plays an important 
role in the assembly or stability of the module (Figure 6.16). 
The induction of wild-type NDUFC2 in Patient A-1 fibroblasts resulted in an increase in 
protein levels but it did not reach levels comparable to endogenous levels observed in 
controls. The induction also resulted in the partial rescue of steady-state levels of other 
complex I subunits and levels of fully assembled complex I (Figure 6.12 and Figure 
6.13). In Patient B fibroblasts, induction resulted in NDUFC2 levels appearing similar to 
endogenous levels in controls, but steady-state levels of other complex I subunits and 
levels of fully assembled complex I did not reach control levels (Figure 6.12 and Figure 
6.13). Assembly of complex I is suggested to require just 24 hours (Guerrero-Castillo et 
al., 2017) meaning the 72 hours of doxycycline induction should have provided sufficient 
time for the expressed wild-type NDUFC2 to incorporate and assemble into complex I. 
Despite protein levels not reaching endogenous levels in rescued patient cell lines, results 
clearly demonstrate that the lentiviral expression of wild-type NDUFC2 ameliorates the 
biochemical phenotype, leading to observable increases in steady-state levels of complex 
I subunits, and more importantly the incorporation of the expressed wild-type NDUFC2 
into complex I as observed in the increased levels of fully-assembled complex I.  
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It is worth noting that the patient cell populations were each transduced in single dishes, 
subjected to puromycin selection, and then propagated into multiple flasks for the 
uninduced and various induced concentrations tested. The cell lines were not grown up 
from single colonies of transduced fibroblasts as these were primary fibroblasts and 
growing enough cells for use in the experiments from a single transduced fibroblast cell 
was not possible due to the number of rounds of cell division required. Whilst the genetic 
integration will not have been in the same location in each cell, the wild-type NDUFC2 
should be as a single copy and is under the same inducible promoter in each cell so similar 
expression levels in each cell are expected. This is supported by the fact that multiple 
transductions were carried out independently and no noticeable difference is observed in 
NDUFC2 expression between each population of transduced cells. Some individual 
clones may well have had better expression than others if it were possible to use a clonal 
selection method, but this effect is expected to be relatively minor and producing 
reproducible data with multiple heterogeneous populations of transduced cells minimises 
the chance of observing off target effects from one specific clone. Overall, the results 
strongly support the pathogenicity of both NDUFC2 variants identified in the patients. 
Current work on complex I assembly states that the Q-intermediate binds to the ND1 
module and the membrane spanning assembly factor TIMMDC1 forming complex I 
intermediate containing the Q module and ND1 module subunits (Figure 6.17A) 
(Guerrero-Castillo et al., 2017; Formosa et al., 2018; Signes and Fernandez-Vizarra, 
2018). We identified an assembly intermediate in the NDUFC2 patients consisting of the 
Q module and the assembly factors ACAD9, ECSIT, NDUFAF1 and TMEM126B, which 
comprise the MCIA, the assembly factor TIMMDC1 and NDUFA13 (Figure 6.17C;  
Figure 6.14, Patient A-1 and Patient B, green dashed boxes). ND1 and NDUFA8 subunits 
were not detected despite being previously associated with this stage of assembly, but this 
may be due to the sensitivity of the assay. NDUFA13 is the only ND1 module subunit 
that was detected in a Q-intermediate in both patients (~300 kDa,  
Figure 6.14, orange dashed boxes, Figure 6.16A; Figure 6.17B). A similar assembly 
intermediate, lacking the MCIA factors, was previously observed in cases harbouring 
pathogenic variants in TMEM126B (an MCIA factor) where control complexome data 
showed a Q module intermediate lacking the TIMMDC1 assembly factor, similar to the 
present control complexome (Alston et al., 2016a). No other ND1 module subunits, or 
subunits from the neighbouring ND2 module, were detected in our NDUFC2 patients. 
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The observed complex I assembly intermediates suggest the MCIA complex is involved 




Figure 6.17 Molecular consequences of defects in NDUFC2 on complex I  
A Assembly sequence of complex I modules according to current state of knowledge in 
human cells (Guerrero-Castillo et al., 2017; Formosa et al., 2018; Signes and 
Fernandez-Vizarra, 2018). The ND1 module (ND1m), ND2 module (ND2m), ND4 
module (ND4m) and ND5 module (ND5m) are identified by these abbreviations. 
B Left, structural modules of complex I highlighted in colours based on mouse cryo-EM 
structure (PDB: 6g2j) (Agip et al., 2018). NDUFC2 is shown in black. Right, surface 
view indicates subunits interacting in a neighbourhood of less than 10 Å to NDUFC2. 
All other subunits not interacting on any part of the protein are in transparent cartoon 
view.  
C Assembly intermediates/dead end assembly products in mitochondria from Subject 3 
according to data from complexome profiling. Assembled subunits are highlighted in 





In the absence of NDUFC2, the ND2 module was not detected and an alternative complex 
I assembly intermediate was formed in the complexomes of the NDUFC2 patients (~715-
800 kDa,  
Figure 6.14, Patient A-1 and Patient B, green dashed boxes; Figure 6.15C).  
NDUFC2 is a complex I subunit assigned to the membrane bound ND2 module and 
molecular data obtained from collaborators at Goethe-Universität in Frankfurt, Germany, 
indicate NDUFC2 plays an important role in the assembly of the membrane arm of the 
complex (Figure 6.17B). NDUFC2 extends into the intermembrane space and has contact 
with 12 other subunits (Figure 6.17B, right panel) including NDUFA8 subunits of the 
ND1 module, neighbouring ND2 subunits (ND2, NDUFA10, NDUFA11, NDUFC1 and 
NDUFS5), and ND4 module subunits (ND4, NDUFB1, NDUFB5, NDUFB10 and 
NDUFB11) (Zhu et al., 2016; Agip et al., 2018). All these contact sites could be crucial 
for the assembly and stability of complex I. Complexome profiling of both NDUFC2 
patients showed a loss of ND1 and ND2 module subunits associated with it which is 
consistent with the suggested model. 
The data also support the stalled complex I assembly following the formation of the Q 
module due to the failed formation of fully assembled ND1 in the inner mitochondrial 
membrane. The absence of ND1 and ND2 modules (and most of their subunits) in the 
complexome data of the patients indicates that the modules do not assemble 
independently and suggest that NDUFC2 might be important in the formation of the ND1 
module. 
By contrast, the ND4 module, which is comprised of ND4, NDUFB1, NDUFB5, 
NDUFB10 and NDUFB11 subunits along with its assembly factors FOXRED1 and 
TMEM70, was detected as a stable complex I intermediate in Patient B and less 
apparently in Patient A-1 (~260 kDa, Figure 6.14, Patient A-1 and Patient B, blue dashed 
boxes; Figure 6.16B; Figure 6.17C). This finding is consistent with previous models of 
complex I assembly and human complexome data show independent assembly of the 
membrane-bound module (Alston et al., 2016b; Stroud et al., 2016; Guerrero-Castillo et 
al., 2017; Alston et al., 2020). The N and ND5 modules were not detected in the 
complexome data of our NDUFC2 patients suggesting that assembly intermediates of 
these distal modules are either unstable, they are governed by middle stage assembly, or 
they are turned over by mitochondrial proteases (Szczepanowska et al., 2020).  
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A number of pathogenic variants in ND2 module subunits have been previously reported 
in NDUFA1, NDUFA10 and NDUFA11. Although they all affect the same module, 
variable clinical presentations were reported in the patient, which is common observation 
in mitochondrial disease patients. Patients harbouring pathogenic variants in NDUFA1 or 
NDUFA10 mostly presented with Leigh syndrome or Leigh-like symptoms, while a 
single patient with an NDUFA11 variant presented with early-onset fatal 
encephalocardiomyopathy (Fernandez-Moreira et al., 2007; Berger et al., 2008; Hoefs et 
al., 2011; Minoia et al., 2017). A variety of biochemical, molecular and functional 
investigations were performed in these cases, which revealed defects in complex I 
assembly (NDUFA1 and NDUFA10) and complex I enzyme deficiency (NDUFA1, 
NDUFA10 and NDUFA11). These reports support the association of pathogenic variants 
in ND2 module subunits with paediatric mitochondrial disease. Recently, an increasing 
number of complexome profiling data has been acquired from cell lines of cases with 
complex I deficiency due to bi-allelic mutations in NDUFA6 encoding a complex I 
subunit, and in TMEM126B and NDUFAF8 encoding complex I assembly factors; some 
cases presented with Leigh syndrome (Alston et al., 2016a; Alston et al., 2018; Alston et 
al., 2020). This provided a means of assessing previously extrapolated steps of complex 
I assembly. These investigations of pathogenic variants in complex I structural subunits 
and assembly factors and their effects on complex I assembly revealed novel assembly 
intermediates indicating stalled assembly. To date, data from patient-derived functional 
investigations provide supporting evidence for the independent assembly of the Q and 
ND4 modules and have highlighted the important roles of novel assembly factors 
TMEM126B and NDUFAF8. In addition, they have described the functional 
consequence of pathogenic variants within structural complex I subunits (e.g., NDUFA6) 
and their effect on the assembly of complex I 
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Chapter 7. General discussion 
 
The introduction of targeted NGS technologies has revolutionised the approach in 
diagnosing and understanding the aetiology of genetic disorders in the past decade. The 
employment of WES and WGS on cohorts of patients suspected of genetic disorders has 
resulted in the rapid diagnosis and discovery of novel candidate genes associated genetic 
disorders including mitochondrial disorders (Haack et al., 2012; Saunders et al., 2012; 
Lieber et al., 2013; Yang et al., 2013; Gilissen et al., 2014; Soden et al., 2014; Taylor et 
al., 2014; Wortmann et al., 2015; Pronicka et al., 2016). Clinical heterogeneity and often 
weak genotype-phenotype correlations observed in mitochondrial disease patients pose a 
challenge in the pursuit of a diagnosis since mitochondrial functions are governed by 
proteins encoded in both mtDNA and nDNA. Of the 1,158 proteins purported to comprise 
the mitochondrial proteome (Calvo et al., 2016), over 300 genes have been associated 
with mitochondrial disorders thus far with the continued discovery of novel candidate 
genes by utilising NGS technologies (Pagliarini et al., 2008; Stenton and Prokisch, 2020). 
The foundation of my study is to apply unbiased WES to a well-characterised patient 
cohort from Kuwait to diagnose Mendelian mitochondrial disease, to improve diagnostic 
yield by utilising selection criteria, to expand clinical spectrums of disease and determine 
genetic architecture, to identify novel candidate genes and deepen our understanding of 
mitochondrial disease phenocopies. 
 The role of patient recruitment on the diagnostic rate 
The high diagnostic yield in my study was heavily attributed to the recruitment process. 
Available clinical information and investigation results were first reviewed by Dr 
Buthaina Albash (a specialist in paediatric metabolic disorders at KMGC), then I 
reviewed the cases she referred and scored them based on a modified MDC scoring 
scheme that I developed (Chapter 3). Finally, the high scoring cases were reviewed by 
Professor Robert McFarland (a mitochondrial disease specialist and paediatric 
neurologist at the Wellcome Centre for Mitochondrial Research) for his input on which 
cases were likely suspected of mitochondrial disease as opposed to other neurological 
disorders. Furthermore, Professor McFarland was invited to KMGC in 2016 and 2018 to 
assess potential candidates for my study that were selected by Dr Albash. This multistep 
approach of reviewing referred cases ensured that cases were highly suspected of 
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mitochondrial disease involvement prior to being analysed using WES. Some factors and 
findings heavily influenced this recruitment process namely case referrals to KMGC, 
clinical information and investigation results available, and family participation which I 
will discuss below. 
 Limitations of recruiting candidate cases from Kuwait 
The recruitment and selection of candidate patients and families from Kuwait exhibited 
numerous challenges including the limited referral of cases to KMGC, the lack of clinical 
information and investigations performed. From 2010 until 2016, patients referred to 
KMGC upon suspicion of mitochondrial disease involvement were genetically 
investigated by sequencing mtDNA for previously reported pathogenic mutations 
associated with disease. During that period, the lack of expertise in mitochondrial disease 
at KMGC resulted in a low diagnosis rate amongst the investigated patients. The arrival 
of Buthaina Albash at KMGC played a major role in the selection of candidate patients 
highly suspected of mitochondrial disease. However, the specialist reported many 
missing clinical details that needed to be obtained in order to review the case fully. This 
resulted in requesting missing clinical details from families and the referring clinicians in 
addition to requesting further investigations involving blood tests and radiological MRI 
scans in cases lacking such crucial information. Some families did not return calls, some 
families no longer reside in Kuwait, and some families opted not to participate in the 
study due to the frustration of pursuing a diagnosis for many years with no conclusive 
results from the hospitals or KMGC. Genetic counselling was provided to such families 
and clinicians explained the complexity reaching a diagnosis in genetic disorders, but the 
families had the final say in their consent and participation. 
Referral of patients to KMGC from primary clinicians often came with limited referral 
clinical notes and investigations (should results be available). This resulted in many 
referred cases with insufficient information to assess their candidacy accurately. A 
thorough clinical history including family history was important in the recruitment 
process as it improved evaluation of patient candidacy and suspicion of mitochondrial 
disease in a highly consanguineous population where newborns with complications due 
to genetic diseases, including mitochondrial disease, are likely to go unreported after 
passing away. Such cases are often not investigated further, and families are consequently 
likely to go on to have multiple similarly affected siblings (Chaman et al., 2014). 
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Of the clinical information available, radiological MRI findings suggestive of 
mitochondrial disease involvement greatly increased the candidacy of patients as it was 
heavily weighted in previously suggested MDC (Morava et al., 2006; Joost et al., 2012; 
Chi, 2015; Witters et al., 2018) which led to it being included in the modified MDC I 
developed and used in the reviewing of cases (Figure 3.3). The mitochondrial disease 
criteria employed here and those previously suggested generally sacrifice sensitivity for 
specificity in relation to mitochondrial disease (Witters et al., 2018). With both the 
‘Metabolic/Imaging’ and ‘Tissue Findings’ categories having high max limits in the 
modified MDC employed, only the former could influence the candidacy of recruited 
patients since no tissue investigations have been performed in Kuwait. 
 WES as a first-tier genetic analysis technique 
Of the available NGS tools, the gene agnostic approach of WES has proven to be a rapid 
and cost-effective approach in diagnosing genetic disorders, including mitochondrial 
disorders, in patients from the highly consanguineous Middle Eastern population with a 
diagnostic rate of 45% (Alahmad et al., 2019). WES can help provide families with a 
rapid genetic diagnosis and genetic counselling thereafter to discuss possible options for 
future pregnancies. Therefore, WES was the tool of choice in my study to investigate and 
diagnose the recruited candidate families living in Kuwait.  
The recruitment process is an important step in selecting a cohort of patients that were 
investigated upon suspicion of mitochondrial disease involvement based on clinical 
selection criteria. Using WES as a first-tier genetic analysis approach, I was able to 
achieve a genetic diagnosis in 14 of the 22 families recruited in my cohort (63.6% 
diagnosis rate) (Chapter 4). This diagnostic rate mirrors the rates achieved in previous 
studies investigating mitochondrial disease patients (Taylor et al., 2014; Wortmann et al., 
2015; Pronicka et al., 2016; Theunissen et al., 2018). The bioinformatics filtering 
pipelines developed and used in the WES results were optimised for identifying variants 
in genes associated with mitochondrial function and disease. The filtering pipelines also 
included for identification of variants in genes associated with neurological disorders that 
were phenocopies of mitochondrial disease (RNASEH2C, TREX1, VPS13B, and 
ATP8A2). There remain 8 families without a diagnosis in my cohort, one reason for this 
could be that the reported clinical presentations were caused by trauma or environmental 
factors rather than genetic factors. On the other hand, genetic factors are suspected due to 
high rates of consanguinity in the recruited cohort, therefore it is possible that the 
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causative variants reside in non-coding regulatory regions of the genome or there could 
be copy number variations (CNVs) which are not well covered by WES analysis (Turner 
et al., 2016; Shaikh, 2017; Burdick et al., 2020). Although the alternative WGS can help 
overcome these obstacles, cost was a deciding factor in choosing WES which has already 
proven its high diagnostic rate when utilised as a first-tier genetic analysis test at the start 
of my study (Belkadi et al., 2015). 
 Functional validation of segregated variants 
KMGC does not currently have access to functional laboratory testing to validate 
candidate genetic variants and confirm their pathogenicity; this includes the absence of 
skin biopsy and tissue culture facilities. A large number of novel genetic variants in both 
mitochondrial and non-mitochondrial genes were identified in my study cohort, including 
missense and truncating variants that prompted further investigations to study their effect 
on protein expression and OXPHOS complex assembly. With family consent, I liaised 
with Dr Ahmad Alaqeel, a clinician at KMGC, to acquire patient skin biopsies from 4 
recruited families with segregating novel variants (MPC1, TTC19, NDUFA13 and 
TREX1). These biopsies were sent to Newcastle to establish fibroblast cell lines allowing 
the functional investigations of variant pathogenicity presented in my thesis (Chapter 5). 
 LETM1 is a novel mitochondrial disease gene 
As a novel mitochondrial disease gene, skin biopsies could have helped validate the 
pathogenicity of the LETM1 variants identified in both families 1 (NM_012318.2; 
c.754_756delAAG; p.Lys252del) and family 6 (c.881G>A; p.Arg294Gln). 
Unfortunately, as all affected patients were deceased, no functional analysis was possible 
for either family. Due to a lack of available samples, the functional analysis required to 
confirm pathogenicity such as western blots, BN-PAGE and rescue experiments were not 
possible. The utilisation of functional investigation techniques to study the effect of novel 
variants and variants in novel candidate genes is a key step in validating the pathogenicity 
of the identified variants. These functional techniques were used to investigate and 
validate NDUFC2 variants in 2 unrelated families which initiated a multicentre 
collaboration (Chapter 6).  
 GeneMatcher facilitated the NDUFC2 collaboration 
Dr Seham Alameer, a specialist in paediatric metabolic disorders, reported a patient 
homozygous for a NDUFC2 deletion at their centre in Jeddah, Kingdom of Saudi Arabia. 
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GeneMatcher (https://genematcher.org/ (Sobreira et al., 2015)) identified another patient 
homozygous for a missense NDUFC2 variant reported by Professor Daniele Ghezzi, a 
mitochondrial disease specialist working in Milan, Italy. Both the Saudi Arabian and 
Italian groups had obtained skin biopsies from their genotyped patients and established 
fibroblast cell lines. I obtained these fibroblast cell lines and began functional analysis 
using western blotting and BN-PAGE and used these techniques to assess the effect of 
expressing wild-type NDUFC2 in patient cell lines using a lentiviral rescue experiment. 
Furthermore, patient cell lines were also sent to Professor Ilka Wittig for complexome 
profiling to assess how the NDUFC2 variants affected complex I assembly. This 
multicentre collaboration began with a single matching of identified gene variants in 
GeneMatcher and the availability of patient cell lines from Saudi Arabia and Italy 
facilitated the functional investigations performed through extensive collaboration. This 
allowed the designation of different functional analyses to be performed simultaneously 
at different centres based on their specialisation and expertise. This led to a more rapid 
validation of pathogenicity and the comprehensive characterisation of the consequences 
due to the identified variants in a novel mitochondrial disease gene. NDUFC2 is a subunit 
of complex I’s IMM embedded ND2 submodule that houses a proton pumping channel; 
its absence resulted in the stalling of complex I assembly and thus led to complex I 
deficiency, an established phenotype associated with mitochondrial disease.  
 Future approaches to diagnosing mitochondrial disease patients 
When it comes to diagnosing mitochondrial disease in suspected patients, functional 
evidence was primarily used for clinical diagnosis; this requires invasive surgery to 
acquire a muscle biopsy. With the introduction of rapid NGS technologies that can 
extensively sequence the patients’ exomes or genomes, a shift to “genetics first” approach 
was implemented to avoid the necessity of a muscle biopsy in all cases. The identification 
of novel variants and novel candidate genes was a key outcome of this approach that 
increased the rate of diagnoses. However, many cases remain undiagnosed such as the 
with the 8 undiagnosed patients in my study. These cases require further investigations 
that could lead to a diagnosis. 
Worldwide, undiagnosed cases that have been investigated using NGS technologies are 
being followed up with a “multi-omics” approach that can help search for and identify 
the cause of disease in patients (Stenton et al., 2020; Thompson et al., 2020b). This 
includes sequencing RNA (transcriptomics), assessing protein levels (proteomics), 
 267 
measuring metabolite levels (metabolomics) in patient cells. The source of the assessed 
cells is a challenge to overcome but this multi-disciplined approach is likely to lead to 
higher levels of diagnosis in patients primarily sequenced for genomic variants.  
The 8 undiagnosed families in my study are difficult to investigate further using the 
aforementioned approach as biopsies and cell lines are not easily acquired in Kuwait. 
Further investigations might be implemented with WGS likely being the next stage of 
investigation prior to any investigations involving patient cells. 
 Future work 
I plan to continue my work investigating genetic disease patients at KMGC and will 
advocate for the establishing of a core NGS facility to allow access to genetic analysis 
techniques with higher diagnostic rates and more rapid results. This includes WES, and 
possibly WGS, for patients highly suspected of a genetic disease involvement. A robust 
variant filtration pipeline also needs to be established to assist in the identification of 
candidate variants among the genotyped variants.  
In addition to expanding the genetic analysis methods and techniques at KMGC, I will 
advocate for the expansion of the tissue culture laboratories to include facilities for 
functional analysis on patient tissues and cell lines. This includes performing techniques 
such as western blotting and BN-PAGE and later expanding with further techniques as 
deemed necessary. This will help validate the pathogenicity of novel variants which are 
likely to be identified in the highly consanguineous population as demonstrated in my 
study (12 out of 15 identified mutations were novel).  
Should the establishment of an independent tissue culture facility be successful, I plan on 
establishing a cell line bank of patient fibroblast cell lines (parallel to the DNA bank at 
KMGC containing DNA samples) for future functional analysis should a diagnosis be 
reached or should functional analyses help narrow down the scope of candidate genes to 
investigate or interrogate in the WES results. 
The clinical review of patients by specialists at KMGC can be improved by 
recommending diagnostic criteria to score and assess patient information such as the 
modified MDC I used in my study. Founder mutations identified in the population and in 
neighbouring populations should be prioritised when suspecting mitochondrial disease in 
Kuwait (Alahmad et al., 2019). A database of founder mutations related to various genetic 
disorders in the population should also be organised with associated clinical presentations 
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and findings and the database should be routinely expanded as new founder mutations are 
discovered. This will help connect the clinical, genetic, and functional investigations at 
KMGC to better serve the local community through rapid and accurate genetic screening. 
 Concluding remarks 
To summarise, patients from 22 families who were suspected of mitochondrial disease 
involvement were selected into my study cohort by reviewing patient phenotypes with 
the help of expertise from a paediatric specialist based in Kuwait, the scoring of referred 
patients using a developed MDC, and the review of the high scoring patient by a 
mitochondrial disease specialist based in Newcastle. WES performed on the patient 
cohort led to a genetic diagnosis in 14 of the families (63.6%) and functional analysis was 
carried out patient cell lines from 4 of these families to validate pathogenicity and 
functionally characterise the effect of the novel variants. A large collaboration involving 
research centres in Saudi Arabia, Italy and Germany led to the functional investigation of 
patients harbouring pathogenic variants in a novel mitochondrial disease gene (NDUFC2) 
which resulted in the validation of variant pathogenicity and added to the phenotypic 
diversity of mitochondrial disease. The methods of investigation implemented in my 
study can be used to expand the provided services at KMGC’s diagnostic labs to help 
better serve patients and their families in Kuwait by providing more rapid genetic 
diagnoses and functional validation methods. 
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Appendix 
Appendix A - Primers used to Sanger sequence genetic variants identified in patients using WES 
Family Gene Ref Exon/ 
Intron 





1 LETM1 NM_012318 Exon 5 c.754_756del p.252delLys F- 5'-TGAGAGTCAGTGTGTTGTGAA-3' 
R- 5'-GGGTAAACTTTCAAGCGCCA-3' 
385 bp 62°C  No 
2 SLC19A3 NM_025243 Exon 3 c.175T>C p.Trp59Arg F- 5'-CCGGGGTTTATCTAAGTGTGTAC-3' 
R- 5'-CACTCCTTGGCCAAACAACA-3' 
366 bp 62°C  No 
3 PDHX NM_003477 Exon 6 c.742C>T p.Gln248Ter F- 5'-ACATCTCACCTGCGTTTTCTG-3' 
R- 5'-ACTTAGAGAACACTACCACTGCA-3' 
271 bp 58°C  Yes 
4 SURF1 NM_003172 Exon 5 c.367_368delCT  p.Arg123fsTer4 F- 5'-GTTTTCCAGCCAAACCTTGC-3' 
R- 5'-GCTCCCACATGTCCTACTCA-3' 
260 bp 62°C  No 
5 MPC1 NM_016098 Exon 3 c.109C>T p.Pro37Ser F - 5'-GTAGGGACCTTGGGAAGCTG-3' 
R - 5'-CCTCCCAATTATCCAAATCTGCA-3' 
383 bp 62°C  No 
6 LETM1 NM_012318 Exon 6 c.881G>A p.Arg294Gln F - 5'-AGTGGTTTGAGTCCCTGAGG-3' 
R - 5'-CGATCGTTCAGCATCTTCCA-3' 
429 bp 62°C  No 
7 TTC19 NM_017775 Exon 8 c.779_780del p.Try260Ter F - 5'-TGTTCCCTAAGTGACATGTGG-3' 
R - 5'-TGAGGGTGCTGGTGATAAGAA-3' 
407 bp 62°C  No 
8 NDUFA13 NM_015965 Exon 1 c.22C>T p.Gln8Ter F - 5'-CTTCCGCCACACTCATCAT-3' 
R - 5'-CCCGGCGCAGAGTGATAC-3' 
190 bp 62°C  No 
9 NDUFB9 NM_005005 Exon 2 c.191T>C p.Leu64Pro F - 5'-CACTGCCCATCCAGAAGGTA-3' 
R - 5'-CCTTGAAGGGCAAGTGATTT-3' 
390 bp 62°C  No 
10 RRM2B NM_015713 Exon 6 c.574G>A p.Ala192Thr F - 5'-CATGTGTGGTGCACACGTAA-3' 
R - 5'-
ATGGAAAAGAAAAATAGATGAACATCA-3' 
502 bp 62°C  No 
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DMSO: dimethylsulphoxide; Ref: Reference Sequence 
  
Family Gene Ref Exon/ 
Intron 





11 RNASEH2C NM_032193 Exon 2 c.202C>G p.Leu68Val F - 5'-TACCCGCCACACTGCATC-3' 
R - 5'-AGGGTGAAGCGGCTGAAG-3' 
565 bp 58°C  Yes 




F - 5'-CCCCATGCTCCTCTCCAG-3' 
R - 5'-ACAGAAGGCACCATCCAGAG-3' 
500 bp 62°C  No 
13 VPS13B NM_015243 Exon 
11 
c.1512del p.Glu505Lysfs F - 5'-GGCAAAATAGTCAATGAAGGTGG-3' 
R - 5'-TCATACAATGTGTCCACCCAA-'3 
357 bp 62°C  No 
14 ATP8A2 NM_016529 Intron 
3 
c.321+1G>T p.? retain intron 3? F - 5'-CTTGAGGATGATTGCAGTGACT-3' 
R - 5'-AGCCCAATTTCCTGCCTTAA-3' 
474 bp 58°C  No 
Ch 6 NDUFC2 NM_004549 Exon 3 c.346_*7del p.His116_Arg119delins21 F - 5’-ACATGAACATTCAGACCACAGC-3’ 
R - 5’-CAAGGTGTCAACATACAGATTAGCA-3’ 
286 bp 62°C  No 
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Appendix B - Antibodies used in immunoblotting Western blot and BN-PAGE membranes 
 
Protein  OXPHOS 
complex 
Company Catalogue number Dilution Predicted size/Observed 
size (kDa) 
Mono/polyclonal Secondary 
NDUFV1 I Proteintech 11238-1-AP 1:1000 51 Polyclonal Rabbit 
NDUFA9 I abcam ab14713 1:1000 35 Monoclonal Mouse 
NDUFB8 I abcam ab110242 1:1000 17 Monoclonal Mouse 
NDUFC2 I abcam ab192265 1:1000 14 Monoclonal Rabbit 
NDUFAF3 I AF Sigma HPA035377 1:1000 12 Polyclonal Rabbit 
NDUFA13 I abcam ab110240 1:1000 17 Monoclonal Mouse 
SDHA II abcam ab14715 1:2000 73 Monoclonal Mouse 
UQCRC2 
(CORE2) 
III abcam ab14745 1:1000 48 Monoclonal Mouse 
UQCRFS1 III abcam ab14746 1:1000 25 Monoclonal Mouse 
MTCO1 
(COX-1) 
IV abcam ab14705 1:1000 40 Monoclonal Mouse 
MTCO2 
(COX-2) 
IV abcam ab110258 1:1000 21 Monoclonal Mouse 
ATP5A V abcam ab14748 1:2000 53 Monoclonal Mouse 
TTC19 III AF abcam ab181191 1:1000 32 Monoclonal Rabbit 
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Protein  OXPHOS 
complex 













1:1000 53 ATP5A (V) 
48 UQCRC2 (III) 
33 SDHB (II) 
20 MTCO-2 (IV) 





MPC1 IMM Cell 
Signaling 
14462 1:1000 12 Monoclonal Rabbit 
TREX1 Cytosol Cell 
Signaling 
12215 1:1000 33 Monoclonal Rabbit 
Beta actin Cytosol Cloud Clone CAB340Hu22 1:10,000 42 Monoclonal Mouse 
Mouse 
secondary 
- DAKO P0260 1:2000 - - - 
Rabbit 
Secondary 
- DAKO P0399 1:3000 - - - 
I: complex I subunit; II complex II subunit; III complex III subunit; IMM: inner mitochondrial membrane; IV: complex IV subunit; V complex V 
subunit; I AF: complex I assembly factor; III AF: complex III assembly factor. 
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Appendix C - 299 genes amplified in custom gene panel in Italy* 
ALKBH1 COQ9 HSD17B10 MTCH2 NDUFS6 RARS2 TIMMDC1 
AARS2 COX10 HSPA9 MTFMT NDUFS7 RCC1L TK2 
ABCB7 COX14 HSPD1 MTO1 NDUFS8 RMND1 TMCO6 
ACAD9 COX15 HSPE1 MTPAP NDUFV1 RNASEH1 TMEM126A 
ACN9 COX20 IARS NARS2 NDUFV2 RPUSD4 TMEM126B 
ACO2 COX4I1 IARS2 NAXE NDUFV3 RRM2B TMEM65 
ADCK3 COX4I2 IBA57 NDUFA1 NFU1 RTN4IP1 TMEM70 
AFG3L2 COX6B1 ISCA1 NDUFA10 NSUN3 SARS2 TOP2A 
AGK DARS ISCA2 NDUFA11 NUBPL SCO1 TOP2B 
AIFM1 DARS2 ISCU NDUFA12 OPA1 SCO2 TPK1 
APEX1 DGUOK KARS NDUFA13 OPA3 SDHA TRIAP1 
APOPT1 DIAPH1 LARS2 NDUFA2 OXA1L SDHAF1 TRMU 
APTX DLAT LIAS NDUFA3 PARS2 SDHAF2 TRNT1 
ARMCX1 DLD LIPT1 NDUFA4 PC SDHB TSFM 
ATAD3A DNA2 LIPT2 NDUFA5 PCK2 SDHC TTC19 
ATP5A1 DNAJC19 LRPPRC NDUFA6 PDHA1 SDHD TUFM 
ATP5D DNM1L LYRM4 NDUFA7 PDHA2 SERAC1 TYMP 
ATP5E DPYD LYRM7 NDUFA8 PDHB SLC19A2 UQCRB 
ATP5ML E4F1 MARS2 NDUFA9 PDHX SLC19A3 UQCRC1 
ATPAF2 EARS2 MCUR1 NDUFAB1 PDK1 SLC25A1 UQCRC2 
AUH ECHS1 MDH2 NDUFAF1 PDK2 SLC25A19 UQCRFS1 
BCS1L ECSIT MECR NDUFAF2 PDK3 SLC25A21 UQCRQ 
BOLA3 ELAC2 MFF NDUFAF3 PDK4 SLC25A22 USMG5 
C10orf2 ENDOG MFN1 NDUFAF4 PDP1 SLC25A3 VARS2 
c12orf65 ETFA MFN2 NDUFAF5 PDP2 SLC25A4 WARS2 
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C1QBP ETFB MGME1 NDUFAF6 PDPR SLC25A42 WFS1 
CAD ETFDH MICU1 NDUFAF7 PDSS1 SLC25A46 YARS2 
CARS2 ETHE1 MMAA NDUFB1 PDSS2 SLC39A8 YBEY 
CHCHD10 FARS2 MPC1 NDUFB10 PET100 SPART YME1L1 
CHCHD4 FASTKD2 MPC2 NDUFB11 PET117 SPATA5  
CISD2 FBXL4 MPV17 NDUFB2 PNKD SPG7  
CLPP FDXR MPV17L NDUFB3 PNPT1 SQSTM1  
CLUH FGF21 MPV17L2 NDUFB4 POLG SSBP1  
COA5 FLAD1 MRPL12 NDUFB5 POLG2 SUCLA2  
COA6 FOXRED1 MRPL23 NDUFB6 POLRMT SUCLG1  
COA7 FTSJ2 MRPL24 NDUFB7 PPA2 SURF1  
COASY GARS MRPL3 NDUFB8 PREPL TACO1  
COQ10A GDAP1 MRPL44 NDUFB9 PRPS1 TANGO2  
COQ10B GFER MRPL50 NDUFC1 PRUNE TARS2  
COQ2 GFM1 MRPS16 NDUFC2 PTCD1 TAZ  
COQ3 GLRX5 MRPS2 NDUFS1 PTCD2 TFAM  
COQ4 GTPBP3 MRPS22 NDUFS2 PTCD3 TFG  
COQ5 HARS2 MRPS34 NDUFS3 PUS1 THG1L  
COQ6 HCCS MRPS7 NDUFS4 QRSL1 TIMM50  
COQ7 HSCB MSTO1 NDUFS5 RANBP2 TIMM8A  
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